

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07C 45/41, C07D 301/03, 303/04, 311/74, C12P 1/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/01650</b> <b>(43) International Publication Date:</b> 13 January 2000 (13.01.00)
<b>(21) International Application Number:</b> PCT/US99/15264 <b>(22) International Filing Date:</b> 6 July 1999 (06.07.99)  <b>(30) Priority Data:</b> 60/091,983 6 July 1998 (06.07.98) US 60/091,951 6 July 1998 (06.07.98) US 60/091,964 6 July 1998 (06.07.98) US  <b>(71) Applicant:</b> DCV, INC. doing business as BIO-TECHNICAL RESOURCES [US/US]; 1035 South Seventh Street, Manitowoc, WI 54220 (US).  <b>(72) Inventors:</b> MILLIS, James, R.; 512 Audubon Road, Kohler, WI 53044 (US). SAUCY, Gabriel, G.; 125 Fells Road, Essex Fells, NJ 07021 (US). MAURINA-BRUNKER, Julie; 825 Covenant Lane, Appleton, WI 54915 (US). McMULLIN, Thomas, W.; 1010 West Crescent Dr., Manitowoc, WI 54220 (US).  <b>(74) Agents:</b> CONNELL, Gary, J. et al.; Sheridan Ross P.C., Suite 1200, 1560 Broadway, Denver, CO 80202-5141 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD OF VITAMIN PRODUCTION  <b>(57) Abstract</b>  The invention provides a method of producing $\alpha$ -tocopherol and $\alpha$ -tocopheryl esters and a method of producing vitamin A or $\beta$ -carotene. The methods comprise using a biological system to produce farnesol or geranylgeraniol. Then, the farnesol or geranylgeraniol is chemically converted into $\alpha$ -tocopherol, an $\alpha$ -tocopheryl ester, vitamin A or $\beta$ carotene.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						





" METHOD OF VITAMIN PRODUCTION "

## FIELD OF THE INVENTION


The present invention relates to methods of producing  
5 vitamins, particularly vitamins A and E and related  
compounds.

## BACKGROUND OF THE INVENTION

Vitamin E (d-alpha-tocopherol, 1) is an important  
10 nutritional supplement in humans and animals. Compound 1  
is obtained commercially by isolation from a variety of  
plant oils, or semisynthetically by ring methylation of the  
related naturally occurring d-gamma-tocopherol 2. A more  
important source of vitamin E is total synthesis, which  
15 provides d,l-alpha-tocopherol 3. Although a mixture of  
isomers, 3 provides much of the biological activity of 1  
and is widely used due to its lower cost and greater  
availability. For a general discussion of vitamin E, see  
L. Machlin, ed., "Vitamin E: A Comprehensive Treatise",  
20 Marcel Dekker, NY, 1980.




2



d,1- $\alpha$ -Tocopherol 3 is obtained by reacting trimethylhydroquinone 4 with either phytol 5 or isophytol 6 in the presence of an acid catalyst, often a Lewis acid such as zinc chloride. This technology was reviewed by S. Kasperek in L. Machlin, ed., Vitamin E: A Comprehensive Treatise, chapter 2, pp. 8-65, Marcel Dekker, NY, 1965. References 140 - 166 of this chapter provide the primary references to detailed methods of preparing compound 3.

10



The isophytol 6 or phytol 5 required for the preparation of 3 are obtained through multistep synthesis. Starting materials typically include acetone (see Kasperek, in Machlin, Vitamin E: A Comprehensive Treatise, pp. 44-45, Dekker, NY 1980, and references cited therein) and cyclic

isoprene trimer (Pond et al., US 3,917,710 and 3,862,988 (1975)).

In addition, *gamma*-tocopherol was first made by total synthesis by Jacob, Steiger, Todd and Wilcox (J. Chem. Soc.  
5 1939, 542). These workers produced the vitamin by reacting the monobenzoate ester of 2,3-dimethylhydroquinone with phytyl bromide in the presence of zinc chloride, followed by removal of the benzoate to give a low yield (22%) of *gamma*-tocopherol. Published syntheses of the tocopherols  
10 and tocotrienols were reviewed by S. Kasperek in L. Machlin, "Vitamin E - A Comprehensive Treatise", Dekker, NY, 1980; however, no further methods of preparing *gamma*-tocopherol have been recorded.

Despite the various known methods for preparing or  
15 isolating members of the vitamin E family of compounds, there remains a need for improved and more efficient methods of production.

Vitamin A (retinol) and the provitamin A  $\beta$ -carotene are used in pharmaceuticals, food fortification and dietary  
20 supplements. Vitamin A acetate (retinyl acetate), propionate (retinyl propionate) and palmitate (retinyl palmitate) are the vitamin A derivatives most generally used. All of the vitamin A, vitamin A esters and  $\beta$ -carotene currently produced commercially are produced by  
25 total chemical synthesis, except for some vitamin A which is isolated from food sources. See generally Kirk-Othmer Encyclopedia of Chemical Technology, volume 24, pages 140-158 (3rd ed. 1984).

There remains a need for improved and economical methods of production of vitamin A and vitamin A esters.

#### BRIEF DESCRIPTION OF THE DRAWINGS

5        Fig. 1A illustrates a diagrammatic representation of the mevalonate-dependent isoprenoid biosynthetic pathway.

Fig. 1B illustrates a diagrammatic representation of the mevalonate-independent isoprenoid biosynthetic pathway.

10       Fig. 2 illustrates an embodiment of a route for chemical synthesis of vitamin E from geranylgeraniol.

Fig. 3 illustrates an embodiment of a route for chemical synthesis of vitamin E from farnesol.

Fig. 4 illustrates the growth and farnesol production of strains derived from strain MBNA1-13.

15       Fig. 5 illustrates the growth of wild-type, *erg9* and repaired *ERG9* strains.

Fig. 6 illustrates the production of farnesol in microorganisms with amplified production of HMG CoA reductase.

20       Fig. 7 illustrates the production of farnesol and GG in strains overexpressing GGPP synthases.

Fig. 8 illustrates the effect of amplified production of FPP synthase on farnesol and GG production.

25       Fig. 9 illustrates the pathway for metabolic conversion of isoprenol and prenol to farnesol.

Fig. 10 illustrates a chemical synthesis route for the production of vitamin A acetate from farnesol.

Fig. 11 illustrates an alternative chemical synthesis route for the production of vitamin A acetate from farnesol.

Fig. 12 illustrates a method for preparing  $\beta$ -carotene from retinal using a carbonyl coupling reaction.

5 Fig. 13 illustrates a method for preparing  $\beta$ -carotene using an alkylation reaction.

## DETAILED DESCRIPTION OF THE INVENTION

### 1.0 Introduction

10 The present invention provides a method for producing  $\alpha$ -tocopherol and  $\alpha$ -tocopheryl esters in which a biological system is used to produce farnesol or geranylgeraniol (GG). Farnesol can be used as a starting material to chemically synthesize the final product,  $\alpha$ -tocopheryl esters.

15 Alternatively, the farnesol can be converted chemically to GG. GG, produced biologically or by synthesis from farnesol, can then be used as a starting material to make  $\alpha$ -tocopheryl and  $\alpha$ -tocopheryl esters. The present invention also includes various aspects of biological

20 materials and intermediates useful in the production of farnesol or GG by biological production. The present invention also includes methods of producing  $\alpha$ -tocopherol and  $\alpha$ -tocopheryl esters using farnesol and/or GG produced by any means as the starting material.

25 The present invention is also directed to a method for producing vitamin A from farnesol. In a preferred embodiment, farnesol is produced biologically.

### 2.0 Biological Production of Farnesol and GG

Isoprenoids are the largest family of natural products, with about 22,000 different structures known. All isoprenoids are derived from the C<sub>5</sub> compound isopentylpyrophosphate (IPP). Thus, the carbon skeletons  
5 of all isoprenoid compounds are created by sequential additions of the C<sub>5</sub> units to the growing polyprenoid chain.

While the biosynthetic steps leading from IPP to isoprenoids are universal, two different pathways leading  
10 to IPP exist. Fungi (such as yeast) and animals possess the well known mevalonate-dependent pathway (depicted in Fig. 1A) which uses acetyl CoA as the initial precursor. Bacteria and higher plants, on the other hand, possess a newly discovered mevalonate independent pathway, also  
15 referred to herein as the non-mevalonate pathway, (depicted in Fig. 1B) leading from pyruvate and glyceraldehyde 3-phosphate [Lois et al., *Proc. Natl. Acad. Sci. USA*, **95**, 2105-2110 (1998); Rohmer et al., *J. Am. Chem. Soc.* **118**, 2564-2566 (1996); Arigoni, et al., *Proc. Natl. Acad. Sci.*  
20 *USA*, **94**, 10600-10605 (1997); Lange et al., *Proc. Natl. Acad. Sci. USA*, **95**, 2100-2104 (1998)]. In plants (including microalgae), there is evidence that both the mevalonate-dependent and -independent pathways exist, the former being cytosolic and the latter being plastidial  
25 [Arigoni, et al., *Proc. Natl. Acad. Sci. USA*, **94**, 10600-10605 (1997); Lange et al., *Proc. Natl. Acad. Sci. USA*, **95**, 2100-2104 (1998)]. Several steps of the mevalonate-independent pathway have been established. The first step, catalyzed by D-1-deoxyxylulose 5-phosphate synthase, forms

D-1-deoxyxylulose 5-phosphate from pyruvate and glyceraldehyde 3-phosphate. The second and third steps, catalyzed by D-1-deoxyxylulose 5-phosphate reductoisomerase, catalyze the conversion of D-1-deoxyxylulose 5-phosphate to 2-C-methyl D erythritol-4-P (MEP). Several further reactions are required to convert MEP to IPP, and these enzymes are unknown at this time [Lois et al., *Proc. Natl. Acad. Sci. USA*, **95**, 2105-2110 (1998); Takahashi et al., *Proc. Natl. Acad. Sci. USA*, **95**, 2100-2104 (1998); Duvold et al. *Tetrahedron Letters*, **38**, 4769-4772 (1997)].

Farnesol and GG are prenyl alcohols produced by dephosphorylation of farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), respectively. FPP and GGPP are intermediates in the biosynthesis of isoprenoid compounds, including sterols, ubiquinones, heme, dolichols, and carotenoids, and are used in the post-translational prenylation of proteins. Both FPP and GGPP are derived from IPP. Embodiments of the present invention include the biological production of farnesol or GG in prokaryotic or eukaryotic cell cultures and cell-free systems, irrespective of whether the organism utilizes the mevalonate-dependent or -independent pathway for the biosynthesis of the precursor of all isoprenoids, IPP. Reference herein to farnesyl phosphate or geranylgeranyl phosphate refers to the respective mono-, di- and tri-phosphate compounds, unless one specific form is specifically designated.

## 2.1 Modified Microorganism

Suitable biological systems for producing farnesol and GG include prokaryotic and eukaryotic cell cultures and cell-free systems. Preferred biological systems include fungal, bacterial and microalgal systems. More preferred biological systems are fungal cell cultures, more preferably a yeast cell culture, and most preferably a *Saccharomyces cerevisiae* cell culture. Fungi are preferred since they have a long history of use in industrial processes and can be manipulated by both classical microbiological and genetic engineering techniques. Yeast, in particular, are well-characterized genetically. Indeed, the entire genome of *S. cerevisiae* has been sequenced, and the genes coding for enzymes in the isoprenoid pathway have already been cloned. Also, *S. cerevisiae* grows to high cell densities, and amounts of squalene and ergosterol (see Fig. 1) up to 16% of cell dry weight have been reported in genetically-engineered strains. For a recent review of the isoprenoid pathway in yeast, see Parks and Casey, *Annu. Rev. Microbiol.* **49**:95-116 (1995).

The preferred prokaryote is *E. coli*. *E. coli* is well established as an industrial microorganism used in the production of metabolites (amino acids, vitamins) and several recombinant proteins. The entire *E. coli* genome has also been sequenced, and the genetic systems are highly developed. As mentioned above, *E. coli* uses the mevalonate-independent pathway for synthesis of IPP. The *E. coli* *dxs*, *dxr*, *idi*, and *ispA* genes, encoding D-1-deoxyxylulose 5-phosphate synthase, D-1-deoxyxylulose 5-



phosphate reductoisomerase, IPP isomerase, and FPP synthase, respectively, have been cloned and sequenced [Fujisaki, et. al, *J. Biochem.* **108**, 995-1000 (1990); Lois et al., *Proc. Natl. Acad. Sci. USA*, **95**, 2105-2110 (1998);  
5 Hemmi et al. , *J. Biochem.*, **123**, 1088-1096 (1998)].

Preferred microalga for use in the present invention include *Chlorella* and *Prototheca*.

Suitable organisms useful in producing farnesol and GG are available from numerous sources, such as the American  
10 Type Culture Collection (ATCC), Rockville, MD, Culture Collection of Algae (UTEX), Austin, TX, the Northern Regional Research Laboratory (NRRL), Peoria, IL and the *E. coli* Genetic Stock Center (CGSC), New Haven, CT. In particular, there are culture collections of *S. cerevisiae*  
15 that have been used to study the isoprenoid pathway which are available from, e.g., Jasper Rine at the University of California, Berkeley, CA and from Leo Parks at North Carolina State University, Raleigh, NC.

Preferably the cells used in the cell culture are  
20 genetically modified to increase the yield of farnesol or GG. Cells may be genetically modified by genetic engineering techniques (i.e., recombinant technology), classical microbiological techniques, or a combination of such techniques and can also include naturally occurring  
25 genetic variants. Some of such techniques are generally disclosed, for example, in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Labs Press. The reference Sambrook et al., *ibid.*, is incorporated by reference herein in its entirety. A

genetically modified microorganism can include a microorganism in which nucleic acid molecules have been inserted, deleted or modified (i.e., mutated; e.g., by insertion, deletion, substitution, and/or inversion of nucleotides), in such a manner that such modifications provide the desired effect of increased yields of farnesol or GG within the microorganism or in the culture supernatant. As used herein, genetic modifications which result in a decrease in gene expression, in the function of the gene, or in the function of the gene product (i.e., the protein encoded by the gene) can be referred to as inactivation (complete or partial), deletion, interruption, blockage or down-regulation of a gene. For example, a genetic modification in a gene which results in a decrease in the function of the protein encoded by such gene, can be the result of a complete deletion of the gene (i.e., the gene does not exist, and therefore the protein does not exist), a mutation in the gene which results in incomplete or no translation of the protein (e.g., the protein is not expressed), or a mutation in the gene which decreases or abolishes the natural function of the protein (e.g., a protein is expressed which has decreased or no enzymatic activity). Genetic modifications which result in an increase in gene expression or function can be referred to as amplification, overproduction, overexpression, activation, enhancement, addition, or up-regulation of a gene. Addition of cloned genes to increase gene expression can include maintaining the cloned gene(s) on replicating plasmids or integrating the cloned gene(s) into the genome

of the production organism. Furthermore, increasing the expression of desired cloned genes can include operatively linking the cloned gene(s) to native or heterologous transcriptional control elements.

5           2.1.1 Squalene Synthase Modifications

Embodiments of the present invention include biological production of farnesol or GG by culturing a microorganism, preferably yeast, which has been genetically modified to modulate the activity of one or more of the  
10 enzymes in its isoprenoid biosynthetic pathway. In one embodiment, a microorganism has been genetically modified by decreasing (including eliminating) the action of squalene synthase activity (see Fig. 1). For instance, yeast *erg9* mutants that are unable to convert mevalonate  
15 into squalene, and which accumulate farnesol, have been produced. Karst and Lacroute, *Molec. Gen. Genet.*, 154, 269-277 (1977); U.S. Patent No. 5,589,372. As used herein, reference to *erg9* mutant or mutation generally refers to a genetic modification that decreases the action of squalene  
20 synthase, such as by blocking or reducing the production of squalene synthase, reducing squalene synthase activity, or inhibiting the activity of squalene synthase, which results in the accumulation of farnesyl diphosphate (FPP) unless the FPP is otherwise converted to another compound, such as  
25 farnesol by phosphatase activity. Blocking or reducing the production of squalene synthase can include placing the *ERG9* gene under the control of a promoter that requires the presence of an inducing compound in the growth medium. By establishing conditions such that the inducer becomes

depleted from the medium, the expression of *ERG9* (and therefore, squalene synthase synthesis) could be turned off. Also, some promoters are turned off by the presence of a repressing compound. For example, the promoters from the yeast *CTR3* or *CTR1* genes can be repressed by addition of copper. Blocking or reducing the activity of squalene synthase could also include using an excision technology approach similar to that described in U.S. Patent No. 4,743,546, incorporated herein by reference. In this approach, the *ERG9* gene is cloned between specific genetic sequences that allow specific, controlled excision of the *ERG9* gene from the genome. Excision could be prompted by, for example, a shift in the cultivation temperature of the culture, as in U.S. Patent No. 4,743,546, or by some other physical or nutritional signal. Such a genetic modification includes any type of modification and specifically includes modifications made by recombinant technology and by classical mutagenesis. Inhibitors of squalene synthase are known (see U.S. Patent No. 4,871,721 and the references cited in U.S. Patent No. 5,475,029) and can be added to cell cultures. In another embodiment, an organism having the mevalonate-independent pathway of isoprenoid biosynthesis (such as *E. coli*) is genetically modified so that it accumulates FPP and/or farnesol. For example, decreasing the activity of octaprenyl pyrophosphate synthase (the product of the *ispB* gene) would be expected to result in FPP accumulation in *E. coli*. (Asai, et al., Biochem. Biophys. Res. Comm. 202, 340-345 (1994)). The

action of a phosphatase could further result in farnesol accumulation in *E. coli*.

Yeast strains need ergosterol for cell membrane fluidity, so mutants blocked in the ergosterol pathway, such as *erg9* mutants, need extraneous ergosterol or other sterols added to the medium for the cells to remain viable. The cells normally cannot utilize this additional sterol unless grown under anaerobic conditions. Therefore, a further embodiment of the present invention is the use of a yeast in which the action of squalene synthase is reduced, such as an *erg9* mutant, and which takes up exogenously supplied sterols under aerobic conditions. Genetic modifications which allow yeast to utilize sterols under aerobic conditions are demonstrated below in the Examples section (see Example 1) and are also known in the art. For example, such genetic modifications include *upc* (uptake control mutation which allows cells to take up sterols under aerobic conditions) and *hem1* (the *HEM1* gene encodes aminolevulinic acid synthase which is the first committed step to the heme biosynthetic pathway from FPP, and *hem1* mutants are capable of taking up ergosterol under aerobic conditions following a disruption in the ergosterol biosynthetic pathway, provided the cultures are supplemented with unsaturated fatty acids). Yeast strains having these mutations can be produced using known techniques and also are available from, e.g., Dr. Leo Parks, North Carolina State University, Raleigh, NC. Haploid cells containing these mutations can be used to generate other mutants by genetic crosses with other

haploid cells. Also, overexpression of the *SUT1* (sterol uptake) gene can be used to allow for uptake of sterols under aerobic conditions. The *SUT1* gene has been cloned and sequenced. Bourot and Karst, *Gene*, 165: 97-102 (1995).

5 In a further embodiment, microorganisms of the present invention can be used to produce farnesol and/or GG by culturing microorganisms in the presence of a squalene synthase inhibitor. In this manner, the action of squalene synthase is reduced. Squalene synthase inhibitors are  
10 known to those skilled in the art. (See, for example, U.S. Patent No. 5,556,990.

#### 2.1.2 HMG-CoA Reductase Modifications

A further embodiment of the present invention is the use of a microorganism which has been genetically modified  
15 to increase the action of HMG-CoA reductase. It should be noted that reference to increasing the action of HMG-CoA reductase and other enzymes discussed herein refers to any genetic modification in the microorganism in question which results in increased functionality of the enzymes and  
20 includes higher activity of the enzymes, reduced inhibition or degradation of the enzymes and overexpression of the enzymes. For example, gene copy number can be increased, expression levels can be increased by use of a promoter that gives higher levels of expression than that of the  
25 native promoter, or a gene can be altered by genetic engineering or classical mutagenesis to increase the activity of an enzyme. One of the key enzymes in the mevalonate-dependent isoprenoid biosynthetic pathway is HMG-CoA reductase which catalyzes the reduction of 3-

hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). This is the primary rate-limiting and first irreversible step in the pathway, and increasing HMG-CoA reductase activity leads to higher yields of squalene and ergosterol in a wild-type strain of *S. cerevisiae*, and farnesol in an *erg9* strain. One mechanism by which the action of HMG-CoA reductase can be increased is by reducing inhibition of the enzyme, by either genetically modifying the enzyme or by modifying the system to remove the inhibitor. For instance, both sterol and non-sterol products of the isoprenoid pathway feedback inhibit this enzyme (see, e.g., Parks and Casey, *Annu. Rev. Microbiol.* 49:95-116 (1995)). Alternatively or in addition, the gene(s) coding for HMG-CoA reductase can be altered by genetic engineering or classical mutagenesis techniques to decrease or prevent inhibition. Also, the action of HMG-CoA reductase can be increased by increasing the gene copy number, by increasing the level of expression of the HMG-CoA reductase gene(s), or by altering the HMG-CoA reductase gene(s) by genetic engineering or classical mutagenesis to increase the activity of the enzyme. See U.S. Patent No. 5,460,949, the entire contents of which are incorporated herein by reference. For example, truncated HMG-CoA reductases have been produced in which the regulatory domain has been removed and the use of gene copy numbers up to about six also gives increased activity. *Id.* See also, Downing et al., *Biochem. Biophys. Res. Commun.*, 94, 974-79 (1980) describing two yeast mutants having increased levels of HMG-CoA reductase. Two isozymes of HMGCoA reductase, encoded by the *HMG1* and *HMG2* genes, exist in *S.*

*cerevisiae*. The activity of these two isozymes is regulated by several mechanisms including regulation of transcription, regulation of translation, and for Hmg2p, degradation of the enzyme in the endoplasmic reticulum (Hampton and Rine, 1994; Donald, et. al. 1997). In both Hmg1p and Hmg2p, the catalytic domain resides in the COOH terminal portion of the enzyme, while the regulatory domain resides in the membrane spanning NH<sub>2</sub>-terminal region. It has been shown that overexpression of just the catalytic domain of Hmg1p in *S. cerevisiae* increases carbon flow through the isoprenoid pathway, resulting in overproduction of squalene (Saunders, et. al. 1995; Donald, et. al., 1997). The present inventors have expressed the catalytic domain of the *S. cerevisiae* Hmg2p in strains having a normal (i.e., unblocked) isoprenoid pathway and observed a significant increase in the production of squalene. Furthermore, overexpression of the catalytic domain of Hmg2p resulted in increased farnesol production in an *erg9* mutant, and increased farnesol and GG production in an *erg9* mutant overexpressing GGPP synthase, grown in fermentors.

### 2.1.3 GGPP Synthase Modifications

A further embodiment of the present invention is the use of a microorganism which has been genetically modified to increase the action of GGPP synthase. Genes coding for this enzyme from a variety of sources, including bacteria, fungi, plants, mammals, and archaeobacteria, have been identified. See, Brinkhaus et al., *Arch. Biochem. Biophys.*, 266, 607-612 (1988); Carattoli et al., *J. Biol.*



Chem., 266, 5854-59 (1991); Chen et al., *J. Biol. Chem.*, 268, 11002-11007 (1993); Dogbo et al., *Biochim. Biophys. Acta*, 920, 140-148 (1987); Jiang et al., *J. Biol. Chem.*, 270, 21793-99 (1995); Kuntz et al., *Plant J.*, 2, 25-34 (1992);

5 Laferriere, et al., *Biochim. Biophys. Acta*, 1077, 167-72 (1991); Math et al., *Proc. Natl. Acad. Sci. USA*, 89, 6761-64 (1992); Ohnuma et al., *J. Biol. Chem.*, 269, 14792-97 (1994); Sagami et al., *Arch. Biochem. Biophys.*, 297, 314-20 (1992); Sagami et al., *J. Biol. Chem.*, 269, 20561-66

10 (1994); Sandmann et al., *J. Photochem. Photobiol. B: Biol.*, 18, 245-51 (1993); Scolnik et al., *Plant Physiol.*, 104, 1469-70 (1994); Tachibana et al., *Biosci. Biotech. Biochem.*, 7, 1129-33 (1993); Tachibana et al., *J. Biochem.*, 114, 389-92 (1993); Wiedemann et al., *Arch. Biochem. Biophys.*, 306, 152-57 (1993).

15 Some organisms have a bifunctional enzyme which also serves as an FPP synthase, so it is involved in the overall conversion of IPP and DMAPP to FPP to GGPP (see Fig. 1). Some enzymes, such as those found in plants, have relaxed specificity, converting

20 IPP and DMAPP to GGPP (see Fig. 1). Genetic modifications of GGPP synthase, as used herein, encompass engineering a bifunctional FPP/GGPP synthase to enhance the GGPP synthase activity component of the enzyme. A preferred GGPP synthase gene is the *BTS1* gene from *S. cerevisiae*. The *BTS1*

25 gene and its isolation are described in Jiang et al., *J. Biol. Chem.*, 270, 21793-99 (1995) and copending application Serial No. 08/761,344, filed on December 6, 1996, the complete disclosure of which incorporated herein by

reference. However, GGPP synthases of other hosts can be used, and the use of the bifunctional GGPP synthases may be particularly advantageous in terms of channeling carbon flow through FPP to GGPP, thereby avoiding loss of FPP to competing reactions in the cell.

In further embodiments of the invention, in addition to the modifications of GGPP synthase described above, the wild type GGPP synthase is eliminated from the production organism. This would serve, for example, to eliminate competition between the modified GGPP synthase and the wild type enzyme for the substrates, FPP and IPP. Deletion of the wild-type gene encoding GGPP synthase could also improve the stability of the cloned GGPP synthase gene by removing regions of high genetic sequence homology, thereby avoiding potentially detrimental genetic recombination.

#### 2.1.4 FPP Synthase Modifications

A further embodiment of the present invention is the use of a microorganism which has been genetically modified to increase the action of FPP synthase .

Genes coding for this enzyme from a variety of sources have been identified. See, Anderson et al., *J. Biol. Chem.*, **264**, 19176-19184 (1989); Attucci, et al., *Arch. Biochem. Biophys.*, **321**, 493-500 (1995); Cane et al., *J. Am. Chem. Soc.*, **105**, 122-124 (1983); Chambon et al., *Current Genetics*, **18**, 41-46 (1990);, Chambon et al., *Lipids*, **26**, 633-36 (1991); Chen al., *Protein Science*, **3**, 600-607 (1994); Davisson, et al., *J. Am. Chem. Soc.*, **115**, 1235-45 (1993); Ding et al., *Biochem. J.*, **275**, 61-65 (1991); Hugueney et al., *FEBS Letters*, **273**, 235-38 (1990); Joly et

al., *J. Biol. Chem.*, **268**, 26983-89 (1993); Koyama al., *J. Biochem.*, **113**, 355-63 (1993); Sheares, et al., *Biochem.*, **28**, 8129-35 (1989); Song et al., *Proc. Natl. Acad. Sci. USA*, **91**, 3044-48 (1994); Spear et al., *J. Biol. Chem.*, **267**,  
5 14662-69 (1992); Spear et al., *J. Biol. Chem.*, **269**, 25212-18 (1994). Anderson et al., *J. Biol. Chem.*, **264**, 19176-19184 (1989) reported a 2-3 fold overexpression of FPP synthase with the *S. cerevisiae* gene in a yeast shuttle vector.

10 As described in the Examples section, it has been surprisingly found that overexpression of FPP synthase did not lead to an increase in farnesol production, but unexpectedly lead to an increase in the production of GG in the absence of any overexpression of GGPP synthase.

15 In further embodiments of the invention, in addition to the modifications of FPP synthase described above, the wild type FPP synthase is eliminated from the production organism. This would serve, for example, to eliminate competition between the modified FPP synthase and the wild  
20 type enzyme for the substrates, IPP, DMAPP and GPP. Deletion of the wild-type gene encoding FPP synthase could also improve the stability of the cloned FPP synthase gene by removing regions of high genetic sequence homology, thereby avoiding potentially detrimental genetic  
25 recombination.

#### 2.1.5 Phosphatase Modifications

A further embodiment of the present invention is the use of a microorganism which has been genetically modified to increase phosphatase action to increase conversion of

FPP to farnesol or GGPP to GG. For example, both *S. cerevisiae* and *E. coli* contain numerous phosphatase activities. By testing several phosphatases for efficient dephosphorylation of FPP or GGPP, one could select an appropriate phosphatase and express the gene encoding this enzyme in a production organism to enhance farnesol or GG production. In addition to (or instead of) increasing the action of a desired phosphatase to enhance farnesol or GG production, one could eliminate, through genetic means, undesirable phosphatase activities. For example, one could eliminate through mutation the activity of a phosphatase that specifically acts on FPP, so that the FPP that was spared would be available for conversion to GGPP and subsequently GG.

#### 2.1.6 Additional Genetic Modifications.

##### Modifications of Other Isoprenoid Pathway Enzymes.

Modifications that can be made to increase the action of HMGCoA reductase, GGPP synthase and phosphatases are described above. Modification of the action of isoprenoid pathway enzymes is not limited to those specific examples, and similar strategies can be applied to modify the action of other isoprenoid pathway enzymes such as acetoacetyl Co-A thiolase, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, IPP isomerase, farnesyl pyrophosphate synthase or D-1-deoxyxylulose 5-phosphate synthase D-1-deoxyxylulose 5-phosphate reductoisomerase.

Engineering of Central Metabolism to Increase Precursor Supply to the Isoprenoid Pathway. In organisms

having the mevalonate-dependent isoprenoid pathway, the biosynthesis of farnesol or GG begins with acetyl CoA (refer to Figure 1). One embodiment of the present invention is genetic modification of the production organism such that the intracellular level of acetyl CoA is increased, thereby making more acetyl CoA available for direction to the isoprenoid pathway (and hence to farnesol and/or GG). For example, the supply to acetyl CoA can be increased by increasing the action of the pyruvate dehydrogenase complex. The supply of acetyl CoA can be further increased by increasing the level of pyruvate in the cell by increasing the action of pyruvate kinase. In organisms having the mevalonate-independent isoprenoid pathway, the biosynthesis of isoprenoids begins with pyruvate and glyceraldehyde 3-phosphate. The supply of pyruvate and glyceraldehyde 3-phosphate available for isoprenoid biosynthesis can be increased by increasing the action of pyruvate kinase and triphosphate isomerase, respectively.

The examples above are provided only to illustrate the concept of engineering central metabolism for the purpose of increasing production of isoprenoid compounds, and are not an exhaustive list of approaches that can be taken. Numerous other strategies could be successfully applied to achieve this goal.

Blocking Pathways that Compete for FPP or GGPP. In yeast, FPP is a branch point intermediate leading to the biosynthesis of sterols, heme, dolichol, ubiquinone, GGPP and farnesylated proteins. In *E. coli*, FPP serves as the

substrate for octaprenyl pyrophosphate synthase in the pathway leading to ubiquinone. In bacteria that synthesize carotenoids, such as *Erwinia uredovora*, FPP is converted to GGPP by GGPP synthase in the first step leading to the carotenoids. To increase the production of farnesol or GG, it is desirable to inactivate genes encoding enzymes that use FPP or GGPP as substrate, or to reduce the activity of the enzymes themselves, either through mutation or the use of specific enzyme inhibitors (as was discussed above for squalene synthase). In *S. cerevisiae*, for example, it may be advantageous to inactivate the first step in the pathway from FPP to heme, in addition to inactivating *ERG9*. As discussed earlier, in *E. coli*, partial or complete inactivation of the octaprenyl pyrophosphate synthase could increase the availability of FPP for conversion of farnesol. Finally, in bacteria that produce carotenoids, such as *Erwinia uredovora*, elimination of GGPP synthase can increase the level of FPP for conversion of farnesol, while inactivating or reducing the activity of phytoene synthase (the *crtB* gene product) can increase the level of GGPP available for conversion to GG.

It is possible that blocking pathways leading away from FPP or GGPP could have negative effects on the growth and physiology of the production organism. It is further contemplated that additional genetic modifications required to offset these complications can be made. The isolation of mutants of *S. cerevisiae* that are blocked in the isoprenoid pathway and take up sterols under aerobic conditions, as described above, illustrates that

compensating mutations can be obtained that overcome the effects of the primary genetic modifications.

Isolation of Production Strains that are Resistant to Farnesol or GG. In the Examples section, production of high levels of farnesol and GG by genetically modified strains of *S. cerevisiae* is described. It is recognized that as further increases in farnesol or GG production are made, these compounds may reach levels that are toxic to the production organism. Indeed, product toxicity is a common problem encountered in biological production processes. However, just as common are the genetic modifications made by classical methods or recombinant technology that overcome product toxicity. The present invention anticipates encountering product toxicity. Thus a further embodiment of this invention is the isolation of mutants with increased resistance to farnesol and/or GG.

Isolation of Production Organisms with Improved Growth Properties. One effect of blocking the isoprenoid pathway in *S. cerevisiae* is that the mutant organisms (in the present invention, *erg9* mutants) grow more slowly than their parent (unblocked) strains, despite the addition of ergosterol to the culture medium. That the slower growth of the *erg9* mutants is due to the block at *erg9* is illustrated in Example 1.G, which shows that repairing the *erg9* mutation restores the growth rate of the strain to about that of the wild-type parent. The slower growth of the *erg9* mutants could be due to differences related to growing on exogenously supplied ergosterol vs. ergosterol synthesized in the cell, or could be due to other

physiological factors. One embodiment of the present invention is to isolate variants of the farnesol or GG producing strains with improved growth properties. This could be achieved, for example by continuous culture, selecting for faster growing variants. Such variants could occur spontaneously or could be obtained by classical mutagenesis or molecular genetic approaches.

## 2.2 Incorporation of Prenol and Isoprenol

In a further embodiment of the present invention, farnesol or GG is produced by the introduction of isoprenol and/or prenol into a fermentation medium. With reference to Fig. 9, each of these compounds, when taken up by an organism is phosphorylated with a pyrophosphate group to form, respectively, 3-isopentenyl pyrophosphate and 3,3-dimethylallyl pyrophosphate. These two compounds interconvert by the action of isopentenyl pyrophosphate isomerase. These compounds are then converted to farnesyl pyrophosphate by the action of FPP synthase. Farnesol is formed by dephosphorylation of farnesyl pyrophosphate. Farnesyl pyrophosphate can be further converted to geranylgeranyl pyrophosphate. Geranylgeraniol is formed by dephosphorylation of geranylgeranyl pyrophosphate. GG would be formed from FPP by the combined action of GGPP synthase and a phosphatase. Isoprenol and prenol are commercially available compounds and can be produced by methods known in the art

In this embodiment, the microorganism used in the fermentation can be any microorganism as described elsewhere herein. In addition, the microorganism can be



genetically modified to increase the action of dimethylallyl transferase to promote the production of geranyl pyrophosphate and farnesol pyrophosphate. Genes coding for this enzyme from a variety of sources have been identified [Chen et al., *Protein Sci.*, 3, 600-607 (1994)]. In addition a microorganism can be genetically modified to increase the action of isoprenol kinase or prenil kinase. Although these enzymes have not been discovered, similar enzymes that phosphorylate farnesol and geranylgeraniol have been described [Bentinger et al., *Arch. Biochem. Biophys.*, 353, 191-198 (1998); Ohnuma et al., *J. Biochem.*, 119, 541-547 (1996)].

### 2.3 Fermentation Media and Conditions

In the method for production of farnesol or GG, a microorganism having a genetically modification, as discussed above is cultured in a fermentation medium for production of farnesol or GG. An appropriate, or effective, fermentation medium refers to any medium in which a genetically modified microorganism of the present invention, when cultured, is capable of producing farnesol or GG. Such a medium is typically an aqueous medium comprising assimilable carbon, nitrogen and phosphate sources. Such a medium can also include appropriate salts, minerals, metals and other nutrients. In addition, when an organism which is blocked in the ergosterol pathway and requires exogenous sterols, the fermentation medium must contain such exogenous sterols. Appropriate exemplary media are shown in the discussion below and in the Examples section. It should be recognized, however, that a variety

of fermentation conditions are suitable and can be selected by those skilled in the art.

Sources of assimilable carbon which can be used in a suitable fermentation medium include, but are not limited to, sugars and their polymers, including, dextrin, sucrose, maltose, lactose, glucose, fructose, mannose, sorbose, arabinose and xylose; fatty acids; organic acids such as acetate; primary alcohols such as ethanol and n-propanol; and polyalcohols such as glycerine. Preferred carbon sources in the present invention include monosaccharides, disaccharides, and trisaccharides. The most preferred carbon source is glucose.

The concentration of a carbon source, such as glucose, in the fermentation medium should promote cell growth, but not be so high as to repress growth of the microorganism used. Typically, fermentations are run with a carbon source, such as glucose, being added at levels to achieve the desired level of growth and biomass, but at undetectable levels (with detection limits being about <0.1g/l). In other embodiments, the concentration of a carbon source, such as glucose, in the fermentation medium is greater than about 1 g/L, preferably greater than about 2 g/L, and more preferably greater than about 5 g/L. In addition, the concentration of a carbon source, such as glucose, in the fermentation medium is typically less than about 100 g/L, preferably less than about 50 g/L, and more preferably less than about 20 g/L. It should be noted that references to fermentation component concentrations can refer to both initial and/or ongoing component

concentrations. In some cases, it may be desirable to allow the fermentation medium to become depleted of a carbon source during fermentation.

Sources of assimilable nitrogen which can be used in a suitable fermentation medium include, but are not limited to, simple nitrogen sources, organic nitrogen sources and complex nitrogen sources. Such nitrogen sources include anhydrous ammonia, ammonium salts and substances of animal, vegetable and/or microbial origin. Suitable nitrogen sources include, but are not limited to, protein hydrolysates, microbial biomass hydrolysates, peptone, yeast extract, ammonium sulfate, urea, and amino acids. Typically, the concentration of the nitrogen sources, in the fermentation medium is greater than about 0.1 g/L, preferably greater than about 0.25 g/L, and more preferably greater than about 1.0 g/L. Beyond certain concentrations, however, the addition of a nitrogen source to the fermentation medium is not advantageous for the growth of the microorganisms. As a result, the concentration of the nitrogen sources, in the fermentation medium is less than about 20 g/L, preferably less than about 10 g/L and more preferably less than about 5 g/L. Further, in some instances it may be desirable to allow the fermentation medium to become depleted of the nitrogen sources during fermentation.

The effective fermentation medium can contain other compounds such as inorganic salts, vitamins, trace metals or growth promoters. Such other compounds can also be present in carbon, nitrogen or mineral sources in the

effective medium or can be added specifically to the medium.

The fermentation medium can also contain a suitable phosphate source. Such phosphate sources include both  
5 inorganic and organic phosphate sources. Preferred phosphate sources include, but are not limited to, phosphate salts such as mono or dibasic sodium and potassium phosphates, ammonium phosphate and mixtures thereof. Typically, the concentration of phosphate in the  
10 fermentation medium is greater than about 1.0 g/L, preferably greater than about 2.0 g/L and more preferably greater than about 5.0 g/L. Beyond certain concentrations, however, the addition of phosphate to the fermentation medium is not advantageous for the growth of the  
15 microorganisms. Accordingly, the concentration of phosphate in the fermentation medium is typically less than about 20 g/L, preferably less than about 15 g/L and more preferably less than about 10 g/L.

A suitable fermentation medium can also include a  
20 source of magnesium, preferably in the form of a physiologically acceptable salt, such as magnesium sulfate heptahydrate, although other magnesium sources in concentrations which contribute similar amounts of magnesium can be used. Typically, the concentration of  
25 magnesium in the fermentation medium is greater than about 0.5 g/L, preferably greater than about 1.0 g/L, and more preferably greater than about 2.0 g/L. Beyond certain concentrations, however, the addition of magnesium to the fermentation medium is not advantageous for the growth of

the microorganisms. Accordingly, the concentration of magnesium in the fermentation medium is typically less than about 10 g/L, preferably less than about 5 g/L, and more preferably less than about 3 g/L. Further, in some instances it may be desirable to allow the fermentation medium to become depleted of a magnesium source during fermentation.

The fermentation medium can also include a biologically acceptable chelating agent, such as the dihydrate of trisodium citrate. In such instance, the concentration of a chelating agent in the fermentation medium is greater than about 0.2 g/L, preferably greater than about 0.5 g/L, and more preferably greater than about 1 g/L. Beyond certain concentrations, however, the addition of a chelating agent to the fermentation medium is not advantageous for the growth of the microorganisms. Accordingly, the concentration of a chelating agent in the fermentation medium is typically less than about 10 g/L, preferably less than about 5 g/L, and more preferably less than about 2 g/L.

The fermentation medium can also initially include a biologically acceptable acid or base to maintain the desired pH of the fermentation medium. Biologically acceptable acids include, but are not limited to, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and mixtures thereof. Biologically acceptable bases include, but are not limited to, ammonium hydroxide, sodium hydroxide, potassium hydroxide and mixtures thereof. In a

preferred embodiment of the present invention, the base used is ammonium hydroxide .

The fermentation medium can also include a biologically acceptable calcium source, including, but not  
5 limited to, calcium chloride. Typically, the concentration of the calcium source, such as calcium chloride, dihydrate, in the fermentation medium is within the range of from about 5 mg/L to about 2000 mg/L, preferably within the range of from about 20 mg/L to about 1000 mg/L, and more  
10 preferably in the range of from about 50 mg/L to about 500 mg/L.

The fermentation medium can also include sodium chloride. Typically, the concentration of sodium chloride in the fermentation medium is within the range of from  
15 about 0.1 g/L to about 5 g/L, preferably within the range of from about 1 g/L to about 4 g/L, and more preferably in the range of from about 2 g/L to about 4 g/L.

As previously discussed, the fermentation medium can  
20 also include trace metals. Such trace metals can be added to the fermentation medium as a stock solution that, for convenience, can be prepared separately from the rest of the fermentation medium. A suitable trace metals stock solution for use in the fermentation medium is shown below  
25 in Table 1. Typically, the amount of such a trace metals solution added to the fermentation medium is greater than about 1 ml/L, preferably greater than about 5 mL/L, and more preferably greater than about 10 mL/L. Beyond certain concentrations, however, the addition of a trace metals to

the fermentation medium is not advantageous for the growth of the microorganisms. Accordingly, the amount of such a trace metals solution added to the fermentation medium is typically less than about 100 mL/L, preferably less than about 50 mL/L, and more preferably less than about 30 mL/L. It should be noted that, in addition to adding trace metals in a stock solution, the individual components can be added separately, each within ranges corresponding independently to the amounts of the components dictated by the above ranges of the trace metals solution.

As shown below in Table 1, a suitable trace metals solution for use in the present invention can include, but is not limited to ferrous sulfate, heptahydrate; cupric sulfate, pentahydrate; zinc sulfate, heptahydrate; sodium molybdate, dihydrate; cobaltous chloride, hexahydrate; and manganous sulfate, monohydrate. Hydrochloric acid is added to the stock solution to keep the trace metal salts in solution.

20

TABLE 1

TRACE METALS STOCK SOLUTION

COMPOUND	CONCENTRATION (mg/L)
Ferrous sulfate heptahydrate	280
Cupric sulfate, pentahydrate	80
Zinc (II) sulfate, heptahydrate	290
Sodium molybdate, dihydrate	240
Cobaltous chloride, hexahydrate	240
Manganous sulfate, monohydrate	170
Hydrochloric acid	0.1 ml

The fermentation medium can also include vitamins. Such vitamins can be added to the fermentation medium as a stock solution that, for convenience, can be prepared separately from the rest of the fermentation medium. A  
5 suitable vitamin stock solution for use in the fermentation medium is shown below in Table 2. Typically, the amount of such vitamin solution added to the fermentation medium is greater than 1 ml/L, preferably greater than 5 ml/L and more preferably greater than 10 ml/L. Beyond certain  
10 concentrations, however, the addition of vitamins to the fermentation medium is not advantageous for the growth of the microorganisms. Accordingly, the amount of such a vitamin solution added to the fermentation medium is typically less than about 50 ml/L, preferably less than 30  
15 ml/L and more preferably less than 20 ml/L. It should be noted that, in addition to adding vitamins in a stock solution, the individual components can be added separately each within the ranges corresponding independently to the amounts of the components dictated by the above ranges of  
20 the vitamin stock solution.

As shown in Table 2, a suitable vitamin solution for use in the present invention can include, but is not limited to, biotin, calcium pantothenate, inositol, pyridoxine-HCl and thiamine-HCl.



Table 2

5	COMPOUND	CONCENTRATION (mg/L)
	Biotin	10
	Calcium pantothenate	120
	Inositol	600
	Pyridoxine-HCl	120
	Thiamine-HCl	120

As stated above, when an organism is blocked in the sterol pathway, an exogenous sterol must be added to the fermentation medium. Such sterols include, but are not limited to, ergosterol and cholesterol. Such sterols can be added to the fermentation medium as a stock solution that is prepared separately from the rest of the fermentation medium. Sterol stock solutions can be prepared using a detergent to aid in solubilization of the sterol. A typical ergosterol stock solution is described in Example 1.D. Typically, an amount of sterol stock solution is added to the fermentation medium such that the final concentration of the sterol in the fermentation medium is within the range of from about 1 mg/L to 3000 mg/L, preferably within the range from about 2 mg/L to 2000 mg/L, and more preferably within the range from about 5 mg/L to 2000 mg/L.

Microorganisms of the present invention can be cultured in conventional fermentation modes, which include, but are not limited to, batch, fed-batch, cell recycle, and continuous. It is preferred, however, that the

fermentation be carried out in fed-batch mode. In such a case, during fermentation some of the components of the medium are depleted. It is possible to initiate the fermentation with relatively high concentrations of such components so that growth is supported for a period of time before additions are required. The preferred ranges of these components are maintained throughout the fermentation by making additions as levels are depleted by fermentation. Levels of components in the fermentation medium can be monitored by, for example, sampling the fermentation medium periodically and assaying for concentrations. Alternatively, once a standard fermentation procedure is developed, additions can be made at timed intervals corresponding to known levels at particular times throughout the fermentation. As will be recognized by those in the art, the rate of consumption of nutrient increases during fermentation as the cell density of the medium increases. Moreover, to avoid introduction of foreign microorganisms into the fermentation medium, addition is performed using aseptic addition methods, as are known in the art. In addition, a small amount of anti-foaming agent may be added during the fermentation.

The temperature of the fermentation medium can be any temperature suitable for growth and production of farnesol or GG. For example, prior to inoculation of the fermentation medium with an inoculum, the fermentation

medium can be brought to and maintained at a temperature in the range of from about 20°C to about 45°C, preferably to a temperature in the range of from about 25°C to about 40°C, and more preferably in the range of from about 28°C to about 32°C.

The pH of the fermentation medium can be controlled by the addition of acid or base to the fermentation medium. In such cases when ammonia is used to control pH, it also conveniently serves as a nitrogen source in the fermentation medium. Preferably, the pH is maintained from about 3.0 to about 8.0, more preferably from about 3.5 to about 7.0, and most preferably from about 4.0 to about 6.5.

The fermentation medium can also be maintained to have a dissolved oxygen content during the course of fermentation to maintain cell growth and to maintain cell metabolism for production of farnesol or GG. The oxygen concentration of the fermentation medium can be monitored using known methods, such as through the use of an oxygen electrode. Oxygen can be added to the fermentation medium using methods known in the art, for , through agitation and aeration of the medium by stirring, shaking or sparging. Preferably, the oxygen concentration in the fermentation medium is in the range of from about 20% to about 100% of the saturation value of oxygen in the medium based upon the solubility of oxygen in the fermentation medium at atmospheric pressure and at a temperature in the range of

from about 20°C to about 40°C. Periodic drops in the oxygen concentration below this range may occur during fermentation, however, without adversely affecting the fermentation.

- 5        Although aeration of the medium has been described herein in relation to the use of air, other sources of oxygen can be used. Particularly useful is the use of an aerating gas which contains a volume fraction of oxygen greater than the volume fraction of oxygen in ambient air.
- 10      In addition, such aerating gases can include other gases which do not negatively affect the fermentation.

         In an embodiment of the fermentation process of the present invention, a fermentation medium is prepared as described above and in Example 1.H. This fermentation

15      medium is inoculated with an actively growing culture of microorganisms of the present invention in an amount sufficient to produce, after a reasonable growth period, a high cell density. Typical inoculation cell densities are within the range of from about 0.01 g/L to about 10 g/L,

20      preferably from about 0.2 g/L to about 5 g/L and more preferably from about 0.05 g/L to about 1.0 g/L, based on the dry weight of the cells. In production scale fermentors, however, greater inoculum cell densities are preferred. The cells are then grown to a cell density in

25      the range of from about 10 g/L to about 100 g/L preferably from about 20 g/L to about 80 g/L, and more preferably from

about 50 g/L to about 70 g/L. The residence times for the microorganisms to reach the desired cell densities during fermentation are typically less than about 200 hours, preferably less than about 120 hours, and more preferably  
5 less than about 96 hours.

In one mode of operation of the present invention, the carbon source concentration, such as the glucose concentration, of the fermentation medium is monitored during fermentation. Glucose concentration of the  
10 fermentation medium can be monitored using known techniques, such as, for example, use of the glucose oxidase enzyme test or high pressure liquid chromatography, which can be used to monitor glucose concentration in the supernatant, e.g., a cell-free component of the  
15 fermentation medium. As stated previously, the carbon source concentration should be kept below the level at which cell growth inhibition occurs. Although such concentration may vary from organism to organism, for glucose as a carbon source, cell growth inhibition occurs  
20 at glucose concentrations greater than at about 60 g/L, and can be determined readily by trial. Accordingly, when glucose is used as a carbon source the glucose is preferably fed to the fermentor and maintained below detection limits. Alternatively, the glucose concentration  
25 in the fermentation medium is maintained in the range of from about 1 g/L to about 100 g/L, more preferably in the

range of from about 2 g/L to about 50 g/L, and yet more preferably in the range of from about 5 g/L to about 20 g/L. Although the carbon source concentration can be maintained within desired levels by addition of, for example, a substantially pure glucose solution, it is acceptable, and may be preferred, to maintain the carbon source concentration of the fermentation medium by addition of aliquots of the original fermentation medium. The use of aliquots of the original fermentation medium may be desirable because the concentrations of other nutrients in the medium (e.g. the nitrogen and phosphate sources) can be maintained simultaneously. Likewise, the trace metals concentrations can be maintained in the fermentation medium by addition of aliquots of the trace metals solution.

#### 2.4 Farnesol and GG Recovery

Once farnesol or GG are produced by a biological system, they are recovered or isolated for subsequent chemical conversion to  $\alpha$ -tocopherol or  $\alpha$ -tocopheryl esters. The present inventors have shown that for both farnesol and GG, the product may be present in culture supernatants and/or associated with the yeast cells. With respect to the cells, the recovery of farnesol or GG includes some method of permeabilizing or lysing the cells. The farnesol or GG in the culture can be recovered using a recovery process including, but not limited to, chromatography, extraction, solvent extraction, membrane

separation, electrodialysis, reverse osmosis, distillation, chemical derivatization and crystallization. When the product is in the phosphate form, i.e., farnesyl phosphate or geranylgeranyl phosphate, it only occurs inside of cells and therefore, requires some method of permeabilizing or lysing the cells.

### 3.0 Chemical Synthesis of GG and Farnesol

#### 3.1 Chemical Synthesis of GG

As noted above, in one embodiment of the invention, GG is produced biologically, and in alternate embodiments, GG can be produced by other methods. For example, GG can also be produced from farnesol by chemical synthesis. Many suitable methods are known in the art. In one such method, farnesol is converted to farnesyl bromide (PBr, in ether) and subjected to displacement with ethyl acetoacetate. The resulting crude keto ester is saponified, decarboxylated, and the resulting ketone purified by distillation. Following the procedure of Klinge and Demuth (*Synlett* 1993, 783), the ketone is subjected to Wittig-Horner reaction with diisopropyl ethylphosphonoacetate (NaH, glyme) to give an approximately 80/20 mixture of t,t,t- and t,t,c-ethyl geranylgeranoate. Reduction of ethyl geranylgeranoate with diisobutylaluminum hydride provides GG cleanly. The t,t,t- and t,t,c- mixture can be separated at the ester (e.g., by distillation) or alcohol (e.g., by crystallization as described in EP

711749) oxidation level. The production of farnesol as a starting material for the chemical production of GG can be accomplished by biological production, such as by use of a modified microorganism having some of the modified characteristics described above.

### 3.2 Chemical Synthesis of Farnesol

As noted above, in one embodiment of the invention, farnesol is produced biologically, and in alternate embodiments, farnesol can be produced by other methods. For example, farnesol can also be produced by chemical synthesis. Many suitable methods are known in the art.

### 4.0 Production of Tocopherol from GG by Chemical Synthesis

In a further embodiment of the present invention, a method for producing vitamin E from geranylgeraniol is provided. Geranylgeraniol contains four olefin moieties. As used in this invention, the olefin moieties of geranylgeraniol are consecutively numbered starting from the hydroxy terminus, i.e., the first olefin moiety refers to C<sub>2</sub>-C<sub>3</sub> double bond, the second olefin moiety refers to C<sub>6</sub>-C<sub>7</sub> double bond, the third olefin moiety refers to C<sub>10</sub>-C<sub>11</sub> double bond and the fourth olefin moiety refers to C<sub>14</sub>-C<sub>15</sub> double bond.

The method of the present invention involves reducing at least one olefin moiety of geranylgeraniol to form an allylic alcohol. Preferably the allylic alcohol is phytol and/or isophytol. The formation of the allylic alcohol can



be achieved by a selective reduction of olefins which reduces at least one of the second, third or fourth olefin moieties without reducing the first olefin moiety. Preferably the reduction reduces all olefin moieties except  
5 the first olefin moiety. The reduction of an olefin moiety can be accomplished by any of the known alkene reduction conditions including diimide reduction; dissolving metal reduction; metal hydride reduction; and hydrogenation in the presence of a metal catalyst such as palladium,  
10 rhodium, nickel, platinum, ruthenium, copper, chromium or a combination thereof. Preferably, the second, third and fourth olefin moieties are reduced by hydrogenation.

If an enantiomerically enriched or enantiomerically pure vitamin E synthesis is desired, one can effect the  
15 reduction of olefin moiety using an asymmetric catalyst such as those known in the art for asymmetric hydrogenation reactions. Alternatively, a racemic mixture of allylic alcohol can be produced and subjected to a chiral separation to provide a desired stereo isomer of the  
20 allylic alcohol.

In one embodiment of the present invention, a protecting group is added to geranylgeraniol prior to reducing the second, third and/or fourth olefin moieties. As used in this invention, a protecting group refers to any  
25 compound which can be added to (or combined with) geranylgeraniol prior to reduction of one or more olefin

moieties and removed after the reduction to provide an allylic alcohol from geranylgeraniol. Preferably, the protecting group is a hydroxy protecting group. The hydroxy protecting group is selected such that reduction of the second, third and fourth olefin moieties can be achieved selectively without reducing the first olefin moiety. A variety of hydroxy protecting groups known in the art may be employed. Examples of many of these possible groups can be found in "Protective Groups in Organic Synthesis" by T.W. Green, John Wiley and Sons, 1981, pp. 10-86, which is incorporated herein by reference in its entirety. Preferably, the hydroxy protecting group is an ester. More preferably, the ester is a sterically hindered (*i.e.*, bulky) ester which provides a sufficient protection of C<sub>2</sub>-C<sub>3</sub> olefin moiety from being reduced under the conditions of reducing geranylgeraniol to a protected allylic alcohol. Exemplary bulky ester groups include isobutyrate and pivaloate.


Vitamin E is formed from the allylic alcohol and a hydroquinone. Preferably, the hydroquinone is a trimethyl hydroquinone, more preferably, the hydroquinone is 2,3,5-trimethyl hydroquinone. It should be appreciated that a formation of compounds related to vitamin E (*i.e.*,  $\alpha$ -tocopherol) can be achieved using a corresponding hydroquinone for a particular tocopherol derivative. For example,  $\beta$ -,  $\gamma$ -, and  $\delta$ -tocopherol can be synthesized from

the allylic alcohol and 2,5-dimethyl hydroquinone, 2,3-dimethyl hydroquinone and 2-methyl hydroquinone, respectively. Without being bound by any theory, it is believed that contacting the allylic alcohol with an acid generates a carbonium ion which reacts with the hydroquinone to form vitamin E. A similar carbonium ion can be generated from a halogen derivative of phytol. For example, contacting a halogenated phytane such as bromo-, chloro- or iodophytane with a Lewis acid such as zinc halide including zinc bromide, zinc chloride and zinc iodide; aluminum halide including aluminum bromide and aluminum chloride; boron halide including boron trichloride and boron trifluoride; silver halide including silver chloride, silver bromide and silver iodide; nickel halide such as nickel chloride and nickel bromide; and other metal halide Lewis acids can generate carbonium ions which can react with a hydroquinone to form vitamin E.

Fig. 2 illustrates a particularly preferred embodiment of vitamin E synthesis from geranylgeraniol. The hydroxy group of geranylgeraniol 2-1 is protected as isobutyrate ester or other bulky ester using the corresponding acid or its derivative such as anhydride or acyl chloride. Geranylgeranylisobutyrate 2-2 is then selectively hydrogenated using a metal catalyst such as palladium on carbon to produce phytylisobutyrate 2-3. Hydrogenation of geranylgeranylisobutyrate 2-2 reduces the second, third and

fourth olefin moieties without affecting the first olefin moiety. It is believed that the steric bulk of isobutyrate decreases the rate of hydrogenation of the first olefin moiety in protected geranylgeraniol, thus leading to a selective hydrogenation of olefin moieties. The hydroxy protecting group is then removed by hydrolysis under a basic condition to provide phytol 2-4. Reacting phytol 2-4 with 2,3,5-trimethyl hydroquinone 2-5 in the presence of an acid then results in a formation of vitamin E 2-6. Alternatively, phytylisobutyrate 2-3 can be deprotected and reacted with 2,3,5-trimethyl hydroquinone 2-5 in a single step by an acid catalyst to form vitamin E 2-6. Vitamin E 2-6 can further be transformed to a protected vitamin E such as vitamin E acetate 2-7 by acetylation of the free hydroxy moiety.

An alternative method of chemical synthesis converting GG into  $\alpha$ -tocopherol or  $\alpha$ -tocopheryl esters includes the following steps: (a) selectively oxidizing the 2,3-carbon-carbon double bond in geranylgeraniol 7 to produce geranylgeraniol-2,3-epoxide 8; (b) hydrogenating the three remaining carbon-carbon double bonds in the epoxide 8 to produce epoxyphytol 9; (c) deoxygenating the epoxyphytol 9 to produce a mixture of phytol 5 and isophytol 6 by reaction with an oxygen acceptor; and (d) reacting the phytol 5 and isophytol 6 mixture with trimethylhydroquinone 4 to produce *alpha*-tocopherol 3.



The step of selectively oxidizing the 2,3-carbon-carbon double bond in geranylgeraniol to produce geranylgeraniol-2,3-epoxide is carried out with any reagent known to selectively epoxidize the olefin functionality of allylic alcohols, such as combinations of tert-butyl hydroperoxide and vanadium or molybdenum catalysts as taught by the method of Sharpless and Michaelson, J. Am. Chem. Soc. **95**, 6136 (1973). Hydrogen peroxide or other alkyl hydroperoxides could replace tert-butyl hydroperoxide, and inert solvents such as aromatic hydrocarbons, aliphatic hydrocarbons, cycloaliphatic hydrocarbons or aliphatic esters may be used. The term "aliphatic hydrocarbon" is used to include straight or branched chain alkanes having five to eight carbon atoms. Heptane is the most preferred aliphatic hydrocarbon. The term "cycloaliphatic hydrocarbon" is used to include C<sub>5</sub> - C<sub>8</sub> cycloalkanes and these substituted with one or more C<sub>1</sub> - C<sub>4</sub> alkyl groups.

The term "aromatic hydrocarbon" is used to include benzene and benzene substituted with one to three  $C_1 - C_4$  alkyl groups. Toluene is the most preferred aromatic hydrocarbon. The term "aliphatic esters" is used to  
5 include aliphatic esters having three to nine carbon having the formula  $R_1CO_2R_2$  wherein  $R_1$  and  $R_2$  independently represent a straight or branched chain  $C_1 - C_4$  alkyl group, with ethyl acetate being the preferred aliphatic ester.

The step of hydrogenating the three remaining carbon-  
10 carbon double bonds in the epoxide 8 to produce epoxyphytol 9 can be done with any conventional heterogeneous or homogeneous catalyst under an atmosphere of hydrogen. Thus, supported catalysts such as palladium on carbon, platinum on carbon, platinum oxide, Raney nickel, and the  
15 like may be used at a level of about 0.001 to 0.2 parts by weight with respect to 8, with or without an inert solvent such as aliphatic esters, alkanols, aromatic hydrocarbons, aliphatic and cycloaliphatic hydrocarbons or ethers, under a pressure of from about 1 to about 200 atmospheres of  
20 hydrogen pressure at temperatures from about 0 degrees C to about 150 degrees C. The term "alkanol" is used to represent alcohols of the formulae  $R_3 - OH$  and substituted alcohols of the formula  $R_3OCH_2CH_2OH$ , wherein  $R_3$  represents a straight or branched chain  $C_1 - C_4$  alkyl group. The term  
25 "ether" is used to represent ethers having the formula  $R_1 - O - R_2$ , wherein  $R_1$ , and  $R_2$  are as defined above and

tetrahydrofuran. The step of deoxygenating the epoxyphytol 9 to produce a mixture of phytol 5 and isophytol 6 by reaction with an oxygen acceptor can be a rhenium-catalyzed oxygen transfer reaction and can be done  
5 neat or in the presence of an inert solvent such as aromatic hydrocarbons, aliphatic hydrocarbons, cycloaliphatic hydrocarbons, aliphatic esters, alkanols, ethers or water. The reaction can also be carried out in a 2-phase water-organic solvent system with or without the  
10 addition of a phase-transfer catalyst. The catalyst can be a substituted rhenium trioxide or a polymer-supported form of such a rhenium trioxide compound. The catalyst can be used at a level of from about 0.01 - 5.0 weight percent based on 9. The oxygen acceptor must be present at a level  
15 of 1.0 - 3.0 moles per mole of 9 and may be chosen from triarylphosphines, tri-C<sub>1</sub>-C<sub>6</sub> alkylphosphines, triaryl phosphites, tri-C<sub>1</sub>-C<sub>18</sub> alkylphosphites, alkali metal hypophosphites or hypophosphoric acid. Other compounds capable of irreversibly accepting oxygen from 9 may be  
20 used, such as di-C<sub>1</sub>-C<sub>6</sub> alkyl sulfides and certain nitrogen bases such as N - C<sub>1</sub> - C<sub>6</sub> alkylmorpholines. The term "aryl" is used to include phenyl and naphthyl and these substituted with one to three C<sub>1</sub> - C<sub>6</sub> alkyl groups. The term "aralkyl" is used to include monovalent radicals  
25 having the structure aryl(CH<sub>2</sub>)<sub>n</sub> -, wherein n = 1 to 4. The term "substituted rhenium trioxide" is used to include

compounds of the formula  $R - ReO_3$ , wherein R is a hydrocarbyl group selected from the group consisting of  $C_1 - C_{10}$  alkyl,  $C_6 - C_{10}$  aryl, aralkyl, cyclopentadienyl and cyclopentadienyl substituted with one to five  $C_1 - C_4$  alkyl groups.

It should be noted that the step of deoxygenating the epoxyphytol in the present invention, such as by reaction with triphenylphosphine or other suitable oxygen acceptor under catalysis by a rhenium compound such as methylrhenium trioxide, is a novel and unexpected reaction. The use of methylrhenium trioxide as a catalyst in a variety of organic reactions has been reviewed [Schmidt (J. Prakt. Chem./Chem.-Ztg. 339, 493-496 (1997))]. Espenson and Zhu [(J. Molecular Catalysis A:Chemical 103, 87-94 (1995))] gave six examples of the use of MTO to catalyze the transfer of oxygen from epoxides to triphenylphosphine with the formation of olefins. It is to be noted that all of Espenson and Zhu's examples of olefin generation from epoxides involved simple, non-functional hydrocarbons such as cyclohexene, stilbene, cyclododecene, and so forth. These workers did not demonstrate the feasibility of carrying out such a transformation in a molecule containing additional functionality such as a primary hydroxyl group. In fact, Espenson and Zhu subsequently showed [J. Org. Chem. 61, 324-328 (1996)] that MTO catalyses dehydration of primary alcohols with the formation of ethers and olefinic



hydrocarbons. Therefore it is unexpected and surprising to discover that MTO/triphenylphosphine, when applied to epoxyphytol, give a good yield of allylic alcohol products such as isophytol and phytol.

5       The step of reacting the phytol 5 and isophytol 6 mixture with trimethylhydroquinone 4 to produce *alpha*-tocopherol 3 is conducted in the presence of an acid catalyst, often a Lewis acid such as zinc chloride, as is conventionally done in known processes. It has been  
10       determined that a mixture of phytol 5 and isophytol 6 can be used to prepare *alpha*-tocopherol in the same yield as either precursor alone.

Specific exemplary compounds of generic terms used herein which are suitable for use in the present invention  
15       are as follows. Typical aromatic solvents include benzene, toluene, and o, m or p-xylene or mixtures thereof. Toluene is the preferred aromatic solvent. Typical aliphatic solvents include n-pentane, n-hexane, n-heptane and n-octane and isomers thereof, n-Heptane is the preferred  
20       aliphatic hydrocarbon. Typical cycloaliphatic hydrocarbons include cyclopentane, cyclohexane, methylcyclohexane and cycloheptane. Typical aliphatic esters include methyl acetate, ethyl acetate, n-propyl acetate, n-butyl acetate, isopropyl acetate, methyl propionate, ethyl propionate,  
25       methyl butyrate and ethyl butyrate. Ethyl acetate is the preferred aliphatic ester. Typical alkanols and

substituted alkanols include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, 2-methoxyethanol, 2-ethoxyethanol and 2-isopropoxyethanol. Typical ethers include diethyl ether, diisopropyl ether, dibutyl ether, n-butyl methyl ether, t-butyl methyl ether and tetrahydrofuran. Typical useful Lewis acids include zinc chloride, aluminum chloride, boron trifluoride, ferric chloride and phosphoric acid. Zinc chloride is the preferred Lewis acid.

10 5.0 Farnesol to Vitamin E

In yet another embodiment of the present invention, a method for producing vitamin E from farnesol is provided. This method generally involves converting farnesol to a first intermediate compound which comprises a sufficient number of carbon atoms to form at least a trimethyltridecyl substituent group of vitamin E when the intermediate is subsequently reacted with an appropriate hydroquinone to form vitamin E. The method further includes reacting the intermediate compound with a hydroquinone to form vitamin E. Preferably, the intermediate compound contains a sufficient number of carbon atoms to form both the methyl and trimethyltridecyl substituents in the 2-position of the chromane ring moiety of vitamin E. More preferably the intermediate compound is selected from the group consisting of phytol and isophytol.

The intermediate compound can be prepared by oxidizing farnesol to farnesal. Examples of oxidation of an alcohol to an aldehyde can be found in "Advanced Organic Chemistry Part B: Reactions and Synthesis" 2nd Ed., Carey and Sundberg, Plenum Press, 1983, pp. 481-490, which is incorporated herein by reference in its entirety. For example, farnesol can be oxidized to farnesal using manganese dioxide; chromium oxides such as chromium trioxide and dichromates; silver oxide; Swern oxidation conditions; and Oppenauer oxidation conditions. In addition, farnesol can be oxidized via a catalytic air oxidation using a catalyst as disclosed by Marko et al., *Science*, 1996, 274, 2044. Generally, this air oxidation of farnesol to farnesal involves using a catalytic amounts of cuprous chloride, 1,10-phenanthroline, di-*t*-butylhydrazodicarboxylate, and excess potassium carbonate in a relatively non-polar solvent such as toluene or benzene at about 80 °C.

The method of producing vitamin E from farnesol can further include forming a methyl ketone from farnesal. The methyl ketone can be formed by a variety of methods including aldol condensation with an appropriate ketone such as acetone or its equivalents. For example, aldol condensation of farnesal with acetoacetate followed by a decarboxylation reaction provides the same methyl ketone product as an aldol condensation of farnesal with acetone.

The methyl ketone can also be formed using an appropriate Wittig or Horner-Emmons-Wadsworth reagents. Use of these reagents are disclosed, for example, in "Advanced Organic Chemistry", 3rd Ed., J. March, John Wiley & Sons, 1985, pp. 845-854, which is incorporated by reference herein in its entirety.

The method of producing vitamin E from farnesol can further include reducing olefin moieties in the methyl ketone to form an alkyl methyl ketone. A reduction of olefin moieties is discussed above in the section regarding production of vitamin E from GG and is incorporated herein by reference. Preferably, the alkyl methyl ketone is 6,10,14-trimethyl pentadecan-2-one. The alkyl methyl ketone is then converted to an allylic alcohol. The allylic alcohol can be produced by adding an acetylide such as lithium acetylide, sodium acetylide and magnesium halide acetylide and partially reducing the resulting acetylene group to a vinyl group. Alternatively, the allylic alcohol can be formed directly by other methods well known in the art, such as by reacting the alkyl methyl ketone with a vinyl anion such as vinyl magnesium halide, vinyl lithium or vinyl sodium.

Formation of vitamin from an allylic alcohol is discussed above with regard to production of vitamin from geranylgeraniol.

A particularly preferred embodiment of synthesizing vitamin E from farnesol is illustrated in Fig. 3. Farnesol 3-8 is oxidized to farnesal 3-9 under Oppenauer oxidation conditions using aluminum isopropoxide and acetone. Farnesal 3-9 is then converted to dehydrofarnesyl acetone 3-10 by an aldol condensation reaction with acetone. Reduction of olefin moieties on dehydrofarnesyl acetone 3-10 by hydrogenation then produces 6,10,14-trimethyl pentadecan-2-one 3-11. Addition of acetylide to the ketone 3-11 then generates propargylic alcohol 3-12 which is partially reduced using Lindlar hydrogenation condition to produce isophytol 3-13. Reaction of isophytol 3-13 with 2,3,5-trimethyl hydroquinone 3-5 in the presence of an acid catalyst then produces vitamin E.

6.0 Biological production of phytol from GGPP or GG.

The present invention provides methods for the chemical conversion of GG to phytol or a mixture of phytol and isophytol. Phytol or a phytol plus isophytol mixture can then be reacted with a hydroquinone in the presence of an acid to form vitamin E, as described elsewhere herein.

Recently, the gene encoding the enzyme geranylgeranyl reductase was cloned from *Arabidopsis thaliana* ecotype Columbia [Keller et al., *Eur. J. Biochem.* 251:413-417 (1998)]. This enzyme catalyzes the stepwise reduction of geranylgeranyl-chlorophyll to phytyl-chlorophyll as well as the reduction of GGPP to phytyl diphosphate. With regard


to the present invention, a geranylgeranyl reductase is used in a biological system to substitute for the chemical conversion of GG to phytol. For example, geranylgeranyl reductase is expressed in an *erg9* mutant strain of *S. cerevisiae* that also expresses a GGPP synthase activity. The reductase reacts with GGPP formed *in vivo* to produce phytyl diphosphate. A phosphatase then converts the phytyl diphosphate to phytol, as occurs in the farnesol- and GG-producing strains described in earlier sections. The resulting microorganism produces phytol directly from a growth substrate such as glucose in a single fermentation.

Alternatively, for a geranylgeranyl reductase able to use GG as a substrate, a biological process is provided where GG is produced by fermentation (as described in earlier sections) and purified to the extent necessary to use it as a feedstock for a biotransformation process. The biotransformation uses geranylgeranyl reductase to convert GG to phytol in one step. This biotransformation uses either isolated geranylgeranyl reductase or whole cells containing geranylgeranyl reductase activity. The enzyme or cells are immobilized on a support or by cross-linking to enhance the biotransformation. It is anticipated that geranylgeranyl reductase would be modified by genetic manipulations to enhance its activity for the production of phytol in an industrial biological process.

The phytol formed in a biological process using geranylgeranyl reductase is recovered and purified to the extent necessary to allow reaction with a hydroquinone in the presence of an acid to afford vitamin E.

5    7.0 Chemical Production of Vitamin A from Farnesol

As noted above, the present method includes preparing an  $\alpha,\beta$ -unsaturated polyene carbonyl compound from farnesol. As used in this invention, an  $\alpha,\beta$ -unsaturated polyene carbonyl compound refers to a compound having two or more  
10    olefin moieties, where at least one of the olefin moieties is conjugated to the carbonyl group. A carbonyl group refers to a presence of carbon-oxygen double bond moiety. Exemplary carbonyl groups include aldehydes, ketones, esters, acids, anhydrides and acyl halides. Preferably the  
15     $\alpha,\beta$ -unsaturated polyene carbonyl compound is of the formula:



wherein Z is O or  $\text{CHCO}_2\text{R}$ , and R is hydrogen or  $\text{C}_1\text{-C}_{10}$   
20    hydrocarbyl.

Hydrocarbyl groups according to the present invention include aliphatic, cyclic or aromatic hydrocarbons having 1 to about 10 carbon atoms. Hydrocarbyl groups can be

straight or branched. Furthermore, hydrocarbyl groups optionally can be substituted with one or more substituents, such as halo, aryl, hydroxy, alkoxy, carboxy, oxo and cycloalkyl. There may be optionally inserted along  
5 the hydrocarbyl group one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms. Exemplary hydrocarbyl groups include methyl, ethyl, *i*-propyl, *n*-butyl, *t*-butyl, *n*-pentyl, *i*-pentyl, heptyl and octyl.


The  $\alpha,\beta$ -unsaturated polyene carbonyl compound can be  
10 prepared from farnesol in a variety of ways. In a particularly preferred embodiment of the present invention, farnesol is oxidized to farnesal which is then subsequently converted to the  $\alpha,\beta$ -unsaturated polyene carbonyl compound. Examples of oxidation of an alcohol (e.g., farnesol) to an  
15 aldehyde (e.g., farnesal) can be found in "Advanced Organic Chemistry Part B: Reactions and Synthesis" 2nd Ed., Carey and Sundberg, Plenum Press, 1983, pp. 481-490, which is incorporated herein by reference in its entirety. For example, farnesol can be oxidized to farnesal using  
20 manganese dioxide; chromium oxides such as chromium trioxide and dichromates; silver oxide; Swern oxidation conditions; and Oppenauer oxidation conditions. In addition, farnesol can be oxidized via a catalytic air oxidation using a catalyst as disclosed by Marko *et al.*,  
25 *Science*, 1996, 274, 2044. Generally, this air oxidation of farnesol to farnesal involves using a catalytic amounts of



cuprous chloride, 1,10-phenanthroline, di-*t*-butylhydrazodicarboxylate, and excess potassium carbonate in a relatively non-polar solvent such as toluene or benzene at about 80 °C.

5       The method for producing vitamin A from farnesol can further include cyclizing the  $\alpha,\beta$ -unsaturated polyene carbonyl compound to form a cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound. Preferably the cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound is of the formula:

10



where Z is O or  $\text{CHCO}_2\text{R}$ , and R is  $\text{C}_1\text{-C}_{10}$  hydrocarbyl. When Z is O, the method can include transforming O to  $\text{CHCO}_2\text{R}$  or  $\text{CHCN}$ . This transformation can be achieved by an aldol  
15       condensation using an appropriate reagent. For example, aldol condensation of the cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound with  $\text{NCCH}_2\text{CO}_2\text{R}$ , where R is hydrogen or  $\text{C}_1\text{-C}_{10}$  hydrocarbyl, followed by removal of  $\text{CO}_2\text{R}$  moiety, e.g., by decarboxylation, provides a compound in which carbonyl  
20       oxygen has been replaced by  $\text{CHCN}$  moiety. Alternatively, using  $\text{R}'\text{O}_2\text{CCH}_2\text{CO}_2\text{R}$ , where R and R' are independently hydrogen or  $\text{C}_1\text{-C}_{10}$  hydrocarbyl, in place of  $\text{NCCH}_2\text{CO}_2\text{R}$  provides a

compound in which carbonyl oxygen has been replaced by CO<sub>2</sub>R moiety.

The method for producing vitamin A from farnesol can further include a step of reducing the ester group (CHCO<sub>2</sub>R) or the nitrile group (CHCN) to an alcohol.

Fig. 10 illustrates a particularly preferred embodiment of vitamin A synthesis from farnesol 1. An aldol condensation between acetone and farnesal 2, which is derived from oxidation of farnesol 1, results in a formation of dehydrofarnesyl acetone 3. A variety of methods are available to synthesize dehydrofarnesyl acetone 3 from farnesal 2. In one aspect of the present invention, a mixture comprising farnesal 2 and acetone in the presence of a base is subjected to a reaction condition sufficient to produce the dehydrofarnesyl acetone 3. The initial product of the aldol condensation reaction is  $\beta$ -hydroxy ketone, which typically undergoes elimination under the reaction condition to produce dehydrofarnesyl acetone 3. In some cases, however, some or all the  $\beta$ -hydroxy ketone intermediate can be obtained as the product. Where this is the case, simply subjecting the  $\beta$ -hydroxy ketone to an acidic or basic condition can result in elimination of the hydroxy group to produce the desired dehydrofarnesyl acetone 3.

The dehydrofarnesyl acetone 3 can also be obtained from farnesal 2 by subjecting a mixture of farnesal 2 and

a compound of the formula  $R_1CH_2C(=O)CH_2R_2$  to a reaction condition sufficient to produce dehydrofarnesyl acetone 3, wherein  $R_1$  is a moiety of the formula  $-CO_2R_3$ ,  $R_2$  is hydrogen or a moiety of the formula  $-CO_2R_3$ , and  $R_3$  is a hydrocarbyl having from 1 to about 10 carbon atoms. In order to obtain dehydrofarnesyl acetone 3 from a reaction between farnesal 2 and a moiety of the formula  $R_1CH_2C(=O)CH_2R_2$ , it may be necessary to subject the resulting product to a decarboxylation condition to remove the  $R_1$  and/or  $R_2$  carboxylate group(s). Typically, this decarboxylation requires conversion of the ester group to carboxylic acid or a salt thereof, which can be achieved by saponification of the ester by either an acidic or a basic condition.

Referring again to Fig. 10, a mixture comprising dehydrofarnesyl acetone 3 and a compound of the formula  $XCH_2CO_2R$  (wherein  $R$  is hydrogen or  $C_1$ - $C_{10}$  hydrocarbyl and  $X$  is a halide) is subjected to a basic condition sufficient to produce  $C_{20}$ -glycidic ester 4. Preferably  $R$  is selected from the group consisting of methyl, ethyl, and *t*-butyl. Preferably  $X$  is selected from the group consisting of chlorine, bromide and iodide. The  $C_{20}$ -glycidic ester 4 is then subjected to a condition sufficient for rearrangement and dehydration to produce pseudoretinoic acid ester 5. Generally, the rearrangement is affected by contacting the  $C_{20}$ -glycidic ester 4 with an acid to form a  $C_{20}$ -hydroxy compound (not shown). The  $C_{20}$ -hydroxy compound is then

dehydrated under the reaction condition or is subjected to a separate dehydration condition to produce the desired pseudoretinoic acid ester 5. The dehydration of C<sub>20</sub>-hydroxy compound can be achieved under either an acidic or a basic condition. Subjecting the pseudoretinoic acid ester 5 to a condition sufficient for cyclization produces retinoic acid ester 6. A typical cyclization condition involves contacting the pseudoretinoic acid ester 5 with an acid. The acid should be strong enough to protonate an olefin moiety, thus generating a carbonium ion, i.e., a carbocation, which can undergo a cyclization. Also a relatively weak nucleophile, such as a halide and/or a carboxylic acid, can be added to trap the resulting cyclized carbocation. When a weak nucleophile is present, the resulting cyclized product may contain a nucleophile which may undergo elimination under the reaction condition or it can be removed by elimination in a separate reaction. Preferably the acid is selected from the group consisting of hydrochloric acid; phosphoric acid; fluorosulfonic acid; sulfuric acid; and carboxylic acids such as formic acid, and acetic acid; and a mixture thereof. Reaction conditions for cyclization of a 1,5-diene, such as farnesyl acetate, using an acid are disclosed in Muntyan et al., *Izev. Akad. Nauk SSSR, Ser. Khim.*, 1973, 633, and Stork and Burgstahler, *J. Amer. Chem. Soc.*, 1955, 77, 5068, which are incorporated herein by reference in their entirety.

Alternatively, the pseudoretinoic acid ester 5 can be cyclized using an enzyme. For example, it is well known that lycopene cyclase cyclizes appropriate C<sub>40</sub> chains to produce carotenoids. Similarly, a cyclase enzyme can be used to cyclize pseudoretinoic acid ester or its derivative to produce retinoic acid ester or its derivative.

Again referring to Fig. 10, in one particular embodiment, retinoic acid ester 6 is reduced to vitamin A (retinol). This reduction can be achieved by any of the known ester reduction reactions such as a hydride reduction using a compound including, but not limited to, LiAlH<sub>4</sub>, sodium bis(2-methoxyethoxy)aluminum hydride, and diisobutylaluminum hydride. Alternatively, retinoic acid ester 6 can be saponified or hydrolyzed under acidic or basic conditions to produce retinoic acid, which can then be reduced using a compound including, but not limited to, borane (B<sub>2</sub>H<sub>6</sub>) to selectively reduce the carboxylic acid group in the presence of olefins to produce vitamin A (retinol) 8.

As shown in Fig. 10, in another aspect of the present invention, the retinoic acid ester 6 is first reduced to retinal 7 by contacting the retinoic acid ester 6 with a first reducing agent. The retinal 7 is then contacted with a second reducing agent to produce vitamin A (8). The first reducing agent reduces an ester to an aldehyde. There are variety of methods and reducing agents currently

available for reducing an ester to an aldehyde. Such reducing agents include, but are not limited to, diisobutylaluminum hydride. The second reducing agent typically reduces an aldehyde to an alcohol, but some of these reducing agents can also reduce an ester directly to an alcohol. Exemplary second reducing agents include, but are not limited to,  $\text{LiAlH}_4$ , diisobutylaluminum hydride, sodium bis(2-methoxyethoxy)aluminum hydride, and sodium borohydride.

10 An acetate 9 or other vitamin A ester derivative can be obtained by contacting vitamin A with an acetylation agent or other acyl transfer agents at a condition sufficient to produce vitamin A acetate or other vitamin A ester derivatives, respectively. Exemplary acetylating agent and acyl transfer agent include, but are not limited to, anhydrides or acyl chlorides of acetic acid, propanoic acid, formic acid, butanoic acid and mixed anhydrides. Typically, a catalyst or a base is also used in acyl transfer reactions. Exemplary bases useful in acyl transfer include, but are not limited to, hydroxides; carbonates and bicarbonates of sodium, lithium and potassium; and amines such as pyridine and triethyl amine. An acyl transfer catalyst can also be used to facilitate the reaction and/or to shorten the reaction time. Exemplary acyl transfer catalysts include, but are not limited to, dimethylaminopyridine (DMAP).

Another particularly preferred embodiment of producing vitamin A from farnesal is shown in Fig. 11. Dehydrofarnesyl acetone 3 (production described above) is subjected to a dehydrogenating condition sufficient to produce a bis(dehydro)-C<sub>18</sub>-ketone 10. Dehydrogenation of dehydrofarnesyl acetone 3 can be achieved by contacting dehydrofarnesyl acetone 3 with a dehydrogenating agent. Exemplary dehydrogenating agents include, but are not limited to, quinones such as 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ); metal catalysts such as palladium, platinum and nickel; and other suitable dehydrogenating agents.

The bis(dehydro)-C<sub>18</sub>-ketone 10 is then subjected to a condition sufficient to undergo a cyclization to form a cyclic C<sub>18</sub>-ketone 11. Typical cyclization condition involves contacting the bis(dehydro)-C<sub>18</sub>-ketone 10 with an acid. A typical reaction condition for cyclization of a 1,5-diene, such as farnesyl acetate, is discussed above, and can be used for this cyclization. The cyclization can also be affected by a metal catalyst which are known to one skilled in the art, including nickel and rhodium. The bis(dehydro)-C<sub>18</sub>-ketone 10 can also be cyclized using an enzyme. Such useful enzymes are discussed above.

Referring again to Fig. 11, a mixture comprising the cyclic C<sub>18</sub>-ketone 11 and a compound of the formula NCCH<sub>2</sub>CO<sub>2</sub>R is subjected to a reaction condition sufficient to form a

$C_{20}$ -nitrile 12, wherein R is hydrogen or  $C_1$ - $C_{10}$  hydrocarbyl. When R is hydrogen,  $\alpha$ -nitrile acetic acid is contacted with a base to deprotonate the carboxylic proton as well as the  $\alpha$ -proton of the carbonyl group. These two protons can be removed using two different bases, one for the carboxylic proton and another for the  $\alpha$ -proton, or both protons can be removed using a base that is strong enough to deprotonate both protons. If R is  $C_1$ - $C_{10}$  hydrocarbyl, then a base which is strong enough to deprotonate  $\alpha$ -nitrile acetate is used. Since  $NCCH_2CO_2R$  contains two electron withdrawing groups, a relatively weak base, such as a hydroxide or an amine, can be used to deprotonate an  $\alpha$ -proton. Deprotonated  $\alpha$ -nitrile acetate then undergoes a condensation reaction with the cyclic  $C_{18}$ -ketone 11, followed by dehydration and decarboxylation processes to produce a  $C_{20}$ -nitrile compound 12. The dehydration can occur under the condensation reaction condition or it can be affected in a separate reaction condition. If R is  $C_1$ - $C_{10}$  hydrocarbyl, it is necessary to saponify, i.e., hydrolyze, the alkyl group to form a carboxylic acid or a carboxylate anion before subjecting the condensed product to a decarboxylation condition. The decarboxylation condition of the condensed product generally requires subjecting the condensed product to an elevated temperature.

25        The  $C_{20}$ -nitrile 12 is then contacted with a first reducing agent at a condition sufficient to produce retinal



7, or it can be reduced with a sufficiently strong reducing agent to produce vitamin A (8). Retinal 7 can be reduced using a second reducing agent to provide vitamin A. Suitable reducing conditions and agents for these  
5 reductions are those described above. Vitamin A can further be converted to a vitamin A ester derivative by reacting vitamin A with an appropriate esterifying agent, as discussed above.

In another embodiment of the present invention,  
10 retinal 7 that is produced by any of the above described process is subjected to a condition sufficient to produce  $\beta$ -carotene 13. For example, as shown in Fig. 12, two molecules of retinal 7 undergo a coupling reaction when subjected to what is commonly known in the art as a McMurry  
15 coupling reaction condition. The McMurry coupling reaction is well known in the art of organic chemistry and is described by John McMurry in U.S. Patent No. 4,225,734, which is incorporated herein by reference in its entirety. Briefly, the McMurry coupling reaction involves a  
20 production of olefins from a reductive coupling of carbonyl groups such as ketones and aldehydes with reactive Ti(II) and/or Ti(0) species. Generally, the reactive species are generated *in situ* by reduction of Ti(III) or Ti(IV) with the reducing agent selected from the group consisting of  
25  $\text{LiAlH}_4$ , Na, K, Zn, Mg,  $\text{NaBH}_4$ ,  $\text{CaH}_2$  and  $\text{LiBH}_4$ . Ti(III) and

Ti(IV) species are typically titanium halides such as  $\text{TiCl}_3$  and  $\text{TiCl}_4$ , respectively.

In another embodiment of the present invention,  $\beta$ -carotene 13 is produced from vitamin A which is produced by any of the above described methods. As shown in Fig. 13, the method generally involves reacting a retinyl halide 15 with retinylphenyl sulfone 14. A retinyl halide 15 can be produced by contacting vitamin A that is produced by the process described above with a reaction mixture selected from the group comprising  $\text{HX}$ ,  $\text{P(X)}_3$ , and a mixture of  $\text{P(R}_4)_3$  and  $\text{X}_2$  at a condition sufficient to produce the retinyl halide, wherein  $\text{X}$  is a halide,  $\text{X}_2$  is a halogen and  $\text{R}_4$  is  $\text{C}_1$ - $\text{C}_{10}$  hydrocarbyl. The retinyl halide 15 is then contacted with an anion of retinylphenylsulfone 14 at a condition sufficient to produce  $\text{C}_{40}$ -sulfone 16. In cases where retinylphenylsulfone 14 is deprotonated with the base prior to being contacted with the retinyl halide 15, the base is strong enough to deprotonate substantially all of retinylphenylsulfone 14. Exemplary bases for deprotonating substantially all of retinylphenylsulfone 14 prior to contacting it with the retinyl halide 15 include, but are not limited to, lithium diisopropylamide (LDA), sodium hexamethyldisilazide (NaHMDS), methyl lithium, butyl lithium, *t*-butyl lithium, *sec*-butyl lithium, potassium hydride, sodium hydride, and *t*-butoxide. Alternatively, the retinyl halide 15, retinylphenylsulfone 14 and the base

are all combined in a reaction apparatus and the base is allowed to deprotonate some retinylphenylsulfone molecules which can react with the retinyl halide 15 to form the C<sub>40</sub>-sulfone 16, i.e., the reactive anionic species of retinylphenylsulfone 14 is generated *in situ*.

Again referring to Fig. 13, retinylphenylsulfone 14 can be produced by reacting a retinyl ester such as retinyl acetate 9 or a retinyl halide 15 with a reaction mixture comprising phenylsulfinic acid at a condition sufficient to produce retinylphenylsulfone 14. A base can be used to deprotonate phenylsulfinic acid which then undergoes a nucleophilic substitution reaction with retinyl acetate or the retinyl halide 15 to produce retinylphenylsulfone 14. Phenylsulfinic acid can be deprotonated substantially completely prior to contacting with retinyl acetate or the retinyl halide 15 by using a base such as LDA, methyl lithium, NaHMDS, *t*-butyl lithium, *sec*-butyl lithium, NaH, KH, or *t*-butoxide. Alternatively, deprotonated phenylsulfinic acid can be generated *in situ* by using a base, such as the hydroxides, bicarbonates and carbonates of lithium, sodium and calcium, amines such as triethylamine, and diisopropyl ethylamine, and alkoxides such as methoxide, ethoxide, and *t*-butoxide.

The C<sub>40</sub>-sulfone 16 which is produced by a reaction between retinyl halide 15 and retinylphenylsulfone 14 is then subjected to a condition sufficient to eliminate

phenylsulfinic acid to produce  $\beta$ -carotene 13. The elimination of phenylsulfinic acid from the C<sub>40</sub>-sulfone 16 can be achieved by contacting the C<sub>40</sub>-sulfone 16 with a base. Exemplary bases useful for elimination reaction include, but are not limited to, LDA, methyl lithium, diisopropyl ethylamine, hydroxides, and alkoxides such as methoxide, ethoxide and t-butoxide.

The following Examples are provided to illustrate embodiments of the present invention and are not intended to limit the scope of the invention as set forth in the claims.

## EXAMPLES

### Example 1

This example describes the creation of *erg9* mutants by chemical mutagenesis of *S. cerevisiae* strain ATCC 28383 using nitrous acid.

As noted above, one way of increasing yields of farnesol or GG is to decrease or eliminate squalene synthase activity. In *S. cerevisiae*, squalene synthase is encoded by the *ERG9* gene.

#### A. Mutagenesis

Strain 28383 was obtained from the ATCC. It is the parent of strain 60431 used below in some experiments for comparative purposes (also obtained from ATCC). Strain 60431 is an *erg9-1* mutant that produces farnesol.

A kill curve was performed using nitrous acid with ATCC 28383. Using information derived from the kill curve, a mutagenesis of ATCC 28383 with nitrous acid was performed as follows. The 28383 cells were incubated overnight at 30°C in YPD medium (1% Bacto-yeast extract, 2% Bacto-peptone, and 2% glucose) with shaking. The cells were washed and mutagenized. After mutagenesis, the cells were allowed to recover by culturing them in YPDC (YPD plus 4 mg/L cholesterol) at 22°C overnight. The culture was then washed and plated onto YPDC agar (YPDC plus 2% Bacto-agar) containing various levels of nystatin (20, 30, 40, 50 mg/L). These cultures were incubated for two weeks at 22°C.

The antifungal polyene antibiotic nystatin inhibits cell wall synthesis in growing cells by binding specifically to ergosterol, which, in turn, results in an alteration of selective permeability. Some strains that are resistant to nystatin have been shown to have decreased production of ergosterol. Nystatin has little, if any, affinity for cholesterol which, when supplied exogenously, can be used by sterol auxotrophs as efficiently as ergosterol.

Approximately 3,000 nystatin-resistant colonies were obtained. They were screened for temperature sensitivity (ts) and sterol auxotrophy. To determine temperature sensitivity, mutagenized cells were grown on YPDC at a permissive temperature (22°C) and subsequently replica

plated to YPD agar and incubated at a restrictive temperature (37°C). Any cells which fail to grow at the higher temperature would include those with both a conditionally lethal and a constitutively lethal defect in the sterol pathway. Temperature sensitive mutants were screened for sterol auxotrophy by replica plating to YPD agar (lacking cholesterol) and incubation overnight at 28°C. Of the 3,000 nystatin-resistant colonies, 170 were saved after confirmation of ts and sterol auxotrophy.

10

#### B. Tube Assays

The 170 strains were initially evaluated in tube assays for the production of farnesol and other intermediates of the isoprenoid pathway as follows. Cells were cultured in 10 ml YPDC in tubes with screw caps for 48 hours at 28°C with shaking. The cells were centrifuged for 5-10 minutes at 2800 rpm, and the supernatant was transferred to another tube. The cells were washed once with 5 ml distilled water and centrifuged again for 5-10 minutes at 2800 rpm.

The cell pellet was extracted by adding 2.5 ml 0.2% pyrogallol (in methanol) and 1.25 ml 60% KOH (in distilled H<sub>2</sub>O), vortexing to mix, and incubating in a 70-75°C water bath for 1.5 hours. After this saponification, 5 ml hexane were added, and the tube was recapped and vortexed for 15-30 seconds. The tube was centrifuged at 2800 rpm for 5

minutes to separate the phases. The hexane layer was recovered. If necessary, the sample can be concentrated by evaporating solvent under nitrogen and adding back an appropriate amount of hexane for analysis.

5        To extract the supernatant, 5 ml of hexane were added to the supernatant, and the tube was recapped and vortexed for 15-30 seconds. The tube was centrifuged at 2800 rpm for 25 minutes to separate phases. The hexane layer was recovered, and the sample was concentrated by evaporating  
10        under nitrogen and adding back an appropriate amount of hexane for analysis.

         The hexane extracts from this primary screen were analyzed by thin layer chromatography (TLC) with confirmation by gas chromatography (GC)/mass spectrometry  
15        (MS) for the presence of farnesol and other intermediates of the isoprenoid pathway. TLC was performed on reversed-phase C18 silica gel plates using 6:4 (v/v) ethylacetate/acetonitrile (EtOAc/MeCN) as the mobile phase and 2% (w/v) phosphomolybdic acid (PMA) in ethanol for  
20        detection. GC/MS was performed using a Hewlett Packard 5890 GC and a 5970 series mass selective detector. The column used was a Restek Rtx-5MS (15 m length, 0.25 mm ID, 1 $\mu$ m film system. Thirteen mutants were identified as producers of farnesol or other intermediates.

C. Shake Flask Assays

These thirteen mutants were then screened in shake flasks, along with the parental strain, 28383, and the farnesol producing strain, 64031. Fifty ml of YPDC medium  
5 in 250 ml baffled Erlenmeyer flasks were inoculated with overnight cultures to an initial OD at 600 nm of 0.05 and incubated with shaking at 28°C. The flasks were sampled, and OD at 600 nm, dry weight and sterol content were determined. To measure dry weight, 5 ml of the culture  
10 were centrifuged at 8,000 rpm. The cells were washed twice with distilled H<sub>2</sub>O, and the cell pellet was resuspended in 3-5 ml distilled H<sub>2</sub>O and transferred to a pre-weighed dry weight pan. The pan was placed in 100°C oven for 24 hours, then cooled in a desiccator, weighed on an analytical  
15 balance, and the dry weight in g/L determined from the formula:

$$\begin{aligned} & [\text{Total weight (pan + cells)} - \text{pan weight}] \times 200 \\ & = \text{dry weight in g/L.} \end{aligned}$$

For sterol determination, 20 ml of culture were processed,  
20 the cell pellet and supernatant extracted, and farnesol and other sterols measured as described above.

Seven of the 13 mutants appeared to produce intermediates in the ergosterol pathway and were evaluated further in other shake flask experiments (see below). All  
25 13 mutants had been selected by resistance to the highest levels of nystatin.



Overnight cultures were used to inoculate 50 ml of YPDC medium in triplicate shake flasks for each of the seven mutant strains (MBNA1-1, MBNA1-5, MBNA1-9, MBNA1-10, MBNA1-11, MBNA1-13, MBNA1-14,), the parental strain 28383  
5 and mutant strain 64031. The cells and medium were extracted separately at 24, 48, and 72 hours into hexane, as described above. Dry weight analysis (performed as described above) was performed at each of these time points to determine cell density. The hexane extracts were  
10 analyzed by GC/MS for their farnesol, squalene, cholesterol, and ergosterol levels. The farnesol results are presented in Table 3 below.

Low levels of farnesol were found in the culture supernatants with much higher levels accumulating in the  
15 cells. Strain MBNA1-1 produced 1% farnesol and also made 0.1% ergosterol at 72 hours. Strain MBNA1-5 did not make any farnesol, but produced 0.3% squalene. Strain MBNA1-9 produced 0.64% farnesol in 48 hours. MBNA1-10, MBNA1-11, and MBNA1-14 produced very low levels of farnesol in the  
20 cells and appeared to make ergosterol. MBNA1-13 showed the highest farnesol production (2.5%) based on cell dry weight (42,187 ng/ml culture) and did not show any ergosterol production. Thus, among the farnesol-producing strains (MBNA1-1, MBNA1-9 and MBNA1-13), there appeared to be  
25 different degrees of blockage in the ergosterol pathway, since MBNA1-1 and MBNA1-9 produced lower levels of farnesol

and did not require ergosterol for growth, and MBNA1-13 produced the highest level of farnesol and had a strict requirement for sterol supplementation for growth. The parental strain 28383 showed ergosterol production up to 0.4% (no farnesol production), and *erg9* mutant strain 64031 showed farnesol accumulation to approximately 0.4%.

TABLE 3

## Characterization of New Mutants in Shake Flask Experiment

Strain Name	Hours of Growth	Dry weight mg/ml	Farnesol (ng/ml of culture)	Farnesol (% of cell dry weight)
MBNA1-1	24	0.16	0	0.00
	48	1.12	1793	0.16
	72	1.26	13187	1.05
MBNA1-5	24	2.46	0	0.00
	48	1.6	0	0.00
	72	1.06	0	0.00
MBNA1-9	24	1.32	1122	0.09
	48	2.96	19062	0.64
	72	4.34	70625	0.00
MBNA1-10	24	4.76	4636	0.10
	48	9.44	444	0.00
	72	7.9	166	0.00
MBNA1-11	24	1.82	0	0.00
	48	3.58	258	0.01
	72	2.36	281	0.01
MBNA1-13	24	0.18	0	0.00
	48	3.12	3657	0.12
	72	1.66	42187	2.54
MBNA1-14	24	2.42	0	0.00
	48	8.98	0	0.00
	72	7.36	0	0.00
ATCC28383	24	7.36	0	0.00
	48	8.52	0	0.00

Strain Name	Hours of Growth	Dry weight mg/ml	Farnesol (ng/ml of culture)	Farnesol (% of cell dry weight)
	72	8.84	0	0.00
ATCC64031	24	1.58	90	0.01
	48	1.84	6845	0.37
	72	1.28	4874	0.38

#### D. Enzyme Analysis

5 For all enzyme assays, cells were grown in YPDE medium. (YPD medium containing 5 mg/L ergosterol). The cells were harvested by centrifugation. One gram of cells (wet weight) was suspended in 4 ml of 0.1 M Tris • HCl, pH 7.0. The cell suspension was then disrupted by passage  
10 through a French pressure cell (20,000 psi). The resulting (lysed) cell suspension was then centrifuged (15,000 x g) and the supernatant (cell free extract) was used directly for enzyme assays unless noted otherwise.

The mutants were assayed for squalene synthase  
15 activity. The squalene synthase assay involved incubation of a cell-free extract with FPP in the presence the reduced form of nicotinamide adenine dinucleotide phosphate, (NADPH), extraction into ethyl acetate, and squalene detection by GC. Specifically, 0.1 M Tris/HCl pH7 (X $\mu$ L),  
20 0.1 M DTT (2 $\mu$ L), 0.1 M MgCl<sub>2</sub> (10 $\mu$ L), 0.1 M NADPH (4 $\mu$ L), 1 mg/mL FPP (6 $\mu$ L), and cell-free extract (7000 x g supernatant) (Y $\mu$ L), where X + Y = 178  $\mu$ L to make 200  $\mu$ L total, were combined. This mixture was incubated in glass tubes at 37°C for 40 min. Then, it was extracted with 0.15

mL ethyl acetate. The extract was transferred to plastic vials and centrifuged at 15,000 x g for 5 min. The ethyl acetate extract was analyzed using GC/MS.

Table 4 shows squalene synthase levels for mutants MBNA1-1, MBNA1-9, MBNA1-13, and ATCC strains 64031 and 28383. Squalene synthase activity was 0.12  $\mu$ g squalene formed/min x mg protein for the wild-type organism 28383. The activity levels for the other four strains were less than the detectable limits of this assay. Reduced squalene synthase levels would be expected for MBNA1-1, MBNA1-9 and 64031 since they have been characterized as being partially-blocked mutants that produce farnesol and low amounts of ergosterol. MBNA1-13 is a farnesol-producing mutant which cannot grow without added sterol, so this blocked mutant would be expected to have no detectable level of squalene synthase. The extracts of these strains were reassayed with higher concentrations of cell-free extract and longer incubation times. Once again, squalene synthase was not detected in any of the mutants.

TABLE 4

Strain	Squalene Synthase Assay ( $\mu$ g/ min x mg protein)
MBNA1-1	ND
MBNA1-9	ND
MBNA1-13	ND
ATCC 64031	ND
ATCC 28383	0.12

ND = Not detected

An enzyme analysis was performed for the farnesol-producing strains (MBNA1-1, MBNA1-9 and MBNA1-13) and their parental strain, 28283. The enzyme levels compared were those of the acetoacetyl CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, FPP synthase, and a phosphatase. Cell-free extracts were prepared as described above.

For the FPP synthase assay, 0.1 M DTT (2 $\mu$ L), 0.1 M MgCl<sub>2</sub> (2 $\mu$ L), 1 mg/mL IPP (6  $\mu$ L), 1 mg/mL GPP (6  $\mu$ L), cell-free extract (Y), and 0.1 M Tris/HCl (pH 7.0) (X  $\mu$ L), where X + Y = 84  $\mu$ L, were combined, and incubated at 37°C for 15 min. This mixture was then extracted twice with 0.3 mL hexane to remove pre-existing farnesol. Next, 0.1 mL of 2 x glycine buffer (0.2 M glycine, 2 mM MgCl<sub>2</sub>, 2mM Zn Cl<sub>2</sub>) , pH 10.4, and 33 units of alkaline phosphatase were added, and the mixture was incubated at 37°C for an hour. The mixture was extracted with 0.1 mL of ethyl acetate and dried with sodium sulfate. Farnesol was determined with GC. A no-phosphatase control was included in each assay.

HMG-CoA reductase catalyzes the reaction of HMG-CoA with NADPH to form mevalonate, nicotinamide adenine dinucleotide phosphate (NADP) and CoA (see Fig. 1). For these assays, the cell-free extracts were prepared as described above except that the disrupted cell suspensions were centrifuged at 7,000 x g instead of 15,000 x g. The reaction was followed by monitoring consumption of HMG-CoA by high performance liquid chromatography (HPLC). For the

assay, a reaction mixture containing (in a final volume of 0.1 ml) 0.1 M  $\text{Na}_2\text{H}_2\text{P}_2\text{O}_7$ , pH 6.5, 2 mM DTT, 1 mM NADPH, 0.4 mM HMG-CoA, and cell-free extract (the volume of extract was varied, with the balance of the 0.1 ml reaction made up with 0.1 M  $\text{Na}_2\text{H}_2\text{P}_2\text{O}_7$ , pH 6.5) was incubated at 37°C for 15 minutes. The reaction was monitored with HPLC (Luna C18 (Phenomenex) reversed-phase column using a gradient of 0% Solvent B for 1 min. followed by 0-11 % B over 42 min. Solvent A was 86:14 (v/v) 40mM potassium phosphate (pH 6.0)/methanol. Solvent B was methanol. The wavelength for detection was 260 nm).

HMG-CoA synthase converts acetoacetyl CoA and acetyl CoA to HMG-CoA and CoA. The assay monitors the production of HMG-CoA by HPLC. For the assay, 0.1 M  $\text{Na}_2\text{H}_2\text{P}_2\text{O}_7$ , pH 6.5, (X  $\mu\text{L}$ ), 20 mM acetoacetyl CoA (4  $\mu\text{L}$ ), 20 mM acetyl CoA (2  $\mu\text{L}$ ), and cell-free extract (Y  $\mu\text{L}$ ), where X + Y is 94  $\mu\text{L}$  (total volume 100  $\mu\text{L}$ ), were combined and incubated at 37°C for 5 minutes. Then, the reaction mixture was heated at 60°C for 5 minutes to inactive the enzyme, followed by centrifugation in a microfuge at full speed for 5 minutes. The supernatant was analyzed by HPLC.

Acetoactyl CoA thiolase catalyzes a reversible reaction whereby, in the forward direction, two molecules of acetyl CoA are reacted to form acetoacetyl CoA and CoA. The assay monitors the formation of acetyl CoA (reverse reaction) by HPLC. For the assay, 0.1 M  $\text{Na}_2\text{H}_2\text{P}_2\text{O}_7$ , pH 6.5,

(X  $\mu$ L), 20 mM acetoacetyl CoA (2  $\mu$ L), 20 mM CoA (3  $\mu$ L), and cell-free extract (Y  $\mu$ L), where X + Y is 95  $\mu$ L (total volume 100  $\mu$ L), were combined and incubated at 37°C for 5 minutes. Then, the reaction mixture was centrifuged in a 5 Microcon-10 (Amicon) centrifuge to separate the enzyme from the product. The supernatant was analyzed by HPLC.

The phosphatase assay quantitates phosphatase activity by measuring the formation of p-nitrophenol (increased absorbance at 400 nm). For the phosphatase assay, 0.1 M 10 Tris-HCl, pH 7 (X  $\mu$ L), 1 M MgCl<sub>2</sub> (2  $\mu$ L), 50 mM p-nitrophenyl phosphate (10  $\mu$ L) and cell-free extract (Y  $\mu$ L), where X + Y = 1 mL, were combined and incubated at 37°C for 15 minutes, after which the absorbance at 400 nm was measured.

Table 5 shows the levels for each of the five enzymes 15 in these four strains. The acetoacetyl CoA thiolase levels were comparable in all of these strains. The HMG-CoA synthase and HMG-CoA reductase levels appeared to be two to three times higher in the mutant strains. The FPP synthase levels were the same or lower in the mutants than in 28383. 20 The phosphatase levels appeared to be elevated three to four fold in the mutant strains compared to the parent. Since all of these strains were isolated by classical mutagenesis, it is possible that other mutations exist in these strains, besides the *erg9* mutation.

TABLE 5

		MBNA1-1	MBNA1-9	MBNA1-13	ATCC 28383
5	Acetoacetyl CoA Thiolase (nmol AcCoA / min x mg protein)	$2.4 \times 10^2$	$2.7 \times 10^2$	$1.6 \times 10^2$	$2.0 \times 10^2$
10	HMG-CoA Synthase (nmol HMG-CoA / min x mg protein)	5.7	7.2	7.1	2.7
	HMG-CoA Reductase (nmol CoA / min x mg protein)	0.35	0.55	0.36	0.15
15	FPP Synthase (nmol Farnesol / min x mg protein)	1.3	2.0	1.6	2.2
20	General Phosphatase (nmol p-nitrophenol/min x mg protein)	82	83	91	24

#### E. ERG9 Genetic Analysis

25 Chromosomal DNA was prepared from strains ATCC 28383, MBNA1-1, MBNA1-9 and MBNA1-13 according to the method described in Sherman et al. (Sherman, F., G.R. Fink, and J.B. Hicks, 1989, Methods in Yeast Genetics, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY). The genomic

30 DNA was digested with the restriction enzymes *ApaI* and *NsiI*, and subjected to Southern blot analysis using a biotinylated *ERG9* DNA fragment as a probe. The *ERG9* probe consisted of a 2044 bp *ERG9* DNA fragment isolated from an agarose gel after digestion of the plasmid pTWM103 with

35 *ApaI* and *NsiI*. pTWM103 consists of the *ERG9* gene and flanking sequences extending from position #10916 to #13868 of GenBank Accession #U00030 sequence. This plasmid was



constructed by polymerase chain reaction (PCR) amplification of the *ERG9* gene and flanking regions using the following two oligonucleotides:

5'-oligo = VE107-5 CTC AGT ACG CTG GTA CCC GTC AC

5 (denoted herein as SEQ ID NO:1)

3'-oligo = VE105-3 gat gga TCC CAA TAT GTG TAG CTC AGG

(denoted herein as SEQ ID NO:2)

Capital letters designate DNA sequences from *ERG9* flanking region, while small letters designate bases added to create restriction sites. VE107-5 contains sequences from position #10905 to position #10928 of GenBank Accession #U00030 sequence. VE105-3 contains the reverse complement of sequences from position #13868 to position #13847.

15 The amplification conditions were as follows:

Template DNA was genomic DNA isolated from strain S288C (Yeast Genetic Stock Center, Berkeley, CA)

2 min. 94°C/1 cycle

1 min. 94°C, 1min. 52°C, 1.5 min. 74°C/30 cycles

20 5 min. At 74°C/1 cycle

The 2969 bp *ERG9* DNA generated from this PCR reaction was digested with *KpnI* and *BamHI*, then ligated to *KpnI*, *BamHI* digested YEp352 to generate plasmid pTWM103. YEp352 is a yeast/*E. coli* shuttle vector (Hill, J.E., Myers, A.M., Koerner, T.J., and Tzagaloff, A., 1986, Yeast/*E. coli*

Shuttle Vectors with Multiple Unique Restriction Sites,  
Yeast 2: 163-167).

DNA for the *ERG9* probe described above was obtained by  
digesting TWM103 with *Apa*I and *Nsi*I, and purifying the 2044  
5 bp fragment containing the *ERG9* gene and flanking  
sequences. The *ERG9* DNA was then biotinylated using random  
primer extension (NEBlot Phototope Kit, New England  
BioLabs, Beverly, MA).

Approximately 1 µg of biotinylated *ERG9* probe was  
10 hybridized to the Southern blot of *Apa*I, *Nsi*I digested  
genomic DNA from strains ATCC 28383, MBNA1-1, MBNA1-9, and  
MBNA1-13. The blot revealed that all four strains  
contained a single hybridizing sequence located on a 2044  
bp fragment.

15 To clone the *ERG9* genes from these four strains,  
genomic DNA from each was again digested with *Apa*I and  
*Nsi*I. The yeast/*E. coli* shuttle vector pRS315 (Sikorski,  
R.S., and P. Hieter, 1989, A System of Shuttle Vectors and  
Yeast Host Strains Designed for Efficient Manipulation of  
20 DNA in *Saccharomyces cerevisiae*, Genetics, 122: 19-27) was  
digested with *Apa*I and *Pst*I (*Nsi*I and *Pst*I have compatible  
cohesive ends). The digested DNAs were separated on an  
agarose gel, and chromosomal DNA fragments in the size  
range from approximately 1.6 kb to approximately 3 kb, as  
25 well as the 3895 bp band corresponding to digested pRS316  
were cut from the gel and purified using GeneClean (BIO

101, Inc., Visa, CA). The purified genomic DNA fragments from each of the four strains was ligated to pRS316, and transformed into *E. coli*. Transformants containing the pRS316/*ERG9* clones were identified by colony hybridization  
5 using the *ERG9* probe described above. *ERG9* clones derived from each of the four strains were isolated in this manner. The cloned *ERG9* genes from each strain were sequenced by ACGT, Inc., Northbrook, IL, using an Applied Biosystems, Inc. automated DNA sequencer, Model ABI 100.

10 The sequence of the *ERG9* gene from ATCC 28383 was identical to the sequence deposited in GenBank (Accession #U00030). The *erg9* genes from MBNA1-2 and MBNA1-9 were found to have the same mutation, namely, a change from G to A at position #12386 of GenBank Accession #U00030, which  
15 changes a TGG codon to a TGA stop codon. This causes termination of the *ERG9* protein at 237 amino acids instead of the normal 444 amino acids found in the wild-type *ERG9* protein.

The *erg9* gene from MBNA1-13 was found to contain a  
20 deletion of a C at position #12017 of GenBank Accession #U00030, which causes a frameshift and early termination of the *ERG9* protein at 116 amino acids, with the last two amino acids being different from the wild-type *ERG9* protein (due to the frameshift). The *erg9* alleles from MBNA1-1 and  
25 MBNA1-9 retain low levels of activity. This was determined by transforming an ergosterol-requiring *erg9* deletion

mutant with plasmids that carry the mutant *erg9* genes from MBNA1-1 and MBNA1-9. The presence of the cloned genes in the *erg9* deletion strains allowed these transformants to grow, albeit slowly, on medium lacking ergosterol. The  
5 *erg9* allele from MBNA1-13 did not show any residual activity when tested in this manner. The *erg9* deletion strain grew at wild-type levels when transformed with the *ERG9* allele from ATCC 28383.

F. Description of Secondary Mutations

10 *Saccharomyces cerevisiae* does not normally import ergosterol from its environment under aerobic conditions. However, the isolated *erg9* mutants were able to grow aerobically when supplemented with ergosterol or cholesterol, and therefore, must contain secondary  
15 mutations that allow aerobic sterol uptake to occur. The methods used to isolate ergosterol pathway mutants, such as the *erg9* mutant MBNA1-13, included not only a selection for ergosterol pathway mutants, but a selection for cells that import sterols under aerobic conditions as well, since only  
20 mutants with mutations in both a sterol pathway gene and a sterol uptake gene would have survived.

In Example 3 below, the difficulty encountered when attempting to obtain *erg9* knockout mutations by molecular methods, even in a strain carrying the *upc2* mutation, which  
25 is reported to allow uptake of sterols under aerobic conditions (Lewis, T.L., G.A. Keesler, G.P. Fenner and L.W.

Parks, 1988, Pleiotropic mutations in *Saccharomyces cerevisiae* affecting sterol uptake and metabolism, *Yeast* 4: 93-106) is described. It appears that the *upc2* mutation does not confer efficient aerobic sterol uptake in an *erg9* mutant, and that the strains described in Example 3 acquired additional spontaneous mutations (at a low frequency rate) that improve their ability to take up sterols aerobically.

Having the appropriate mutations that enhance aerobic uptake of ergosterol and cholesterol in an otherwise wild type strain allow one to isolate *erg9* mutations in that strain at a much higher frequency than would be obtained with a non-sterol uptake mutant strain. In order to demonstrate that the *erg9* mutant strain MBNA1-13 (and derivatives of this strain) had acquired a mutation(s) that enhances uptake of sterols under aerobic conditions (referred to as sterol uptake enhancement or sue mutations), the frequency of creating an *erg9* knockout in the MBNA1-13 background, which contains the sterol uptake mutation, to the frequency of obtaining the *erg9* knockout mutation in the ATCC 28383 parental background, which presumably lacks the sterol uptake mutation, was compared. This was done with the following two strains representing each strain background. SWE23-ΔHE9 (*ura3*, *his3*, *sue*) was derived from MBNA1-13 and contains a repaired *ERG9* gene. SWY5-ΔH1 (*ura3*, *his3*) is an auxotrophic mutant derived from

strain ATCC 28383. The construction of SWE23- $\Delta$ HE9 and SWY5- $\Delta$ H1 is described in detail in Section G below. Since SWE29- $\Delta$ HE9 was derived from MBNA1-13, this strain served as the host carrying the *sue* mutation, whereas SWY5- $\Delta$ H, which  
5 was derived from ATCC 28383, served as the host without the *sue* mutation. Both strains were transformed with equal amounts (approximately 1  $\mu$ g) of the *erg9 $\Delta$ ::HIS3* DNA fragment obtained by digesting pKML19-41 (plasmid construction described in Example 3) with *Bam*HI and *Xma*I,  
10 and purifying the resulting 2.1 kb fragment. Cells were transformed with this 2.1 kb fragment using the LiAc transformation procedure (Gietz, R.D., R.H. Schiestl, A.R. Willems and R.A. Woods, 1995, Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure, *Yeast* 11: 355-360), and transformants were selected on SCE-  
15 ura medium. SCE medium contains 0.67% Bacto yeast nitrogen base (without amino acids), 2% dextrose, 20 mg/L adenine sulfate, 20 mg/L uracil, 20 mg/L L-tryptophan, 20 mg/L L-histidine, 20 mg/L L-arginine, 20 mg/L L-methionine, 30  
20 mg/L L-tyrosine, 30 mg/L L-leucine, 30 mg/L L-isoleucine, 30 mg/L L-lysine, 50 mg/L L-phenylalanine, 100 mg/L L-glutamic acid, 100 mg/L L-aspartic acid, 150 mg/L L-valine, 200 mg/L L-threonine, 400 mg/L L-serine and 5 mg/L ergosterol. For agar plates, 2% Bacto agar is added to the  
25 SCE medium. SCE-ura medium is SCE lacking uracil.

A total of 24  $HIS^+$  colonies arose from the transformation of SWY5- $\Delta H1$ , while 401  $HIS^+$  colonies were obtained from SWE23- $\Delta HE9$ . Since it was possible for the *erg9 $\Delta$ ::HIS3* gene to integrate at loci other than the *ERG9* locus (and therefore allowing the cells to remain prototrophic for ergosterol), twenty of each type of transformant were tested for an ergosterol requirement by plating onto YPD medium (lacks ergosterol). All 20 of the  $HIS^+$  colonies derived from SWY5- $\Delta H$  were able to grow on YPD which indicated that they still contained a functional *ERG9* gene, and suggested that the *erg9 $\Delta$ ::HIS3* gene was not integrated at the *ERG9* locus. On the other hand, none of the 20  $HIS^+$  colonies derived from SWE23- $\Delta HE9$  were able to grow on YPD indicating that the *erg9 $\Delta$ ::HIS3* DNA had replaced the wild type *ERG9* gene in this strain background at a relatively high frequency. To verify this, nine  $HIS^+$  colonies of each strain were analyzed by PCR to determine the types of *ERG9* alleles present in their genomes. Genomic DNA was prepared as described in Sherman et al. (1989). The oligonucleotides used for the analysis are given below.

5' oligo = 250 UpBam gcgcatCCACGGGCTATATAAA (SEQ ID NO:3)

3' oligo = 1764 LoBam gcggatCCTATTATGTAAGTACTTAG (SEQ ID NO:4)

PCR conditions were as follows:

94°C, 3 min.

94°C, 30 sec.; 50°C, 30 sec.; 72°C, 3 min.; 30 cycles  
72°C, 7 min.

Oligonucleotides 250 UpBam contains sequences  
corresponding to position #11555 to #11570 of the GenBank  
5 Accession #J05091 sequence. Oligo 1764LoBam contains the  
reverse complement of sequences from position #13049 to  
#13068 of the same GenBank sequence file. In all 9 of the  
HIS<sup>+</sup> transformants of SWE23-ΔHE9, the PCR product was 2.1  
kbp indicating that the *ERG9* gene had been replaced by the  
10 *erg9Δ::HIS3* gene. In 8 of the 9 HIS<sup>+</sup> transformants of SWY5-  
ΔH1, the PCR products were 2.1 kbp and 1.5 kbp, indicating  
that the wild type *ERG9* gene remained intact and that the  
*erg9Δ::HIS3* DNA had integrated elsewhere in the genome.  
The ninth HIS<sup>+</sup> transformant showed only the 1.4 kbp PCR  
15 product, also indicating that the *ERG9* gene was intact in  
this strain. In this case, the *HIS3* gene is believed to  
have integrated into the genome without carrying all of the  
*erg9* sequences with it.

These results show that during the course of isolating  
20 strain MBNA1-13, an additional mutation(s), referred to  
herein as *sue*, arose in the strain. Based on the results  
described in Example 3 below, the *sue* mutation appear to be  
different from the previously reported *upc2* mutation and  
confers more efficient uptake of sterols.

25 G. Derivation of New Strains from MBNA1-13



In order to use the *erg9* mutant strain MBNA1-13 for molecular genetic manipulations, the strain was further developed so that it carried auxotrophic markers suitable for this purpose. MBNA1-13 was mutagenized using ethyl methane sulfonate using standard procedures and mutants resistant to 5-fluoroorotic acid (5-FOA) were obtained by plating the mutagenized cells on medium containing 5-FOA. The use of 5-FOA selection was described in Sikorski and Boeke, 1991 (Sikorski, R.S. and Boeke, J.D., 1991, *In Vitro* Mutagenesis and Plasmid Shuffling: From Cloned Gene to Mutant Yeast, *Methods in Enzymology* 194: 302-318). This selection method allowed for the isolation of strains containing mutations in the *URA3* gene, coding for orotidine-5'-phosphate decarboxylase. Several resistant strains were isolated that exhibited 5-FOA resistance (i.e., a *ura<sup>-</sup>* phenotype). To determine which of these strains contained a mutation specifically in the *URA3* gene, the *ura<sup>-</sup>* strains were transformed with pRS316 (Sikorski and Hieter, 1989), which contains the intact *URA3* gene, using the LiOAc transformation procedure (Gietz et al., 1995). Several strains were identified whose lack of growth on medium lacking uracil was restored by pRS316, indicating that those strains carried the *ura3* mutation. One of these strains, EMS9-23 (*ura3*, *erg9*) was chosen for further modification.

Strain EMS9-23 was genetically altered to contain deletions in *leu2*, *trp1*, or *his3* genes using gene transplacement plasmids described in Sikorski and Hieter (1989), and the pop-in/pop-out gene replacement procedure described in Rothstein (1991) (Rothstein, R., 1991, Targeting, Disruption, Replacement, and Allele Rescue: Integrative DNA Transformation in Yeast, Methods in Enzymology 194: 281-301). The *leu2*, *trp1* and *his3* mutants derived from MBNA 1-13 were named SWE23- $\Delta$ L1, SWE23- $\Delta$ T1 and SWE23- $\Delta$ H1, respectively. Strain SWE23- $\Delta$ H1 was further manipulated to exchange the original *erg9* frameshift mutation (see Section E) with the *erg9 $\Delta$ ::HIS3* allele. This was done by transforming SWE23- $\Delta$ H1 (using the LiOAc procedure) with approximately 5  $\mu$ g of a linear DNA fragment containing the *erg9 $\Delta$ ::HIS3* cassette (the construction of the *erg9 $\Delta$ ::HIS3* cassette is described in detail in Example 3). The *erg9 $\Delta$ ::HIS3* cassette was obtained by digesting pKML19-40 with *Bam*HI and *Xma*I, and purifying the 2.1 kbp DNA fragment containing the *erg9 $\Delta$ ::HIS3* fragment. Transformants of SWE23- $\Delta$ H1 in which the *erg9* frameshift allele had been replaced by the *erg9 $\Delta$ ::HIS3* allele were selected by plating the transformants on SCE medium lacking histidine. One of the resulting strains is referred to as SWE23- $\Delta$ E91.

Strain SWE23-DH1 was further modified so as to contain mutations in the *leu2* and *trp1* genes. These mutations were

introduced using the gene transplacement plasmids (Sikorski and Hieter, 1981) and the pop-in/pop-out gene replacement procedure (Rothstein 1991) described above. One of the resulting strains is referred to as SW23-DH1 #42, and  
5 contains *erg9*, *ura3*, *his3*, *leu2*, *trp1*, and *sue* mutations. Strain SW23-DH1 #42 was further modified to exchange the original *erg9* frameshift mutation with the *erg9D::HIS3* allele. This was done by transforming SW23-DH1 #42 (using the LiOAc procedure) with approximately 5 mg of a linear  
10 DNA fragment containing the *erg9D::HIS3* cassette as described above. HIS<sup>+</sup> transformants in which the *erg9* frameshift mutation had been replaced by the *erg9D::HIS3* allele were selected on SCE-his medium. One of the resulting strains is referred to as SW23B, and carries  
15 mutations in the following genes : *ura3*, *leu2*, *trp1*, *his3*, *erg9::HIS3*, *sue*.

A summary of the strains derived from MBNA1-13 and their respective farnesol production in shake flask cultures is given in Table 6. The strains were grown  
20 overnight in YPDE medium (30°C with shaking at 180 rpm). These cultures were used to inoculate 25 ml of YPDE medium in a 250 ml flask such that the initial OD<sub>600</sub> was 0.05. The cells were grown for 72 hours at 30°C (with shaking at 180 rpm). Samples of the whole broth (i.e., cells plus culture  
25 medium) were analyzed for dry cell weight and farnesol as described in Section C above.

Table 6

## Growth and Farnesol Production in Strains Derived from MBNA1-13

Strain	Genotype	Farnesol (% of dry cell weight)
MBNA1-13	<i>erg9, sue</i>	7.9
EMS9-23	<i>erg9, ura3, sue</i>	8.0
SWE23-ΔH1	<i>erg9, ura3, his3-Δ200, sue</i>	7.9
SWE23-ΔL1	<i>erg9, ura3, leu2-Δ1, sue</i>	9.3
SWE23-ΔT1	<i>erg9, ura3, trp1-Δ63, sue</i>	10.8
SWE23-ΔE91	<i>erg9Δ::HIS3, ura3, his3, sue</i>	8.0

Strains MBNA1-13, EMS9-23 and SWE23-ΔE91 were further evaluated for growth and farnesol production in 1-L fermentors using the method described in Section H below. EMS9-23 and SWE23-ΔE91 were each transformed with plasmid YEp352, which contains the cloned *URA3* gene. This obviated the need to add uracil to the fermentation medium for these two strains. Fig. 4 and Table 7 summarize the results of these fermentations. MBNA1-13 and EMS9-23/YEp352 performed similarly. Although the growth of SWE23-ΔE91/YEp352 lagged behind the other two strains, it did reach a cell density and farnesol production level comparable to the other strains.

Table 7

## Comparison of MBNA1-13 and Strains Derived from it in 1-L Fermentors

Strain/Plasmid	Time (hr)	Dry Cell Weight (g/L)	Farnesol	
			g/L	(% of dry cell weight)
MBNA1-13	191	40.8	2.25	5.5
EMS9-23/YEp352	191	42.6	2.46	5.8
SWE23-ΔE91/YEp352	239	37.2	2.23	6.0

Strains EMS9-23 and SWE23- $\Delta$ H1 were further manipulated by repairing their *erg9* mutations back to wild type function. This was done by transforming the two strains (using the LiOAc transformation procedure) with approximately 5  $\mu$ g of a DNA fragment containing the intact *ERG9* gene. The *ERG9* gene DNA fragment was obtained by digesting pTWM103 (see Section E above) with *SacI* and *BamHI*, and purifying the 2.5 kb DNA fragment containing the *ERG9* gene. Transformants of EMS9-23 and SWE23- $\Delta$ H1 in which the *erg9* frameshift mutation had been replaced by the wild type *ERG9* gene were obtained from each strain by selecting for cells that could grow on YPD medium lacking ergosterol. One *erg9*-repaired strain derived from EMS9-23, designated SWE23-E9, and one *erg9*-repaired strain derived from SWE23- $\Delta$ H1, designated SWE23- $\Delta$ HE9, were chosen for further study. In separate experiments, auxotrophic mutations were introduced into the parental strain ATCC 28383. A spontaneous *ura3* mutant of ATCC 28383 was obtained after plating cells on medium containing 5-FOA as described above. Mutants resistant to 5-FOA were transformed with pRS316 (described above) to identify those that had spontaneously acquired a mutation specifically in their *URA3* gene. One strain, SWY5, exhibited a stable *ura*<sup>-</sup> phenotype (low reversion frequency), and was chosen for

further study. SWY5 was further manipulated to carry the *his3* mutation by using the gene transplacement plasmid YRp14/*his3*- $\Delta$ 200 described by Sikorski and Hieter (Sikorski and Hieter, 1989) and the pop-in/pop-out gene replacement procedure described by Rothstein (Rothstein, 1991). One *his3* mutant derived from SWY5, designated SWY5- $\Delta$ H, was chosen for further study.

Table 8 lists the repaired and auxotrophic strains described and their genotypes.

10

Table 8

Repaired and Auxotrophic Strains related to ATCC 28383 and MBNA1-13

Strain	Genotype	Parent
SWE23-E9	<i>ura3, sue</i>	EMS9-23
SWE23- $\Delta$ HE9	<i>ura3, his3, sue</i>	SWE23- $\Delta$ H1
SWY5	<i>ura3</i>	ATCC 28383
SWY5- $\Delta$ H	<i>ura3, his3</i>	SWY5

15

To test whether the *erg9* mutant MBNA1-13 had acquired any additional nutritional requirements during the course of its isolation, a growth experiment was conducted in shake flasks to compare the parental strain ATCC 28383, the *erg9* mutant strain EMS9-23 and the *erg9*-repaired strain SWE23-E9. The cultures were grown in YPD medium at 30°C with shaking at 180 rpm. The EMS9-23 culture was also supplemented with 5 mg/L ergosterol. Growth was monitored by OD<sub>600</sub>.

20

25

The results of this experiment, presented in Fig. 5, show that the growth of the *erg9* mutant was reduced, but that the growth of the wild-type parent strain 28383 and the *erg9*-repaired strain SWE23-E9 grew similarly. The slightly lower final OD<sub>600</sub> in the SWE23-E9 culture was probably due to the fact that this strain is a uracil auxotroph, and the concentration of uracil in the YPD medium was not optimal. These results indicate that the major cause of the growth defect in the *erg9* mutants is the *erg9* mutation itself. Other mutations in the *erg9* mutants, such as the *sue* mutation(s), do not have a significant effect on growth.

#### H. One-Liter Fermentation

Strains MBNA1-13, EMS9-23/YEp352 and SWE23-ΔE91/YEp352 were grown in one-liter fermentors under fed-batch conditions as described below. Under these conditions, farnesol production by these strains ranged from 5.5-6.0% of dry cell weight (data shown in Section G above) in 191-239 hours.

#### Fermentation Conditions And Materials:

The one-liter fermentation was performed by first autoclaving for 45 minutes at 121°C, in the fermenter, the following solution:

	(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>	10.0	g/L
	KH <sub>2</sub> PO <sub>4</sub>	10.0	g/L
	CaCl <sub>2</sub> -2H <sub>2</sub> O	0.5	g/L
30	NaCl	0.5	g/L

	MgSO <sub>4</sub> -7H <sub>2</sub> O	3.0	g/L
	yeast extract (Difco)	2.0	g/L
	salt solution	20.0	mL
	defoamer (Dow 1520)	4.0	drops
5	deionized water	500	mL.

After autoclaving, the following sterile solutions were added:

10	glucose solution (50%) w/v)	5.0	mL
	vitamin solution	15.0	mL
	ergosterol solution	0.2	mL.

15 The glucose and vitamin solutions were sterilized by passage through a 0.45 micron filter. The ergosterol solution is considered sterile (see below).

Glucose feed solution (made up in deionized water)

20	glucose solution (60% w/v)	360	mL
	yeast extract solution (12.5% w/v)	80	mL
	ergosterol solution	5.8	mL

25 Glucose, yeast extract sterilized by autoclaving; ergosterol considered sterile.

Inoculum

30 1 mL cell suspension frozen in 10% glycerol inoculated into 250 mL YPDE medium in 1000 mL baffled flask, incubated 48 hours at 29°C and 150 rpm; used 30 mL inoculum per fermenter.

Fermentation conditions

35 28°C  
pH 4.5  
Agitation 300 - 1000 rpm, aeration 50-200 mL/min as required to maintain dissolved oxygen at 10-60% of air saturation. Glucose feed solution added after initial glucose was depleted. Addition rate to achieve a growth rate of 0.04 hr<sup>-1</sup> considering that cell yield on glucose is 0.25. Maximum feed rate = 3.5 ml/hr.

45 Salt solution (given per liter in deionized water)

	FeSO <sub>4</sub> -7H <sub>2</sub> O	0.28	g
	ZnSO <sub>4</sub> -7H <sub>2</sub> O	0.29	g
	CuSO <sub>4</sub> -5H <sub>2</sub> O	0.08	g
50	Na <sub>2</sub> MoO <sub>4</sub> -2H <sub>2</sub> O	0.24	g
	CoCl <sub>2</sub> -6H <sub>2</sub> O	0.24	g
	MnSO <sub>4</sub> -H <sub>2</sub> O	0.17	g



HCl 0.10 mL

Vitamin solution (given per liter in deionized water)

5	biotin	10	mg
	Ca-pantothenate	120	mg
	inositol	600	mg
	pyridoxine-HCl	120	mg
	thiamine-HCl	120	mg

10

Ergosterol solution

	ethanol	20	mL
	IGEPAI	20	mL
15	ergosterol	0.4	g

Heat at 50°C with mixing until dissolved, store at - 20°C. IGEPAI is 1,3,3 tetramethyl butyl phenoxy (ethoxy), ethanol (Sigma Chemical Company, St. Louis, MO, Product IGEPAI CA-630, Cat. # I 3021).

20

### Example 2

This example describes the production of *erg9* mutants by chemical mutagenesis of *S. cerevisiae* strain 64031 using ethylmethane sulfonate (EMS). Strain 64031 (obtained from ATCC) is an *erg9-1* mutant that produces low levels of farnesol (see Example 1), and additional mutagenesis produced mutants exhibiting improved yields of farnesol.

A kill curve was performed using EMS, and a mutagenesis of 64031 was performed as described in Example 1. Selection was also performed as described in Example 1.

A total of 163 strains were found to be nystatin-resistant, *ts*, sterol auxotrophs. They were cultured in tubes and shake flasks, and farnesol production was determined as described in Example 1. The amounts of farnesol produced in the shake flask cultures are presented in Table 9.

35

TABLE 9

Strain	Farnesol (mg/ml)		Farnesol (% dry weight)	
	Cell	Medium	Cell extracts	Medium extracts
5 MBEMS8-1	0.038	0.019	1.7	0.8
MBEMS8-2	0.048	0.008	3.6	0.6
MBEMS8-5	0.013	0.022	0.5	1.0
MBEMS8-6	0.045	0.016	5.6	2.0
10 MBEMS8-11	0.024	0.003	2.0	0.2
MBEMS8-12	0.043	0.006	6.9	1.0
MBEMS8-16	0.026	0.001	3.5	0.2
MBEMS8-18	0.040	0.009	1.4	0.3
MBEMS8-19	0.023	0.003	2.8	0.4
MBEMS8-21	0.021	0.009	1.5	0.7
15 MBEMS8-23	0.025	0.008	2.9	0.9
MBEMS8-25	0.018	0.007	1.3	0.5
MBEMS8-26	0.028	0.011	3.7	1.5
MBEMS8-27	0.035	0.010	5.5	1.5
MBEMS8-31	0.020	0.011	1.1	0.6
20 MBEMS8-32	0.016	0.009	0.5	0.3
MBEMS8-33	0.000	0.000	0	0
MBEMS8-34	0.000	0.000	0	0
MBEMS8-35	0.000	0.000	0	0
ATCC64031	0.018	0.005	0.9	0.3
25 ATCC28383	0.000	0.000	0	0

Example 3

30 In Example 1.G. above, the creation of an *erg9* $\Delta$ ::*HIS3* mutant of MBNA1-13 was described. In this example, the construction of other haploid *S. cerevisiae* strains (not derived from MBNA1-13) containing an *erg9* deletion::*HIS3* insertion allele is described.

The *ERG9* gene was PCR amplified using genomic DNA isolated from strain S288C (according to the method of Sherman et al.) as template and the following two primers:

5' oligo = gag cat CCA CGG GCT ATA TAAA (SEQ ID NO:5);

5 250 BamUp

3' oligo = tcc ccc cg GGC GCA GAC TTC ACG CTC (SEQ ID NO:6); 1712 XmaLo

The PCR amplified *ERG9* DNA was digested with *Bam*HI and *Xma*I, then ligated to *Bam*HI, *Xma*I digested pRS316 (Yeast/*E. coli* shuttle vector, Sikorski and Hieter, 1989).

The PCR conditions were:

94°C for 1 min.-	1 cycle
94°C for 30 sec.	} 30 cycles
58°C for 1 min	
72°C for 1 min.	
72°C for 2 min.-	1 cycle

The *ERG9* gene cloned in this manner extends from position #11555 to position #13047 of GenBank Accession #U00030, and the resulting clone was named pJMB98-12. The construction of the deletion in *ERG9* and the insertion of *HIS3* DNA was done as follows:

The *HIS3* gene was obtained by digesting the *HIS3* containing plasmid pRS403 (Stratagene, LaJolla, CA) with *Eco*47III and *Ssp*I, and purifying the 1226 bp fragment containing the *HIS3* gene.

The plasmid pJMB98-12 was digested with *Van*91I, then treated with T4 DNA polymerase to make it blunt-ended. The

plasmid was further digested with *HpaI* so that an internal 589 bp fragment within *ERG9* was deleted. Into this site was ligated the 1226 bp *Eco47III*, *SspI* fragment containing the *HIS3* gene. The resulting plasmid, pKML19-41, has the

5 *HIS3* gene cloned within the deleted *ERG9* gene, with the *HIS3* coding sequence in the same orientation as the *ERG9* coding sequence.

To transform yeast with this *erg9Δ::HIS3* DNA, the plasmid pKML19-41 was digested with *SmaI* and *XbaI*, and the

10 2141 bp fragment containing the *erg9Δ::HIS3* gene was isolated. DNA was purified from agarose gel slices by using GeneClean.

Approximately 5 μg of purified *erg9Δ::HIS3* DNA was used to transform diploid strain CJ3A X CJ3B (*a/α*,  
15 *ura3/ura3*, *his3/his3*, *leu2/leu2*, *trp1/trp1*, *upc2/upc2*, obtained from Dr. L. Parks, N.C. State University, Raleigh, NC) using the lithium acetate transformation procedure described in Gietz, et al. (1995). CJ3A X CJ3B is homozygous for the *upc2* mutation. This mutation allows

20 sterol uptake under aerobic conditions (Lewis, et al., 1988). It was believed that the *upc2* mutation would allow the easy production of a haploid strain carrying a mutation in the *erg9* gene. The histidine auxotrophy was necessary to select for strains carrying the plasmids that contain

25 the functional *HIS3* gene.

The transformed cells were plated onto SCE medium (described in Example 1.F.) lacking histidine (SC-His) to select for HIS<sup>+</sup> transformants.

Hundreds of transformants were obtained. These HIS<sup>+</sup> cells were then patched onto SC-His and allowed to grow for two more days. The transformants were then patched onto sporulation medium (Sherman, et. al, 1986). Sporulation medium contains (per liter of distilled water): 1% potassium acetate, 0.1% Bacto yeast extract, 0.05% dextrose and 2% Bacto agar. The patches were then allowed to grow and sporulate for 3-5 days. A portion of the cells was removed and placed in a solution of lyticase to digest the ascus cell wall. The cells were then spread in a thin line onto a YPD + 2 mg/L ergosterol (YPDE) plate. The sporulated diploid cells form tetrads containing four spores, and the individual spores were separated using a micromanipulator. These individual haploid spores will germinate with each containing a single copy of the chromosomes.

A 2:2 segregation was expected for *erg9Δ::HIS3* knockouts in this strain. Two spores should be viable on YPD since they would contain the copy of the chromosome which was not disrupted (meaning they would not need ergosterol since they have a functioning *ERG9* gene and would be able to grow on YPD because histidine is present in the medium). The other two spores should grow on SC-His

+ 2 mg/L ergosterol (SCE-His) since, if the *erg9Δ::HIS3* DNA integrated at the *ERG9* site, the cells would require ergosterol, but would grow without histidine.

Tetrads from some of the pKML19-41 transformants were  
5 analyzed for phenotypic determination of the *erg9* knockout. The results showed that only two of the four spores were viable when grown aerobically. When these were replica-plated to YPD these two spores survived, but they did not survive on SC-His or SCE-His. This indicated a 2:2  
10 segregation and that the two surviving spores were of the parental type or auxotrophic for histidine. This indicated that the two that did not survive aerobically probably contained the *erg9:HIS3* knockout.

PCR analysis confirmed the results of an *erg9Δ::HIS3*  
15 knockout in several of the strains. Total DNA was isolated using a rapid DNA isolation method from several of the diploid transformants that showed the 2:2 segregation. The total DNA was then used as template for PCR amplification with primers complementing sequence 5' and 3' to the *ERG9*  
20 gene in the chromosome.

The oligonucleotides used for this analysis were as follows:

5'-oligo = 250 *Bam* Up (described above)

3'-oligo = 3*ERG9*-1 = gat ccg cg GCT CAA GCT AGC GGT ATT

25 ATG CC (SEQ ID NO:7)

3*ERG9*-1 contains sequences corresponding to the reverse complement of sequences from position #14812 to position #14790 of the GenBank Accession #U00030 sequence.

Oligonucleotide 250 *Bam* Up lies within the sequence of  
5 the *ERG9* clone used to construct the *erg9Δ::HIS3* allele, whereas oligonucleotide 3*ERG9*-1 lies downstream of the boundary of the cloned *ERG9* DNA. *ERG9* sequences amplified from genomic DNA by these two primers must represent *ERG9* genes located at the actual chromosomal *ERG9* locus, and  
10 will not amplify *erg9Δ::HIS3* sequences that integrated at other chromosomal locations.

The results showed two bands at 3.271 and 3.908 kb, indicating the presence in the diploid strains of one functional copy of the *ERG9* gene and one interrupted copy  
15 that is kb 637 bp larger due to the *HIS3* gene insertion.

Southern blot analysis also was performed to verify the *erg9Δ::HIS3* interruption in the diploids. Genomic DNA from a parental diploid strain carrying two normal copies of *ERG9* gene was compared to three different transformants  
20 believed to carry one normal *ERG9* gene and one disrupted *ERG9* gene. The DNA was digested with either *Acc* I or *Xba* I, separated by gel electrophoresis, transferred to an Immobilon S membrane, and probed with specific probes to examine the *ERG9* genes present. The probe in this case was  
25 a 1.4 kb fragment containing a portion of the *ERG9* gene.

The probe used for Southern blot analysis of genomic DNA was prepared from the PCR amplified *ERG9* gene using oligonucleotides 250 *Bam* Up and 1712 *Xma* Lo (described above). Plasmid pJMB98-12 was used as template. PCR  
5 conditions were:

94°C for 1 min.-	1 cycle
94°C for 30 sec.	} 30 cycles
58°C for 1 min	
72°C for 1 min.	
72°C for 2 min.-	1 cycle

The amplified *ERG9* DNA was purified and biotinylated, as described above. Approximately 1 µg of biotinylated probe was used to hybridize to the blot.

Hybridization of the probe to the specific DNA bands  
10 under stringent conditions identified complementary sequence being present. For the parental diploid, CJ3AxCJ3B, a single band was seen at 2.1 kb for the *Acc* I digest and a single band at 2.8 kb was seen with the *Xba* I digest. The putative *erg9Δ::HIS3* knockouts each contained  
15 two bands: bands at 2.1 kb and 1.3 kb for the *Acc* I digest; and bands at 2.8 kb and 3.4 kb for the *Xba* I digest. These results indicated the presence of one copy of the wild-type *ERG9* gene along with an *erg9Δ::HIS3* disruption in the transformed diploids.

20 Attempts were then made to grow the haploid cells anaerobically on YPDE agar. Strains that are blocked in the ergosterol pathway can take up sterols under anaerobic



conditions. Two of the spores grew rapidly under anaerobic conditions (*ERG9*, *his*-) and two grew very slowly (*erg9Δ::HIS3*). The spores of three of the strains *erg9Δ::HIS3* (KML505, KML510, and KML521) that grew  
5 anaerobically on plates were grown in liquid medium under anaerobic conditions and showed farnesol production. Upon further incubation of the original YPDE plates aerobically, it appeared that a few of the haploid strains that tested positive for farnesol production under anaerobic growth  
10 were growing. Three such viable spores (derived from KML505) arose after prolonged aerobic incubation. These aerobically-growing strains, designated as BKY1-2D, BKY1-7C, and BKY1-8D, all produced farnesol under aerobic conditions.

15 The parent strain KML510 (*a/α*, *ura3/ura3*, *his3/his3*, *trp1/trp1*, *leu2/leu2*, *upc2/upc2*, *ERG9/erg9Δ::HIS3*) containing either pJMB98-12 or pRS316 were sporulated and tetrads were dissected onto YPDE plates. The plates were incubated under aerobic conditions, and the following  
20 patterns of spore growth were observed.

Tetrad analysis of KML510/pJMB98-12 were done with 20 tetrads. 16 tetrads gave rise to two viable, fast-growing spores and two nonviable spores. All viable spores were *his*<sup>-</sup>, *erg*<sup>+</sup>. Three tetrads gave rise to two viable, fast-  
25 growing spores, one viable, slow-growing spore, and one non-viable spore. The viable, fast-growing were all *his*<sup>-</sup>,

erg<sup>+</sup>. The viable, slow-growing spores were all his<sup>+</sup>, erg<sup>-</sup>. One tetrad did not give rise to any viable spores. All of the his<sup>+</sup>, erg<sup>-</sup> spores were also ura<sup>-</sup>, indicating that pJMB98-12 did not segregate into these spores during meiosis. One  
5 of the his<sup>+</sup>, erg<sup>-</sup> spores was used for further studies, and was named BTY19-9C.

Tetrad analysis of KML510/pRS316 was done with 20 tetrads. 18 tetrads gave rise to two viable, fast-growing spores and two non-viable spores. Two tetrads gave rise to  
10 two viable, fast-growing spores, one viable, slow-growing spore, and one non-viable spore. All fast-growing spores were his<sup>-</sup>, erg<sup>+</sup>. All slow-growing spores were his<sup>+</sup>, erg<sup>-</sup>. All his<sup>+</sup>, erg<sup>-</sup> spores were also ura<sup>-</sup>, indicated that pRS316 did not segregate into these spores during meiosis. One of  
15 the his<sup>+</sup>, erg<sup>-</sup> spores was studied further, and was named BTY20-2A.

To confirm that BTY19-9C and BTY20-2A did not carry the wild-type *ERG9* gene, a PCR experiment was conducted using genomic DNA isolated from the two strains, and the  
20 oligonucleotides VE104-5 and VE105-3.

5'oligo = VE104-5 = gac tct AGA AGC GGA AAA CGT ATA  
CAC

3'oligo = VE105-3 = described above

VE104-5 contains sequences corresponding to position #11631  
25 to 116541 of GenBank Accession #U00030 sequence.

The predicted PCR product size for a functional *ERG9* gene was 2.23 kb, and for the *erg9Δ::HIS3* disruption, 2.87 kb. Strains BTY19-9C and BTY20-2A had a PCR product of approximately 2.87 kb, which indicated the presence of the  
5 *erg9Δ::HIS3* disruption.

Five strains (BKY1-2D, BKY1-7C, BKY1-8D, BTY19-9C and BTY20-2A) were evaluated for farnesol production in shake flasks. Strains BKY1-7C and BTY20-2A gave the best production of farnesol of the five strains, but BKY1-7C  
10 grew very slowly.

Transformants KML505, KML510, and KML521 were transferred to sporulation medium. Tetrads were dissected onto YPDE and allowed to grow for extended periods of time under aerobic conditions to look for growth of additional  
15 spores beyond the anticipated 2:2 segregation (viable:nonviable). Two additional spores were viable after further incubation under aerobic conditions. These two strains, BJY7-5D and BJY8-1A, produced farnesol in a tube screen.

20 Strains BJY7-5D and BJY8-1A were evaluated in shake flasks. BJY8-1A gave the best farnesol production (0.29 mg/ml, 4.7% based on cell dry weight) after 72 hours incubation. BJY7-5D gave 0.18 mg farnesol/ml, (3.5% based on cell dry weight).

25

#### Example 4

This example shows the overexpression of HMG CoA reductase in strains with and without a functional *ERG9* gene.

HMG CoA reductase has been proposed to be the key  
5 enzyme regulating the flow of carbon through the isoprenoid pathway. In *S. cerevisiae*, two genes, *HMG1* and *HMG2*, code for the two isozymes of HMG CoA reductase, designated HMGl<sub>p</sub> and HMG2<sub>p</sub>. Regulation of HMG CoA reductase is achieved through a combination of transcriptional and translational  
10 regulation as well as protein degradation. The segments of the *HMG1* and *HMG2* genes that encode the catalytic domains of the HMGl<sub>p</sub> and HMG2<sub>p</sub> isozymes have been cloned under transcriptional control of the strong promoter from the GPD (glyceraldehyde-3-phosphate dehydrogenase) gene. The  
15 plasmids containing these constructions (pRH127-3 and pRH124-31, containing the catalytic domains of HMGl<sub>p</sub> and HMG2<sub>p</sub>, respectively) were obtained from R. Hampton, U.C. San Diego. Strains of *S. cerevisiae* overexpressing the catalytic domain of HMGl<sub>p</sub> were reported to have an elevated  
20 flow of carbon through the isoprenoid pathway. This increased carbon flow was manifested as squalene and ergosterol overproduction (Donald, K.A.G., Hampton, R.Y., and Fritz, I.B., 1997, Effects of Overproduction of the Catalytic Domain of 3-Hydroxy-3Methylglutaryl Coenzyme A  
25 Reductase on Squalene Synthesis in *Saccharomyces*

*cerevisiae*. Applied and Environmental Microbiology 63:3341-3344).

A. HMG CoA Reductase Overexpression in Strains with a Functional *ERG9* Gene

5           In order to confirm that overexpressing HMG CoA reductase would result in increased carbon flow through the isoprenoid pathway in the strains derived from ATCC 28383, similar to other strains of *S. cerevisiae* (Donald, et. al., 1997), the strain SWY5, a *ura3* mutant of the parental  
10 strain ATCC 28383, and SWE23-E9, the *erg9* repaired version of EMS9-23 (strains described in Example 1.G. above), were transformed with plasmids pRH127-3 and pRH124-31. Transformations were performed using the LiOAc procedure (Gietz, et. al., 1995). Control strains carrying the empty  
15 vector YEp352 were also constructed. Representative transformants were tested for squalene and ergosterol production in a shake flask experiment. Cells were grown in 50 ml SCE-ura medium at 30°C, with shaking at 180 rpm for 48 hours. At 24 hours, 10 ml of the culture was  
20 withdrawn, and the cells harvested for HMGC<sub>o</sub>A reductase assays as described in Example I.D. At the end of the 48-hour growth period, an aliquot of the cultures was used to inoculate flasks containing 50 ml YPD medium such that the starting OD<sub>600</sub> of the cultures was 0.1. The cultures in YPD  
25 medium were grown for 72 hours at 30°C, with shaking at 180 rpm, and then analyzed for dry cell weight, squalene and

ergosterol accumulation. The extraction method used for this analysis was as follows. Ten ml of the culture was pelleted by centrifugation at 1,500 x g for 10 minutes. The cell pellet was resuspended in 1 ml of deionized water, and the cells were repelleted. Cell pellets were resuspended in 1 ml of deionized water and disrupted by agitation with zirconium silicate beads (0.5 mm diameter). The broken cell suspension was saponified with 2.5 ml of a 0.2% solution of pyrogallol (in methanol) and 1.25 ml of 60% potassium hydroxide solution at 75 degrees C for 1.5 hours. The samples were then extracted with 5 ml of hexane, vortexed for 3 minutes and centrifuged at 1,000 x g for 20 minutes to separate the phases. The hexane layer was then analyzed by GC-MS as described in Example 1.B.

The data from this experiment are shown in Table 10. Compared to the control strains carrying only the Yep352 vector, the strains that overexpress the catalytic domains of either HMG1p or HMG2p contained high levels of HMGCoA reductase activity and elevated levels of squalene. However, neither of the strains overexpressing HMG1p or HMG2p contained significantly increased levels of ergosterol. Nevertheless, these data show that increasing the activity of HMG CoA reductase in the MBNA1-13 strain lineage increases the carbon flow through the isoprenoid pathway.

Table 10.

Effect of Amplified HMGCoA Reductase Activity on Squalene  
and Ergosterol Production in Strains Having a Normal  
Isoprenoid Pathway

Strain/plasmid	Dry Cell Weight (g/L)	Squalene		Ergosterol		HMG CoA Reductase Activity (nmol/min/ mg)
		µg/ml	% dry wt.	µg/ml	% dry wt.	
SWY5/ YEp352	7.68	0.18	0.003	2.9	0.038	2.4
SWY5/ pRH127-3	6.82	3.50	0.051	5.2	0.076	52
SWY5/ pRH124-31	7.49	4.15	0.055	2.9	0.039	27
SWE23-E9/ YEp352	6.96	0.33	0.005	5.5	0.079	2.7
SWE23-E9/ pRH127-3	6.89	6.78	0.099	8.3	0.121	55
SWE23-E9/ pRH124-31	6.90	4.90	0.071	6.1	0.088	29

B. HMG CoA Reductase Overexpression in an *erg9* Mutant

Having shown that amplification of HMG1p or HMG2p increased carbon flow to squalene, whether overexpression of HMG1 or HMG2 would increase farnesol production in a strain carrying the *erg9* mutation was tested. Strain SWE23-ΔE91 (described in Example 1.G.) was transformed with plasmids pRH127-3 or pRH124-31. Transformation of SWE23-ΔE91 was accomplished using the LiOAc transformation procedure (Gietz et al, 1996). Approximately 2.5 µg of pRH127-3 or pRH124-31 DNA were used in each transformation. Transformants were selected on SCE-ura plates, and several were chosen and restreaked for purification on SCE-ura plates. To test the effect of amplified HMG CoA reductase

on farnesol production, representative transformants were grown for 48 hours in liquid SCE-ura medium. A control strain, SWE23- $\Delta$ E91/YEp352, was also included in the experiment. At the end of the 48 hours growth period, aliquots of the cultures were used to inoculate flasks containing 50 ml of YPDE medium such that the initial OD<sub>600</sub> was 0.5. These cultures were grown for 72 hours at 30°C, with shaking at 180 rpm. At the end of the incubation period, samples were analyzed for dry cell weight and farnesol concentration. To confirm that the HMG CoA reductase genes were being overexpressed in the transformants, 20 ml of the cultures grown in SCE-ura were harvested by centrifugation at 1500 x g for 10 minutes, and HMG CoA reductase activity measured using the permeabilized cell method described in Example I.D. The data from this experiment are shown in Table 11.

Table 11. Effect of Elevated HMG CoA Reductase Activity on Farnesol Production in an *erg9*: $\Delta$ -*HIS3* Mutant Grown in Shake Flask Cultures.

Strain/plasmid	Dry Cell Weight (g/L)	Farnesol		HMG CoA Reductase Activity (nmol/min/mg)
SWE23- $\Delta$ E91/ YEp352	3.31	222	6.7	7.5
SWE23- $\Delta$ E91/ pRH127-3	3.87	104	2.7	47.0
SWE23- $\Delta$ E91/ pRH124-31	3.48	104	3.0	36.0

In both SWE23- $\Delta$ E91/pRH127-3 and SWE23- $\Delta$ E91/pRH124-31, the levels of HMG CoA reductase activity were elevated. However, the farnesol production in these strains was lower



than the control strain SWE23- $\Delta$ E91/YEp352. This unexpected result was observed several times in independent experiments.

Despite the failure of amplified HMG CoA reductase activity to increase farnesol production in an *erg9 $\Delta$ ::HIS3* strain grown in shake flask cultures, the strains listed in Table 12 were tested for farnesol production in 1-L fermentors using the protocol described in Example 1.H. Under these conditions, the expected result was observed; the strains overexpressing HMG CoA reductase produced significantly more farnesol than the control strain. The data are summarized in Figure 6 and Table 12. The elevation of HMG CoA reductase activity in strains SWE23- $\Delta$ E91/pRH127-3 and SWE23- $\Delta$ E91 /pRH124-31 was confirmed by direct enzyme assay using the permeabilized cell method. This is illustrated by the reductase activities at specific time points during the fermentation (shown in Table 12).

Table 12. Effect of Elevated HMG CoA Reductase Activity on Farnesol Production in an *erg9 $\Delta$ ::HIS3* Mutant Grown in 1-L Fermentors.

Strain/plasmid	Time (hr.)	Dry Cell Weight (g/L)	Farnesol		HMG CoA Reductase Activity (nmol/min/mg)
			g/L	% dry cell weight	
SWE23- $\Delta$ E91/YEp352	239	37.2	2.23	6.0	4.1
SWE23- $\Delta$ E91/pRH127-3	310	35.0	3.06	8.7	20
SWE23- $\Delta$ E91/pRH124-31	261	31.7	3.05	9.6	14

Example 5

This example describes the overexpression of various GGPP synthases in *erg9* mutants.

In order to convert FPP produced in *erg9* mutant strains to GGPP (the precursor of desired product, GG), the  
5 genes coding for various GGPP synthases in *erg9* mutants were overexpressed. The genes cloned for this purpose were the *BTS1* gene from *Saccharomyces cerevisiae*, the *crtE* gene from *Erwinia uredovora*, the *al-3* gene from *Neurospora crassa*, and the *ggs* gene from *Gibberella fujikuroi*.  
10 Plasmids carrying these genes were constructed as follows.

To clone the *BTS1* gene, genomic DNA was prepared from *S. cerevisiae* strain S288C according to the method described in Sherman, et. al. (1986). The gene was amplified by PCR using the following two oligonucleotides.

15

5'oligo = VE100-5 gactctAGAGTTTACGAGTCTGGAAAATC (SEQ ID NO:8)

3'oligo = VE101-3 gtaggATCCATGGAATTGAGCAATAGAG (SEQ ID NO:9)

20

The PCR conditions were: 94°C, 3 minutes; 94°C, 1 minute; 52°C, 1 minute; 74°C, 1.5 minutes; 30 cycles; then 74°C, 7 minutes (1 cycle). The PCR product was digested with *Xba*I and *Bam*HI and ligated into *Xba*I, *Bam*HI digested pPGK315 to  
25 generate pTWM101. The plasmid pPGK315 contains the *S. cerevisiae* PGK promoter and terminator separated by a

multiple cloning site. Cloning the *BTS1* gene into pPGK315 as described above placed the *BTS1* gene under control of the strong PGK promoter. Plasmid pPGK315 was constructed by digesting plasmid pRS315 with *SacII* and *SmaI*, then  
5 treating with T4 DNA polymerase to create blunt ends. The plasmid was religated to generate pRS315-DSS. Plasmid pRS315DSS was then digested with *XhoI* and ligated with a 994 bp *SaII*, *XhoI* fragment obtained from plasmid pPGKMCS that contained the PGK promoter and terminator separated by  
10 a multiple cloning site. Plasmid pPGKMCS was constructed by digesting pPGK (Kang et. al., 1990, Mol. Cell. Biol., 10:2582) with *EcoRI* and *BamHI*, then ligating with the following two annealed oligonucleotides.

15 5'oligo = AATTCCAAGCTTGCGGCCGCTCTAGAACGCGTG (SEQ ID NO:10)  
3'oligo = GATCCACGCGTTCTAGAGCGGCCGCAAGCTTG (SEQ ID NO:11)

Plasmid pTWM110-11 was constructed by ligating a 2397 bp *KpnI-SalI* fragment containing the PGK promoter/*BTS1*/PGK  
20 terminator (obtained by digestion of PTWM110 with *KpnI* and *SalI*) into *KpnI-SalI*-digested YEp352.

To clone the *crtE* gene, genomic DNA was isolated from *E. uredovora* strain 20D3 using the PureGene genomic DNA Isolation Kit (Gentra Systems, Inc., Minneapolis, MN) The  
25 *crtE* gene was amplified using the genomic DNA and the following two oligonucleotides.

5'oligo = 20D3Up      gaattcGTTTATAAGGACAGCCCGA (SEQ ID  
NO:12)

3'oligo = 20D3Lo      ctgcagTCCTTAACTGACGGCAGCGA (SEQ ID  
NO:13)

5

Oligo 20D3Up contains sequences corresponding to position  
#206 to #224 of the Genbank Accession #D90087 sequence.  
Oligo 20D3Lo contains the reverse complement of sequences  
from position #1117 to #1136 of the same Genbank sequence  
10 file. The amplified DNA was ligated into the *SrfI* site of  
pCR-Script SK(+) (Stratagene, La Jolla, CA) to generate  
plasmid pSW1-B. This plasmid was then digested with *EcoRI*  
and *SacI*, and the 973 bp fragment containing the *crtE* gene  
was purified and ligated into *EcoRI-SacI* digested pAD314-  
15 956 to generate plasmid pSW2B. Plasmid pSW2-B was digested  
with *BamHI* to generate a 2199 bp fragment containing the  
*ADH1* promoter, *crtE* coding sequence, and *ADH1* terminator,  
and this fragment was ligated into *BamH* digested YEp352 to  
generate pSW4A, which placed the *crtE* gene in the  
20 orientation opposite to that of the *URA3* gene in the  
plasmid, and pSW4B, which placed the *crtE* gene in the same  
orientation as the *URA3* gene.

Plasmid pADH313-956 was generated in the following  
manner. Plasmid pRS313 (Sikorski and Hieter, 1989) was  
25 digested with *SacI* and *XbaI*, treated with T4 DNA polymerase  
to create blunt ends, then relegated to generate plasmid

pDSX313. This plasmid was digested with *Sma*I and *Apa*I, treated with T4 DNA polymerase to create blunt ends, and then relegated to generate pDSXSA313. Plasmid pAAH5 (Ammerer, G., 1983, Meth. Enzymol. 101:192-201), which  
5 carries the *ADH1* promoter and terminator separated by a *Hind*III site, was digested with *Hind*III, then ligated to the following two annealed oligonucleotides to introduce a multiple cloning site and create pAAH5-MCS.

10            5' oligo =MCS1 AGCTGAATTCGAGCTCGGTACCCGGGCTCTAGAGTC  
             GACCTGCAGGCATGCA (SEQ ID NO:14)

3' oligo = MCS2      AGCTTGCATGCCTCCAGGTCGACTCTAGAGCC  
CG    GGTACCGAGCTCGAATTC    (SEQ ID  
NO:15)

15

A PCR reaction containing pADH313-MCS as template and the following two oligonucleotides was performed, and a 1232 bp PCR product containing the *ADH1* promoter, multiple cloning site, and *ADH1* terminator was obtained.

20

5'oligo = ADH1A gacggatCCGTGGAATATTTCCGATATCC (SEQ ID NO:16)

3'oligo = ADH1B      ctcggatccGGACGGATTACAACAGGTATTGTCC  
(SEQ ID NO:17)

25

Oligo ADH1A contains sequences corresponding to position #16 to #37 of the Genbank Accession #V01292 sequence. Oligo ADH1B contains the reverse complement of sequences from position #2092 to #2116 of the same Genbank  
5 sequence file. The 1232 bp PCR product was digested with *Bam*HI and ligated into *Bam*HI digested pDSXSA313 to generate plasmid pADH313-956.

To clone the *N. crassa al-3* gene, genomic DNA was isolated from *N. crassa* strain ATCC 14692 using the method  
10 described by Borges et al. in the methods section of the Fungal Genetics Stock Center's web site ([www.kumc.edu/research/fgsc/fgn37/borges.html](http://www.kumc.edu/research/fgsc/fgn37/borges.html)). The gene was amplified by PCR using the following two oligonucleotides.

15

5'oligo = VE118-5    *cagaatTCACCATGGCCGTGACTTCCTCCTC*  
(SEQ ID NO:18)

3'oligo = VE119-3    *caagatctCATACATTCAATCCTCATGGACAC*  
(SEQ ID NO:19)

20

Oligo VE118-5 contains sequences corresponding to position #1216 to #1240 of the Genbank Accession #U20940 sequence. Oligo VE119-3 contains the reverse complement of sequences from position #2576 to #2599 of the same Genbank  
25 sequence file. The amplified DNA was ligated into the *Srf*I site of pCR-Script SK(+) (Stratagene, La Jolla, CA) to

generate pSW7-1 and pSW7-2, two independent PCR clones of the *al-3* gene. These two plasmids were then digested with *EcoRI* and *BglIII*, and the 1393 bp fragment containing the *al-3* gene was purified and ligated into *EcoRI*, *BamHI*  
5 digested pPGK (Kang et. al., 1990) to generate pSW9-1 and pSW9-2, with the *al-3* sequence in each derived from pSW7-1 and pSW7-2, respectively.

To clone the *ggs* gene, genomic DNA was prepared from *Gibberella fujikui* strain ATCC 12617, using the same  
10 procedure described above for *Neurospora*. The *ggs* gene was amplified by PCR using the following two oligonucleotides.

5'oligo = VE120-5    gagaattCTTAACACGCATGATCCCCACGGC  
(SEQ ID NO:20)

15        3'-oligo = VE121-3    ctggatcCGTCAAATCCGTGAATCGTAACGAG  
(SEQ ID NO:21)

Oligo VE120-5 contains sequences corresponding to position #607 to #630 of the Genbank Accession #X96943  
20 sequence. Oligo VE121-3 contains the reverse complement of sequences from position #1908 to #1932 of the same Genbank sequence file. The amplified DNA was ligated into the *SrfI* site of pCR-Script SK(+) to generate pSW8-1 and pSW8-2, two independent PCR clones of the *ggs* gene. These two plasmids  
25 were then digested with *EcoRI* and *BamHI*, and the 1335 bp fragment containing the *ggs* gene was purified and ligated

into *EcoRI*, *BamHI* digested pPGK to generate pSW10-1 and pSW10-2, with the *ggs* sequence in each derived from pSW8-1 and pSW8-2, respectively.

Strain EMS9-23 (*ura3*, *erg9*, described in Example 1.G.)  
5 was transformed with the plasmids described above using the LiOAc method, and transformants were selected on SCE-ura plates. Transformants were picked and restreaked on SCE-ura plates for purification. Representative transformants were tested for GG production. The strains were grown at  
10 30°C for 48 hours in liquid SCE-ura medium, then used to inoculate flasks containing YPDE medium, such that the initial OD<sub>600</sub> was 0.5. These cultures were incubated at 30°C with shaking for 72 hours and analyzed for dry cell weight, farnesol and GG levels. A second set of flasks containing  
15 20 ml of SCE-ura medium was also inoculated from the same starting cultures and was grown for 48 hours. The cells from these flasks were harvested, washed with 10 ml 50 mM BisTris-Propane buffer, pH 7.0, and repelleted. The cell pellets were then used to prepare permeabilized cell  
20 suspensions for GGPP synthase assays. The cells were permeabilized by resuspending in 1 ml of 50 mM Bis-Tris-Propane buffer, pH 7.0, containing 0.1% Triton X100, and frozen at 80°C until needed. After thawing, the permeabilized cells were used for GGPP synthase assays.  
25 The GGPP synthase assay mixture contained 0.05M Bis-Tris propane buffer, pH 7.0 (Xpl), 0.1M dithiothreitol (1pl), 1



mg/ml FPP (5  $\mu$ l), 1 mg/ml IPP (5  $\mu$ l) and permeabilized cells (Y  $\mu$ l), where X + Y = 87  $\mu$ l. A control reaction was included in which the FPP and IPP were omitted. The assay mixtures were incubated at 37°C for 20 minutes. 0.1 ml of 2X glycine buffer (0.2M glycine, 2mM MgCl<sub>2</sub>, 2mM ZnCl<sub>2</sub>, pH 10.4) and 63 units of alkaline phosphatase (Sigma Chemical Co., St. Louis, MO) were added, and the mixtures were incubated for 60 minutes at 37°C. The mixtures were then extracted with 0.2 ml 1:1 hexane:ethyl acetate, and analyzed for GG by GC/MS. GGPP synthase activity is expressed as nmol GGPP formed/min/mg protein.

The dry cell weights, farnesol production, GG production and GGPP synthase activities for the strains are summarized in Table 13. The control strain, EMS923/YEp352, which lacks a cloned GGPP synthase, made 8.7% farnesol (based on dry cell weight) and essentially no GG. The four other strains, each of which overexpressed a different cloned GGPP synthase, produced approximately the same amount of farnesol as the control (8.0 - 9.74%) and produced levels of GG ranging from 0.62 - 1.73%.

**Table 13. GG Production in Shake Flask Cultures of Strains Overexpressing Four Different Cloned GGPP Synthase Genes.**

Strain	Cloned GGPP synthase gene	Dry cell weight (g/L)	FOH (% of dry cell weight)	GC (% of dry cell weight)	GGPP synthase activity (nmol/min/mg)
EMS9-23/YEp352	-	3.38	8.7	0.01	ND
EMS9-23/pTWM110-11	<i>BTS1</i>	3.12	8.98	1.73	0.065
EMS9-23/pSW4B	<i>crfE</i>	2.02	9.74	1.68	0.094
EMS9-23/pSW9-1	<i>al3</i>	3.38	8.0	0.62	0.032
EMS9-23/pSW10-2	<i>ggs</i>	3.16	9.3	1.0	0.03

The effect of amplification of GGPP synthase activity on GG production was further evaluated in I-L fermentors. Strain EMS9-23 was transformed with plasmid pTWM110-11, carrying the cloned *S. cerevisiae* *BTS1* gene. Strain SWE23-  
5  $\Delta$ E91 (described in Example 1.G. above) was transformed with either Yep352 (vector control) or pSW4A-3 (an individual isolate of plasmid pSW4A, carrying the cloned *crtE* gene). Strains SWE23- $\Delta$ E91/YEp352, EMS9-23/pTWM110-11 and SWE23- $\Delta$ E91/pSW4A-3 were grown in 1-liter fermentors using the  
10 method described in Example 1.H., and growth, farnesol production and GG production were compared.

The results are shown in Figure 7 and Table 14. The growth of the three strains was similar. Strain SWE23- $\Delta$ E91/YEp352 produced 2.32 g/L farnesol in 236 hours, and  
15 did not produce any detectable GG. EMS9-23/pTWM110-11 produced 2.1 g/L farnesol in 239 hours and also produced 0.42 g/L GG in the same time period. Strain SWE23- $\Delta$ E91/pSW4A-3 produced 2.47 g/L farnesol in 236 hours and also produced 0.59 g/L GG in the same period. The GGPP  
20 synthase activity in the control strain was below detectable limits. The production of GG by strains EMS9-23/pTWM110-11 and SWE23- $\Delta$ E91/pSW4A-3 correlated to increased GGPP synthase activity.

Table 14.

Growth, Farnesol and GG Production in Strains Overexpressing GGPP Synthases and Grown in 1-L Fermentors

Strain/Plasmid	Time (hr.)	Dry Cell Weight (g/L)	Farnesol		GG		GGPP Synthase Activity (nmol/min/mg)
			g/L	% Dry Cell Weight	g/L	% Dry Cell Weight	
SWE23-ΔE91/YEp352	236	43.9	2.32	5.3	0	0	not detected
EMS9-23/pTWM110-11	239	41.9	2.10	5.0	0.42	1.0	0.2
SWE23-ΔE91/pSW4A-3	236	43.5	2.47	5.7	0.59	1.4	1.1

Example 6

This example illustrates the effect of overexpressing the *ERG20* gene which encodes FPP synthase.

To determine the effects of elevating FPP synthase levels in *erg9* mutants, the *ERG20* gene coding for FPP synthase from *Saccharomyces cerevisiae* was cloned for overexpression. The *ERG20* gene was amplified by PCR using genomic DNA from *S. cerevisiae* strain S288C (prepared according to the method described in Sherman et al., 1986). and the following two oligonucleotides.

5' oligo = BamFPPUp ggccggatccATATTACGTAGAAATGGCTTCAG  
(SEQ ID NO:22)

3' oligo = XhoFPPLo gccgctcgagGGTCCTTATCTAGTTTG  
(SEQ ID NO:23)

Oligo BamFPPUp contains sequences corresponding to position #790 to #810 of the Genbank Accession # J05091 sequence. Oligo XhoFPPLo contains the reverse complement

of sequences from position #1891 to #1907 of the same Genbank sequence file. The PCR product was digested with *Bam*HI and *Xho*I, and ligated into a vector containing the *S. cerevisiae* GPD (glyceraldehyde-3-phosphate dehydrogenase) promoter and PGK terminator. The promoter/terminator vector was obtained by digesting a plasmid containing the catalytic domain of the *S. cerevisiae* *HMG2* gene cloned between the GPD promoter and PGK terminator, namely pRH124-31 (described in Example 4), with *Bam*HI and *Sal*I to remove the *HMG2* DNA. The 6.3 kb band corresponding to the promoter/terminator vector was purified and ligated to the 1129 bp fragment containing *ERG20* to generate pJMB1931 and pJMB19-32. Plasmids pJMB19-31 and pJMB19-32 were used to transform strain SWE23-ΔE91 (*ura3*, *his3*, *erg9Δ::HIS3*) using the LiOAc method, and transformants were selected on SCE-ura plates. Transformants were picked and restreaked on SCE-ura plates for purification.

To determine the effects of FPP synthase overexpression in *erg9* mutant strains, representative transformants constructed as described above were grown in shake flask cultures and compared for growth, farnesol production, GG production and FPP synthase and GGPP synthase activities. The strains were grown with shaking at 30°C for 48 hours in liquid SCE-ura medium, then used to inoculate flasks containing YPDE medium, such that the initial OD<sub>600</sub> was 0.5. These cultures were incubated at 30°C

with shaking for an additional 72 hours and analyzed for dry cell weight, farnesol and GG levels. A second set of flasks containing 20 ml of SCE-ura medium was also inoculated from the same starting cultures and was grown for 48 hours. The cells from these flasks were harvested, washed with 10 ml 50 mM BisTris-Propane buffer, pH 7.0, and repelleted. The cell pellets were then used to prepare permeabilized cell suspensions for FPP and GGPP synthase assays. The cells were permeabilized by resuspending in 1 ml of 50 mM Bis-Tris-Propane buffer, pH 7.0, containing 0.1% Triton X100, and frozen at 80°C until needed. After thawing, the permeabilized cells were used for assays. The GGPP synthase assay mixture was the same as described in Example 5. The FPP synthase assay mixture contained 0.05 M Bis-Tris propane buffer, pH 7.0 (X  $\mu$ l), 0.1M dithiothreitol (1  $\mu$ l), 0.5M  $MgCl_2$  (2 $\mu$ l), 1 mg/ml IPP (6  $\mu$ l), 1 mg/ml geranyldiphosphate (GPP) (6  $\mu$ l), and permeabilized cells (Y  $\mu$ l), where  $X + Y = 85 \mu$ l. A control reaction was included in which the IPP and GPP were omitted. The assay mixtures were incubated at 37°C for 15 minutes. 0.1 ml of 2X glycine buffer (0.2M glycine, 2mM  $MgCl_2$ , 2mM  $ZnCl_2$ , pH 10.4) and 63 units of alkaline phosphatase (Sigma Chemical Co., St. Louis, MO) were added, and the mixtures were incubated for 60 minutes at 37°C. The mixtures were then extracted with 0.2 ml 1:1 hexane:ethyl acetate, and analyzed for

Farnesol by GC/MS. FPP synthase activity is expressed as nmol FPP formed/min/mg protein.

The data presented in Table 15 show that overexpression of FPP synthase did not increase farnesol production, but did, unexpectedly, increase GG production in these shake flask cultures. The level of GG produced by SWE23-ΔE91/pJMB19-31 or SWE23-ΔE91/pJMB19-32 was even higher than observed for the strain (EMS923/pTWM110-11) overexpressing the *S. cerevisiae* *BTS1* (GGPP synthase) gene.

Table 15. GG production in *erg9* mutants overexpressing FPP synthase and GGPP synthase

Strain/plasmid	Cloned gene (enzyme encoded)	Dry cell weight (g/L)	FOH (% of dry cell weight)	GG (% of dry cell weight)	FPP synthase activity (nmol/min/mg)	GGPP synthase activity (nmol/min/mg)
EMS9-23/YEp352	-	3.32	9.24	0.17	2.3	Not detected
EMS9-23/pTWM110-11	<i>BTS1</i> (GGPP synthase)	3.12	8.98	1.73	Not tested	0.19
SWE23-ΔE-91/pJMB19-31	<i>ERG20</i> (FPP synthase)	3.11	7.85	2.28	53.0	Not tested
SWE23-ΔE-91/pJMB19-32	<i>ERG20</i> (FPP synthase)	3.28	8.08	2.29	51.0	Not tested

The effect of amplification of FPP synthase activity on GG production was further evaluated in 1-L fermentors. Strains SWE23-ΔE91/YEp352 (control), EMS9-23/pSW4A3 (*crtE*, GGPP synthase) and SWE23-ΔE91/pJMB19-32 (*ERG20*, FPP synthase) were grown in 1-liter fermentors using the method

described in Example 1.H., and growth, farnesol production, GG production and GGPP synthase activity were compared (Figure 8 and Table 16). The growth of the three strains was similar, although SWE23- $\Delta$ E91/pJMB19-32 lagged behind before growing at a rate similar to the other strains. Strain SWE23- $\Delta$ E91/YEp352 produced 2.31 g/L farnesol in 258 hours, and did not produce any detectable GG. EMS9-23/pSW4A3 produced 2.52 g/L farnesol and 0.57 g/L GG in 258 hours. Strain SWE23- $\Delta$ E91/pJMB19-32 produced 1.95 g/L farnesol in 258 hours and also produced 0.59 g/L GG in the same period. The unexpected GG production by SWE23- $\Delta$ E91/pJMB19-32 correlated to increased GGPP synthase activity in this strain (see below).

No GGPP synthase activity was detected in the control strain SWE23- $\Delta$ E91 /YEp352. Strain EMS9-23/pSW4A3, expressing the *E. uredovora crtE* (GGPP synthase) gene showed relatively high GGPP synthase activity (1.7 nmol/min/mg in cells from the 258-hour time point). As expected, strain SWE23- $\Delta$ E91/pJMB19-32, which overexpresses the *S. cerevisiae* FPP synthase, contained FPP synthase activity that was elevated >10-fold at all time points across the fermentation compared to a control having only normal levels of FPP synthase (data not shown). Surprisingly, however, strain SWE23- $\Delta$ E91/pJMB19-32 also had elevated GGPP synthase activity (Table 16). This activity

undoubtedly accounts for the unexpected GG production by this strain.

The elevated GGPP synthase activity detected in strain SWE23- $\Delta$ E91/pJMB19-32 could be a result of the overexpression of FPP synthase inducing the activity of the GGPP synthase (the *BTS1* gene product). It is also possible, however, that the FPP synthase has some low level of GGPP synthase activity which is revealed in this strain because of the high degree of overproduction of the FPP synthase.

Table 16. Effect of Amplified FPP Synthase on Growth, Farnesol and GG Production of Strains Grown in 1-L Fermentors

Strain/plasmid	Time (hr.)	Dry Cell Weight (g/L)	Farnesol		GG		GGPP Synthase Activity (nmol/min/mg)
			g/L	% of Dry Cell Weight	g/L	% of Dry Cell Weight	
SWE23- $\Delta$ E91/ Yep352	258	42.2	2.31	5.5	0	0	Not detected
EMS9-23/pSW4A3	258	44.3	2.52	5.3	0.57	1.28	1.7
SWE23- $\Delta$ E91/ pJMB19-32	258	41.1	1.95	4.7	0.55	1.34	1.0

#### Example 7

This example evaluates several farnesol extraction procedures.

In the first experiment, a comparison was made between extraction of the whole broth (cells plus medium) and separate extractions of the cell pellet and medium under



various conditions for MBNA1-13 (farnesol producer) and ATCC 28383 (ergosterol producer) (see Example 1). A 10 ml sample of culture was extracted generally as described in Example 1, but with the changes indicated in Table 17 below. Method 1 in Table 17 is the same as the extraction method described in Example 1. It was found that, for farnesol extraction, a whole broth extraction was just as efficient as a separate cell and medium extraction for methods 1, 2, 3, 5 and 7. The most farnesol was extracted by method 5, which is just a 2 ml addition of 0.2% pyrogallol in methanol prior to extracting the whole broth into hexane. The second highest extraction was method 1.

TABLE 17

15	Extraction method	pyrogallol 0.2% in MeOH	60% KOH in dH2O	Incubation 75°, 1.5h	Hexane
	1	2ml	1ml	yes	5ml
	2	2ml	1ml	no	5ml
	3	2ml	0	yes	5ml
	4	0	1ml	yes	5ml
20	5	2ml	0	no	5ml
	6	0	1ml	no	5ml
	7	0	0	no	5ml

Next, experiments were conducted to determine the effects of the type of extraction solvent (method 1, whole broth), times used for extraction (method 1, hexane extraction, whole broth), and the amount of methanol added prior to extraction (method 1, hexane extraction, whole

broth). The results are presented in the Tables 17-19 below.

Table 17

	Solvent	Farnesol (ng)
5	Hexane	3273
	Chloroform	2262
	Ethyl acetate	3549
	N-heptane	3560
	Hexadecane	Not determined*
10	Dodecane	3529
	Toluene	1055
	Carbon tetrachloride	2023
	Isobutyl Alcohol	2892
15	1-Octanol	1814

\* Solvent peak coeluted with farnesol, making quantification of farnesol impossible using this method.

20

Table 18

	Vortex time (min)	Farnesol (ng)
	0	204
	0.25	2794
25	0.5	2691
	1.0	2894
	1.5	3302
	2.0	3348
	2.5	3357
30	3.0	3545
	3.5	3535

Table 19

	Methanol volume (ml)	Farnesol (ng)
	0	3440
5	0.2	2820
	0.4	3000
	0.6	3440
	0.8	3690
	1.0	3730
10	1.2	4580
	1.4	4350
	1.6	4020
	1.8	3880

15           Further work was done to optimize and simplify the extraction procedure for farnesol, and to adapt the procedure for extraction of GG from fermentation broths. This work resulted in the final extraction protocol described below.

- 20           1. Whole fermentation broth is used undiluted or diluted appropriately with water to a final volume of 2.0 ml in a 15 ml teflon capped glass test tube.
2. 2.0 ml of hexane is added.
- 25           3. 2.0 ml of methanol is added.
4. The tube is vortexed at high speed for 3.5 minutes.
5. The sample is centrifuged at 2,800 rpm in a table top centrifuge for 25-30 minutes to separate the
- 30           phases.

6. The supernatant (organic phase) is removed and placed in a 2.0 ml teflon capped glass GC/MS vial for determination of farnesol and GG by GC/MS.

Example 8

- 5 The following example demonstrates the effect of HMG CoA reductase amplification on GG production by a strain over-expressing GGPP synthase.

In this experiment, a strain was constructed that contained a single copy of a plasmid integrated into its  
10 genome that allows the cells to over-express GGPP synthase. The integrating plasmid is known as pSW35-42, and was constructed as follows. Plasmid pSW4A (see Example 5) was digested with BamHI to generate a 2199 bp fragment containing a fusion of the *ADH1* promoter, *crtE* coding  
15 sequence, and *ADH1* terminator. This fragment was then ligated into BamHI digested YIp351 (Hill et al, 1986, Yeast/E. coli Shuttle Vectors with Multiple Unique Restriction Sites, YEAST 2:163-167) to generate pSW35-42.

To construct a strain containing pSW35-42, this  
20 plasmid was digested with the restriction endonuclease *BstEII* to introduce a single cut within the *LEU2* gene. The linearized plasmid was purified and used to transform strain SWE23-DL1 using the LiOAc method. Transformants in which pSW35-42 had integrated at the *LEU2* locus were  
25 selected on medium lacking leucine. One of the resulting transformed strains is referred to as SWE23-DL1::pSW35-42.

This strain was then transformed with either YEp352 (an empty vector control, Hill et al, 1986, YEAST 2:163-167) or with pRH124-31 (contains the catalytic domain of the *HMG2* gene, see Example 4), which resulted in strains  
5 SWE23-DL1::pSW35-42/YEp352 and SWE23-DL1::pSW35-42/pRH124, respectively. Strain SWE23-DL1::pSW35-42/YEp352 over-expresses GGPP synthase while SWE23-DL1::pSW35-42/pRH124 over-expresses GGPP synthase and HMG CoA reductase.

10 Fermentation experiments of strains SWE23-DL1::pSW35-42/pRH124 and SWE23-DL1::pSW35-42/Yep352 were conducted to compare the GG production by these two strains. The strains were tested for GG production in 1-L fermentors using the protocol described in Example 1.H.  
15 The fermentation data are presented in Table 20. This experiment shows that the fermentation of SWE23-DL1::pSW35-42/pRH124 accumulated more GG than the fermentation of SWE23-DL1::pSW35-42/Yep352, and demonstrates that elevation of HMG CoA reductase activity  
20 in a strain designed to produce GG resulted in a further elevation of GG levels as compared to a similar strain with un-amplified HMG CoA reductase.

TABLE 20

Strain	Dry Cell Weight @192 hr	Famesol @192 hr		GG @192 hr	
	g/l	g/l	% dry wt.	g/l	% dry wt.
5 SWE23-ΔL1::pSW35-42/Yep352	41.4	2.04	4.9	0.30	0.72
SWE23-ΔL1::pSW35-42/pRH124	44.0	3.27	7.4	0.60	1.36

A second approach to achieve over-expression of HMG

10 CoA reductase and GGPP synthase in the same strain was accomplished by cloning both genes into a high copy-number yeast vector, and transforming this plasmid into an *erg9* mutant strain. The plasmid used for this purpose is referred to as pSW46-1, and this was constructed as

15 follows. Plasmid pSW4A (see Example 5) was digested with *EcoRI* and *SacI* and the 0.9 kb fragment containing the *crtE* gene was purified and ligated into *EcoRI*, *SacI* digested pADH313-956 to generate pSW38-10. Two regions of this plasmid were deleted by digestion with restriction enzymes,

20 filling the ends of the DNA using *Pfu* polymerase, and ligating to reform the circular plasmid. The regions deleted in this manner were between the *NdeI* and *SpeI* sites, and between the *HindIII* and *PstI* sites. The resulting plasmid is referred to as pSW43-5. Plasmid

25 pSW43-5 was digested with *BamHI*, and the resulting 2199 bp

fragment containing the *ADH1* promoter, *crtE* gene, and *ADH1* terminator (referred to as the *ADHp/crtE/ADHt* fragment) was purified and ligated into the *BamHI* site of YEp352. The resulting plasmid is referred to as pSW44-17, and differs  
5 from pSW4A in that it contains one instead of two *PstI* sites.

Plasmid pRH124-31 was digested with *XbaI* and *PstI* and the 3.2 kB fragment containing the *GPD* promoter, *HMG2* catalytic domain gene, and the *PGK* terminator (referred to  
10 as the *GPDp/HMG2cat/PGKt* fragment) was cloned into *XbaI*, *PstI* digested pSW44-17 to generate pSW46-1. This plasmid replicates to high copy number in yeast and contains both *HMG2* and *crtE* genes, providing for over-expression of HMG CoA reductase and GGPP synthase. Plasmid pSW46-1 was  
15 transformed into the *erg9* mutant strain SWE-DE91, and URA<sup>+</sup> transformants were isolated. Several of the resulting transformants were tested in a shake flask experiment and were compared to a strain that over-expresses only GGPP synthase (EMS9-23/pSW4A). The results from that experiment  
20 are presented in Table 21, and demonstrate that higher levels of GG accumulate in strains that over-express both HMG CoA reductase and GGPP synthase when compared to a strain that over-expresses only GGPP synthase.

TABLE 21

Strain	Over-expressed Genes	Dry Cell Wt.	GG	
			mg/ml	% Dry Wt.
SWE23-ΔE91/YEp352	control	4.35	0.0007	0.02
EMS9-23/pSW4A	GGPP synthase	2.82	0.0469	1.66
SWE23-ΔE91/pSW46-1	GGPP synthase HMG CoA reductase	3.45	0.0866	2.45

These data support the idea that over-expression of HMG CoA reductase in a strain that is capable of producing elevated levels of GG leads to a further increase in the amount of GG produced.

#### Example 9

The following example describes the production of more stable strains that over-express HMG CoA reductase.

As described in Example 4, strains were constructed that over-expressed HMG CoA reductase due to the presence of high-copy number replicating plasmids containing the *HMG1cat* or *HMG2cat* genes. Since replicating plasmids can frequently be lost during cell division, this mitotic instability of the replicating plasmids can lead eventually to cultures with a high proportion of cells containing only normal HMG CoA reductase levels. In order to obtain more stable strains that over-expressed HMG CoA reductase, copies of the gene coding for the catalytic domain of HMG2p were integrated into the genome of strain SW23B. This was accomplished by first constructing a plasmid that allowed for multiple integrations of the *HMG2* gene into the spacer



region of the rRNA gene. This approach is modeled after the rDNA integration method described by Lopes et al, 1989 (Lopes, T. S., Klotwijk, J., Veenstra, A. E., van der Aar, P. C., van Heerikhuizen, H., Raue, H. A., and Planta, R. J. 1989. High-copy-number integration into the ribosomal DNA of *Saccharomyces cerevisiae*: a new vector for high-level expression. Gene 79:199-206).

PCR was used to amplify two regions of the rDNA locus that lie in the intergenic region between the gene coding for the 35S rRNA and the gene coding for the 5S rDNA, referred to here as the rDNA spacer region. The oligonucleotides used to amplify the first of the two rDNA spacer region fragments contained sequences corresponding to bases # 11161 to #11130 and the reverse complement of #10311 to #10330 of Gene Bank Accession #Z73326. The oligonucleotide sequences are listed below. The lower case letters are used to indicate bases that were altered or added to create restriction endonuclease recognition sites, which are indicated in parentheses following the oligonucleotide sequence.

SEQ ID NO:24:

R6XbaI Lo 5'-tctagaGGCACCTGTCACCTTTGGAAAAAAATATACGC-3'

(XbaI)

25 SEQ ID NO:25:

R7SacII Up      5'-ccgcggGCCGGAAATGCTCTGTTC-3'  
(SacII)

The DNA fragment generated from PCR amplification  
5 using these two oligonucleotides is referred to herein as  
the R6/R7 fragment. The R6/7 fragment generated by PCR was  
cloned initially into the plasmid pCR-Script to generate  
pSW48-1, then cut from this plasmid by digestion with XbaI  
and SacII. The resulting 759 bp fragment was then cloned  
10 into XbaI, SacII digested pBluescript SK- (Stratagene) to  
generate pSW49-1.

The oligonucleotides used to amplify the second rDNA  
spacer region fragment contained sequences corresponding to  
bases #11247 to #11272 and the reverse complement of #12054  
15 to #12072 of Gene Bank Accession #Z73326. The sequences of  
these oligonucleotides are listed below.

SEQ ID NO:26:

R5Sal UpB      5' CACgtCgACCATTCAAACCTTACTAC-3'      (SalI)

20 SEQ ID NO:27:

R4ApaI LoB      5'-GAGGGCccGGTCCAGACAT-3'      (ApaI)

The DNA fragment generated from PCR amplification  
using the two oligonucleotides listed above is referred to  
25 herein as the R4/R5 fragment. The R4/R5 fragment generated

by PCR was digested with *ApaI* and *SalI*, and ligated into *ApaI*, *SalI* digested pSW49-1 to generate pSW52-11.

PCR was used to amplify the *TRP1* gene such that the gene carried an incomplete promoter. The incomplete promoter was intended to reduce expression of the *TRP1* gene, and thereby provide a means of selection for high copy number integration of the final expression cassette. The oligonucleotides used to the *TRP1* gene contained sequences corresponding to bases #53 to #73 and the reverse complement of #804 to #823 of Gene Bank Accession #J01374. The oligonucleotide sequences are listed below.

SEQ ID NO:28:

TRP1 SmaUp      5'-cccgggTATTGAGCACGTGAGTATACG-3'  
(*SmaI*)

SEQ ID NO:29:

TRP1 BamLo      5'-ggatccGGCAAGTGCACAAACAATAC-3'  
(*BamHI*)

In the next step, pSW50-1 was digested with *BamHI* and *SmaI*, and the resulting 779 bp *TRP1* fragment was purified. Plasmid pRH124-31 was digested with *PstI* and *SmaI* to generate a 3261 bp fragment containing the *GPD* promoter, *HMG2 cat* gene, and the *PGK* terminator (referred to as the *GPDp/HMG2cat/PGKt* fragment), and this fragment was purified. The *TRP1* fragment and the *GPDp/HMG2cat/PGKt*

fragment were ligated into *PstI*, *BamHI* digested pSW52-11 in a three fragment ligation to generate pSW58-77 and pSW58-45.

The DNA fragment containing the R6/R7-*TRP1-GPD*  
5 p/*HMG2cat* /*PGK t-R4/R5* gene fusions was cut from pSW58-77 by digestion with the restriction endonucleases *KpnI* and *SacI*. The 5671 bp fragment corresponding to the integrating construct was purified and used to transform strain SW23B. Transformants were selected on SCE-*trp*  
10 medium. Strains isolated in this manner were screened for elevation of HMG CoA reductase activity and by Southern blot analysis for elevation of *HMG2* gene copy number. Strains were identified that carried one copy of the integrating construct, two copies of the integrating  
15 construct, three copies of the integrating construct, and eight copies of the integrating construct, and are referred to as SW23B#19, SW23B#31, SW23B#40, and SW23B#74, respectively. Table 22 gives the specific activity of HMG CoA reductase as determined by *in vitro* enzyme assays, and  
20 copy number of the *HMG cat* gene as determined by Southern blotting. The HMG CoA reductase assay was previously described (Quain, D. E. and Haslam, J. M. 1979. The Effects of Catabolite Derepression on the Accumulation of Steryl Esters and the Activity of  $\beta$ -Hydroxymethylglutaryl-CoA  
25 Reductase in *Saccharomyces cerevisiae*. *J. Gen. Microbiol.* 111:343-351).

TABLE 22

Strain	HMG CoA Reductase	GPDp/HMG2cat/PGKt
	nmol/min mg	copies/cell
SW23B	5.26	0
SW23B#19	14.53	1
SW23B#31	37.47	2
SW23B#40	50.33	3
SW23B#76	59.04	8

These strains require exogenously supplied leucine and uracil for growth due to the *leu2* and *ura3* mutations in these strains. To eliminate the need to supply these nutrients during fermentation experiments, the strains were transformed with a plasmid, pTWM138, containing functional copies of *URA3*, *LEU2*, and *TRP1*. The presence of this plasmid in these strains allowed the strains to grow without leucine and uracil supplementation.

Fermentation experiments were carried out to compare farnesol production by these strains. Also included in this experiment was the strain SWE23-DE91/pRH124-31 which contains the *GPDp/HMG2cat /PGKt* gene fusion on a high copy number plasmid (see Example 4.B). The strains were tested for farnesol production in 1-L fermentors using the protocol described in Example 1.H, and the data from this experiment are presented in Table 23.

TABLE 23

Strain	Genes Amplified	Ferm Time	Dry Cell Weight	Farnesol	
				g/l	% Dry Cell Wt.
	copy no.	hr	g/l		
SW23B/pTWM138	control	216	53.3	3.25	6.10
SW23B#19/pTWM138	HMG2 cat 1 copy	192	52.4	4.58	8.74
SW23B#74/pTWM138	HMG2 cat 8 copies	216	43.5	4.70	10.80
SW23B/pRH124-31	HMG2 cat >20 copies	192	43.8	4.89	11.16

10

These data support the idea that strains with elevated levels of HMG CoA reductase produce more farnesol than a strain with normal levels of HMG CoA reductase. The data also indicate that a strain containing eight integrated copies of the *HMG2cat* gene produce essentially as much farnesol as a strain that carries more than 20 extrachromosomal copies of the *HMG2cat* gene as is the case with strain SW23B/pRH124-31. A strain containing a single integrated copy of the *HMG2 cat* gene produced more farnesol than the control strain, but slightly less than strains with more copies of the *HMG2cat* gene. In addition, the strains containing elevated HMG CoA reductase levels accumulated mevalonate in the culture while the strains with normal levels of HMG CoA reductase did not. This suggests that a step downstream of HMG CoA reductase limits carbon flux in the pathway once the HMG CoA reductase enzyme activity has been elevated (see Example 10). Carbon

25

flux through the pathway is restricted by the activity of one of the enzymes downstream of HMG CoA reductase resulting in mevalonate accumulation in the medium.

Example 10

5        This example shows the effects of over-expression of multiple isoprenoid pathway genes in a strain that has an *erg9* mutation and elevated levels of HMG CoA reductase.

As shown in Examples 4 and 9, elevation of HMG CoA reductase levels led to higher carbon flux through the  
10 isoprenoid/sterol pathway. Over-expression of other isoprenoid pathway genes in strains containing amplified HMG CoA reductase may further increase carbon flux through this pathway. Amplification of isoprenoid pathway genes in strains that have elevated levels of HMG CoA reductase as  
15 well as a defective *erg9* gene may result in further elevation of farnesol levels. Also, amplification of isoprenoid pathway genes may result in further elevation of GG levels in strains that have a defective *erg9* gene and have elevated levels of HMG CoA reductase and GGPP  
20 synthase.

To test these ideas, plasmids were constructed that allowed for the over-expression of multiple isoprenoid pathway genes. One of the plasmids provided for the over-expression of mevalonate kinase, phosphomevalonate  
25 kinase, and diphosphomevalonate decarboxylase, coded by the *ERG12*, *ERG8*, and *ERG19* genes respectively. This plasmid is

referred to as pSW77-69, and was constructed from DNA fragments obtained from a number of plasmids containing single isoprenoid pathway genes. The construction of those plasmids is described first.

5           PCR was used to amplify the *ERG12* gene for cloning. The oligonucleotides used to amplify the *ERG12* gene contained sequences corresponding to bases #2827 to #2846 and the reverse complement of #5247 to #5229 of Gene Bank Accession #Z49809. The sequences of the two  
10 oligonucleotides are given below. The lower case letters are used for bases that were altered or added to create restriction endonuclease recognition sites, which are indicated in parentheses following the oligonucleotide sequence.

15

SEQ ID NO:30:

E12.4SN           5'-CCAAATATAACTCGAGCTTTG-3       (XhoI)

SEQ ID NO:31:

E12.SALI3        5'-GCAAAGTcCaCCACCGCAG-3 (SalI)

20

The *ERG12* gene was amplified using the two oligonucleotides E12.4SN and E12.SALI3 and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into pCR-Script at the *SfrI* site to generate pSW68.

25           The oligonucleotides used to amplify the *ERG19* gene contained sequences corresponding to bases #911 to #937 of



145

Gene Bank Accession #Z71656 and the reverse complement of bases #1930 to #1962 of Gene Bank Accession #Z71658. The sequences of the two oligonucleotides are given below.

5    SEQ ID NO:32:

E19 SMAI            5'-GCCACGTGCCCCCGGGTTTCTCTAGCC-3'

(SmaI)

SEQ ID NO:33:

E19 SACI3            5'-GGAAAAGagCtCGATAATTATTGATGATAGATC-3'

10    (SacI)

The *ERG19* gene was amplified using the two oligonucleotides E19 SMAI, E19 SACI3, and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into pCR-Script at the *SfrI* site to generate pSW69.

The oligonucleotides used to amplify the *ERG8* gene contained sequences corresponding to bases #2729 to #2749 and the reverse complement of #5177 to #5196 of Gene Bank Accession #Z49939. The sequences of the two oligonucleotides are given below.

SEQ ID NO:34:

E8.2135N            5'-CCGTTTTGGATccTAGATCAG-3'            (BamHI)

SEQ ID NO:35:

25    E8SMAI3            5'-gttcccGGGTTATTGTCCTGCATTTG-3'            (SmaI)

The *ERG8* gene was amplified using the two oligonucleotides E8.2135N, E8SMAI3, and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into pCR-Script at the *SfrI* site to generate pSW71.

5        Plasmid pSW71 was digested with *BamHI* and *SmaI*, and the resulting 2459 bp fragment containing the *ERG8* gene was purified. Plasmid pSW69-3 was digested with *SmaI* and *SacI*, and the resulting 2239 bp fragment containing the *ERG19* gene was purified. The high copy number yeast vector  
10    YEp352 (containing a *URA3* selection marker) was digested with *BamHI* and *SacI* and purified. The three purified DNA fragments were ligated together to generate pSW76-11.

Next, pSW68 was digested with *SalI* and *XhoI* and the resulting 2400 bp band containing the *ERG12* gene was  
15    purified and ligated into *SalI* digested pSW76-11 to generate pSW77-69. This plasmid contains *ERG12*, *ERG8*, and *ERG19*, and provides for over-expression of mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase.

20        Another plasmid provided for the over-expression of mevalonate kinase, phospho-mevalonate kinase, diphosphomevalonate decarboxylase, and IPP isomerase, coded by *ERG12*, *ERG8*, *ERG19*, and *IDI1* genes respectively. This plasmid is referred to as pSW78-68, and was constructed as  
25    follows. The *IDI1* gene was amplified by PCR for cloning. The oligonucleotides used to amplify the *IDI1* gene

147

contained sequences corresponding to bases #19577 to #19604 and the reverse complement of #17477 to #17502 of Gene Bank Accession #U43503. The sequences of the two oligonucleotides are given below.

5

SEQ ID NO:36:ISO SACI5        5'-AAGAGctcATCTGATAATAGATCAAGCG-3' (*SacI*)SEQ ID NO:37:ISO SACI3        5'-AGGAGCTCAACGACAATAAATGGCTG-3' (*SacI*)

10

The *IDI1* gene was amplified using the two oligonucleotides ISO SACI5, ISOSACI3, and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into pCR-Script at the *SfrI* site to generate pSW73. Plasmid pSW73 was digested with *SacI* and the resulting 2117 bp fragment containing the *IDI1* gene was ligated with *SacI* digested pSW77-69 to generate pSW78-68. This plasmid contains *ERG12*, *ERG8*, *ERG19*, and *IDI1*, and provides for over-expression of mevalonate kinase, phosphomevalonate kinase, diphosphomevalonate decarboxylase, and IPP isomerase.

15

20

25

Another plasmid provided for the over-expression of acetoacetyl CoA thiolase and HMG CoA synthase, coded by the *ERG10* and *ERG13* genes, respectively. This plasmid is referred to as pSW79-29, and was constructed as follows.

PCR was used to amplify the *ERG13* and *ERG10* genes for cloning. The oligonucleotides used to amplify the *ERG13* gene contained sequences corresponding to the reverse complement of bases #21104 to #21127 and bases #18270 to 5 #18292 of Gene Bank Accession #Z50178. The sequences of the two oligonucleotides are given below.

SEQ ID NO:38:

E13 XBAI5            5'-GTCCTctAGATCTTGAATGAAATC-3'            (*XbaI*)

SEQ ID NO:39:

10    E13 SACI3            5'-CTTTGAGCtcGTACAAGAAGCAG-3'    (*SacI*)

The *ERG13* gene was amplified using the two oligonucleotides E13 XBAI5, E13 SACI3, and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into 15 pCR-Script at the *SfrI* site to generate pSW72.

The oligonucleotides used to amplify the *ERG10* gene contained sequences corresponding to bases #4073 to #4093 and the reverse complement of #6542 to #6565 of Gene Bank Accession #U36624. The sequences of the two 20 oligonucleotides are given below.

SEQ ID NO:40:

E10 HIND5            5'-CTAAGCttTGCGCCCGTGAAG-3'            (*HindIII*)

SEQ ID NO:41:

25    E10 XBAI3-2            5'-GTTCTAGAAGTTTTCAAAGCAGAG-3'  
(*XbaI*)

The *ERG10* gene was amplified using the two oligonucleotides E10 HIND5, E10 XBAI3-2, and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into pCR-Script at the *SfrI* site to generate pSW70.

5        Plasmid pSW70 was digested with *XbaI* and *HindIII*, and the resulting 2482 bp fragment containing the *ERG10* gene was purified. Plasmid pSW72-4 was digested with *XbaI* and *SacI*, and the resulting 2850 bp fragment containing the *ERG13* gene was purified. The two purified DNA fragments  
10        were then ligated together with *SacI*, *HindIII* digested YEp351 (*LEU2* selectable marker) to generate pSW79-30. This plasmid contains the *ERG13* and *ERG10* genes and allows for the over-expression of acetoacetyl CoA thiolase and HMG CoA synthase.

15        Strain SW23B#74 (contains eight integrated copies of the *HMG2 cat* gene, see Example 9) was transformed with pSW77-69 and pSW78-68, and transformants were selected on SCE-ura medium. The resulting strains are referred to as SW23B#74/pSW77-69 and SW23B#74/pSW78-68, respectively.  
20        These strains require added leucine for growth due to the *leu2* mutation. To eliminate the need to supplement these strains with leucine during fermentation experiments, they were transformed with a linear fragment of DNA containing a functional *LEU2* gene, and LEU+ transformants were  
25        isolated. These strains are referred to as SW23B#74L/pSW77-69 and SW23B#74L/pSW78-68, respectively.

SW23B#74 was also transformed with pSW79-30, and transformants were selected on SCE-leu medium. SW23B#74/pSW79-30 requires uracil since it contains a mutation in the *ura3* gene. To eliminate the need to supplement these strains with uracil during fermentation experiments, this strain was transformed with a linear fragment of DNA containing a functional *URA3* gene, and *URA+* transformants were isolated. This strain is referred to as SW23B#74U/pSW79-30.

SW23B#74 was also transformed with both pSW78-68 and pSW79-30, and transformants were isolated that were capable of growing on SCE-ura,-leu medium indicating that the transformants contained both plasmids. The resulting strain is referred to as SW23B#74/pSW78-68/pSW79-30.

Fermentation experiments were carried out with the strains described above to examine the effect of these gene amplifications on farnesol production. The strains were tested in 1-L fermentors using the protocol described in Example 1.H, and data from these experiments are presented in Table 24.

TABLE 24

Strain	Genes Amplified	Ferm. Time (hr)	Dry Cell Weight g/l	Farnesol		Mevalonate	
				g/l	% Dry Wt.	g/l	% Dry Wt.
SW23B#74/pTWM138	<i>HMG2cat</i>	215	45.5	4.95	10.88	0.2	0.4
SW23B#74U/pSW77-69	<i>HMG2cat</i> , <i>ERG8</i> , <i>ERG12</i> , <i>ERG19</i> ,	287	41.6	4.67	11.23	0	0
SW23B#74U	<i>HMG2cat</i> ,	215	46.4	4.87	10.50	0	0

pSW78-68	<i>ERG8</i> , <i>ERG12</i> , <i>ERG19</i> , <i>IDI1</i>						
SW23B#74U/ pSW79-30	<i>HMG2cat</i> , <i>ERG10</i> , <i>ERG13</i>	215	46.1	4.63	10.04	5.4	11.7

5

These data show that a strain which over-expresses HMG CoA reductase accumulates the isoprenoid pathway intermediate mevalonate in the culture medium. Since mevalonate accumulation is not observed in strains with normal levels of HMG CoA reductase, this demonstrates that carbon flux through the isoprenoid pathway has been increased by HMG CoA reductase amplification to the point where another step subsequent to HMG CoA reductase limits the conversion of pathway intermediates. Furthermore, over-expression of the first three enzymes in the isoprenoid pathway, namely acetoacetyl CoA thiolase, HMG CoA synthase, and HMG CoA reductase (coded by *ERG 13*, *ERG10*, and *HMG2cat*, respectively) led to even higher accumulation of mevalonate in the medium. This demonstrates that carbon flux into the isoprenoid pathway has been increased further by amplification of the first three steps, and emphasizes that one of the enzymes downstream of HMG CoA reductase limits conversion of isoprenoid pathway intermediates. Since mevalonate serves as a precursor to farnesol and GG, the modifications described above can be used to increase carbon flux into the isoprenoid pathway, and, if the mevalonate can be more

efficiently metabolized, can lead to increased farnesol and GG accumulation.

In regard to this last point, enzymes downstream of HMG CoA reductase were amplified in a strain that over-expressed HMG CoA reductase. The enzymes amplified were HMG CoA reductase, mevalonate kinase, phosphomevalonate kinase, diphosphomevalonate decarboxylase, and IPP isomerase (coded by *HMG2cat*, *ERG12*, *ERG8*, *ERG19*, and *IDI1*, respectively). These strains accumulated less mevalonate when compared to strains over-expressing only HMG CoA reductase, indicating that the increased flux through the isoprenoid pathway resulting from HMG CoA reductase over-expression was accommodated by elevated levels of the downstream enzymes. Although elevated farnesol levels were not observed in the experiment described above, this may be due to the low level of mevalonate available for conversion. However, these data suggest that amplification of one or more of the enzymes downstream of HMG CoA reductase in a strain with amplified levels of the first three pathway enzymes may lead to increased accumulation of farnesol and GG since flux to mevalonate is greatly increased in these strains. It is likely that over-expression of one or more genes downstream of HMG CoA reductase in a strain that over-expresses acetoacetyl CoA thiolase, HMG CoA synthase, and HMG CoA reductase will lead to significant increases in farnesol and GG accumulation.



EXAMPLE 11

This example describes an experiment in which squalene synthase is blocked by zaragozic acid in a strain with an intact and functional sterol pathway, including a functional *ERG9* gene, and the effect of this squalene synthase inhibitor on farnesol and GG accumulation is observed.

Zaragozic acids are a family of compounds that act as potent inhibitors of squalene synthase (Bergstrom, J. D., Dufresne, C., Bills, G. F., Nallin-Omstead, M., and Byrne, K. 1995. Discovery, Biosynthesis, and Mechanism of Action of the Zaragozic Acids: Potent Inhibitors of Squalene Synthase. *Ann. Rev. Microbiol.* 49:607-639). They are capable of inhibiting cholesterol biosynthesis in mammals and ergosterol biosynthesis in fungi. Since ergosterol is necessary for fungal cell growth, zaragozic acids are potent fungicidal compounds.

Strain SWE23-E9 (*ura3, sue*; see EXAMPLE 1.G) was used in this experiment because it contained the *sue* mutation that provided for the uptake of sterols under aerobic conditions. This allowed the yeast to grow in ergosterol-supplemented medium when squalene synthase was blocked by zaragozic acid. A strain without the *sue* mutation would not be able to take up sterols, including ergosterol, from the medium, and therefore could not grow in the presence of zaragozic acid.

SWE23-E9 containing either an empty vector (Yep352) or plasmids that allow for the over-expression of HMG Co A reductase (pRH124-31), GGPP synthase (pSW4A), or both HMG Co A reductase and GGPP synthase (pSW46-1) were tested in shake flasks by first growing the strains in SCE-ura medium for 48 hr to select for the plasmids. Samples of these cultures were then inoculated into YPDE medium or YPDE medium containing zaragozic acid at 100 µg/ml. The YPDE (+/- zaragozic acid) cultures were incubated at 30°C for 48 hr, then analyzed for dry cell weight and farnesol accumulation. The data from this experiment are shown in Table 25. All of the cultures treated with zaragozic acid exhibited elevated accumulation of farnesol relative to the untreated cultures. GG accumulation was not measured in this experiment.

TABLE 25

Strain	Zaragozic Acid	Dry Cell Weight	Farnesol	
			µg/ml	% Dry Wt.
	@100µg/m	mg/ml		
SWE23-E9/Yep 352	+	7.65	43	0.56
SWE23-E9/Yep352	-	9.72	0	0
SWE23-E9/pRH124-31	+	7.88	11	0.14
SWE23-E9/pRH124-31	-	9.89	0	0
SWE23-E9/pSW4A	+	7.03	45	0.64
SWE23-E9/pSW4A	-	9.05	1	0
SWE23-E9/pSW46-1	+	7.09	51	0.72
SWE23-E9/pSW46-1	-	8.54	0	0

In a separate experiment, SWE23-E9 containing either an empty vector (Yep352) or a plasmid that allows for over-expression of both HMG Co A reductase and GGPP synthase (pSW46-1) were tested in shake flasks by first growing the strains in SCE-ura medium for 48 hr to select for the plasmids. Samples of these cultures were then inoculated into YPDE medium or YPDE medium containing zaragozic acid at 100 mg/ml. The YPDE (+/- zaragozic acid) cultures were incubated at 30°C for 72 hr, then analyzed for dry cell weight and GG. The data are presented in Table 26. The culture of SWE23-E9/pSW46-1 treated with zaragozic acid exhibited a higher level of GG as compared to the same strain grown in the absence of zaragozic acid. These experiments demonstrate that strains without mutations in the sterol biosynthetic pathway can be induced to accumulate farnesol by blocking the pathway using a squalene synthase inhibitor. The amount of farnesol or GG accumulated by the zaragozic acid treated cultures was much less than the amount accumulated by strains with completely defective erg9 genes indicating that a genetic block of squalene synthase is more effective than a block induced by a squalene synthase inhibitor.

TABLE 26

25

Strain	Zaragozic Acid	Dry Cell Weight	GG	
			µg/ml	% Dry Wt.
	@100µg/ml	mg/ml		
SWE23-E9/Yep352	+	7.17	0	0

SWE23-E9/Yep352	-	9.25	0	0
SWE23-E9/pSW46-1	+	6.68	17.8	0.27
SWE23-E9/pSW46-1	-	8.41	6.7	0.08

5

Example 12

An alternative pathway leading to FPP has been described in a number of bacteria and plants, and is referred to as the non-mevalonate or Rohmer pathway (Eisenreich, W., Schwarz, M., Cartayrade, A., Arigoni, D., Zenk, M. H., and Bacher, A., 1998. The Deoxyxylulose Phosphate Pathway of Terpenoid Biosynthesis in Plants and Microorganisms. Chem. Biol. 5: R221-233. Paseshnichenko, V. A., 1998. A New Alternative Non-Mevalonate Pathway for isoprenoid Biosynthesis in Eubacteria and Plants. Biochemistry (Mosc) 63:139-148). Some of the enzymes of the non-mevalonate pathway and their genes have been identified and studied in *E. coli*, and these include the deoxyxylulose-5-phosphate synthase, deoxyxylulose-5-phosphate reductase, IPP isomerase, and FPP synthase, coded by the *dxr*, *dxs*, *idi*, and *ispA* genes, respectively.

In order to construct strains of *E. coli* that accumulate elevated levels of farnesol, plasmids were constructed for the over-expression in *E. coli* of the genes listed above. In some cases, additional genes adjacent to the known isoprenoid pathway gene were included in the cloned DNA.

The *idi* gene coding for IPP isomerase was PCR amplified using the two oligonucleotides listed below and genomic DNA isolated from *E. coli* strain W3110. The oligonucleotides used to amplify the *idi* gene contained  
5 sequences corresponding to bases #42309 to #42335 and the reverse complement of #43699 to #43726 of Gene Bank Accession #U28375. The lower case letters are used for bases that were altered to create restriction endonuclease recognition sites, which are indicated in parentheses  
10 following the oligonucleotide sequence. A natural *EcoRI* site was used in VE145-5.

SEQ ID NO:42:

VE145-5 5'-GGGATTCGAATTCTGTCGCGCTGTAAC-3' (*EcoRI*)

SEQ ID NO:43:

15 VE146-3 5'-TGggATCcGTAACGGCTTTAGCGAGCTG-3' (*BamHI*)

The *idi* PCR product was digested with *EcoRI* and *BamHI*, and ligated into *EcoRI*, *BamHI* digested pUC19. The resulting clone is referred to as pHS-0182.

20 The *dxr* gene was PCR amplified using the two oligonucleotides listed below and genomic DNA isolated from *E. coli* strain W3110. The oligonucleotides used to amplify a region of DNA which included the *frr*, *dxr*, and *yaeS* genes contained sequences corresponding to bases #2131 to #2150  
25 and the reverse complement of #5297 to #5315 of Gene Bank Accession #D83536.

SEQ ID NO:44:

DXR17.SN GATTCCGCGTAAGgATCcCG (BamHI)

SEQ ID NO:45:

DXR3179.ASN CCAGCATctAGACCACCAG (XbaI)

5

The resulting PCR product was digested with *BamHI* and *XbaI*, and ligated into *BamHI*, *XbaI* digested pHS-0182 to generate pHS-0182R.

The *ispA* and *dxs* genes appear to be part of an operon that possibly include two other genes referred to as *xseB* and *yajO*. PCR was used to amplify a region of DNA which included *xseB*, *ispA*, *dxs*, and *yajO* using the oligonucleotides listed below and genomic DNA isolated from *E. coli* strain W3110. The oligonucleotides contained sequences corresponding to bases #4157 to #4183 and the reverse complement of bases # 8938 to #48956 of Gene Bank Accession #AE000148.

15

SEQ ID NO:46:

DXS.5619P 5'-gactgcagCTGGCCGCTGGGTATTCTGTCGTAGTT-3'

20

(PstI)

SEQ ID NO:47:

DXS.820X 5'-gatctagaTCACGCGTACGCAGAAGGTTTGC-3'

(XbaI)

The resulting PCR product was digested with *XbaI* and *PstI* and ligated to *XbaI*, *PstI* digested pUC19 to generate pHS-dxs.

The DNA fragment containing the *dxs* gene will be cut  
5 from pHS-dxs using *XbaI* and *PstI*, and ligated into *XbaI*,  
*PstI* digested pHS-0182R to generate a plasmid that contains  
*dxs*, *dxr*, *ispA*, and *idi*. The resulting plasmid will be  
transformed into *E. coli*, and a transformed strain  
containing the plasmid will be tested for production of  
10 farnesol in shake flask and fermentation experiments.

In order to construct strains of *E. coli* that  
accumulate elevated levels of GG, a plasmid was constructed  
for the over-expression in *E. coli* of GGPP synthase from  
*Erwinia herbicola*. The *crtE* gene coding for GGPP synthase  
15 was amplified by PCR using genomic DNA isolated from  
*Erwinia herbicola* strain Eho10 and the following two  
oligonucleotides. The oligonucleotides contained sequences  
corresponding to bases #3513 to #3531 and the reverse  
complement of bases # 4459 to #4481 of Gene Bank Accession  
20 #M87280.

SEQ ID NO:48:

Eho10E Up 5'-gaattcCAATTCAGCGGGTAACCTT-3' (EcoRI)

SEQ ID NO:49:

Eho10E Lo 5'-aagcttTGCTTGAACCCAAAAGGGCGGTA-3'

25 (HindIII)

The resulting PCR product was digested with *EcoRI* and *HindIII*, and ligated into pET24d(+) (Novagen) so that expression of the *ctrE* gene was controlled by the T7 promoter. The resulting plasmid is referred to as pKL19-63. This plasmid can be transformed into *E. coli* strains such as BL21(DE3) (available from Novagen) which contains an IPTG inducible gene coding for T7 polymerase. This allows IPTG induction of the *crtE* gene in this strain. The T7 promoter/*crtE* gene fusion can be cut from pKL19-63 using *BglII* and *HindIII*, and ligated into *BamHI*, *HindIII* digested pACYC184 (Accession #X06403) to construct a plasmid relying on chloramphenicol resistance for selection. This plasmid contains the p15A origin of replication and would be compatible with plasmids containing the ColE1 origin of replication such as the clones carrying the *E. coli* isoprenoid pathway genes described above. These latter plasmids confer ampicillin resistance, and so *E. coli* transformants can be obtained that carry both the *crtE* plasmid and the plasmid containing the *dxs*, *dxr*, *idi*, and *ispA* genes by transforming *E. coli* with both plasmids and selecting for resistance to chloramphenicol and ampicillin. Therefore, strains of *E. coli* BL21(DE3) will be obtained that contain plasmids for over-expression deoxyxylulose-5-phosphate synthase, deoxyxylulose-5-phosphate reductoisomerase, IPP isomerase, FPP synthase, and GGPP



synthase. These strains will be tested for production of GG in shake flask and fermentation experiments.

### Example 13

5           The following example describes the construction of strains of *Saccharomyces cerevisiae* that are engineered to produce elevated levels of farnesol and GG by expressing enzymes corresponding to the non-mevalonate pathway enzymes.

10           Biosynthesis of IPP occurs in many bacteria and plants starting from pyruvate and glyceraldehyde-3-and proceeding through a series of enzymatic steps known as the non-mevalonate pathway, and includes the enzymes deoxyxylulose-5-phosphate synthase and deoxyxylulose-5-phosphate  
15   reductoisomerase. The compound resulting from these two enzymatic steps is 2-C-methyl-D-erythritol 4-phosphate (also known as MEP), which is further metabolized by unknown enzymes to yield IPP. Plasmids are constructed that express the *E. coli* *dxs* and *dxr* genes in yeast by  
20   fusing the coding regions of those genes to promoter elements that allow for expression in yeast. The *dxs* and *dxs* genes are amplified by PCR with oligonucleotides that include restriction sites to allow cloning into yeast expression vectors which contain promoters such as the *ADHI*  
25   promoter, *PGK* promoter, or *GPD* promoter. The two gene fusions are then combined into a single plasmid by

subcloning one gene fusion into the other plasmid. The resulting plasmid containing both genes is then transformed into an *erg9* mutant of yeast. The resulting strain is capable of synthesizing MEP, which may be further metabolized to IPP by endogenous enzymes capable of carrying out the desired reactions to IPP. This capability may lead to increased accumulation of IPP, which may cause the cells to accumulate elevated levels of farnesol through the action of the endogenous IPP isomerase and FPP synthase enzymes. If this is done in a strain that also over-expresses GGPP synthase, then elevated levels of GG may accumulate in these strains.

#### Example 14

This example describes the construction of a strain of *Saccharomyces cerevisiae* that over-expresses a mutated *ERG20* gene coding for an FPP synthase enzyme exhibiting altered product specificity. Unlike strains over-expressing wild-type FPP synthase, strains expressing the mutated FPP synthase accumulated more GG than farnesol.

Comparison of the amino acid sequences of FPP synthases from a variety of organisms revealed several highly conserved domains including two aspartate rich domains, which are essential for catalytic activity. Researchers have reported that mutations effecting the amino acid located at the fifth position before the first aspartate rich domain can alter the product specificity of

the enzyme such that the enzyme readily catalyzes the formation of GGPP as well as FPP. This has been shown for both avian and *Bacillus stearothermophilus* FPP synthases (Tarshis, L.C., Proteau, P. J., Kellogg, B. A., Sacchettini, J. C., Poulter, C. D. 1996. Regulation of Product Chain Length by Isoprenyl Diphosphate Synthases. Proc. Natl. Acad. Sci. USA 93:15018-15023; Ohnuma, S., Narita, K., Nakazawa, T., Ishida, C., Takeuchi, Y., Ohto, C., and Nichino, T. 1996. A Role of the Amino Acid Residue Located on the Fifth Position Before the First Aspartate-rich Motif of Farnesyl Diphosphate Synthase on Determination of the Final Product. J. Biol. Chem. 271:30748-30754; U.S. Patent 5,766,911). In the case of the *Bacillus* enzyme, the amino acid in the fifth position before the first aspartate rich domain was changed from tyrosine to serine. The avian enzyme contains a phenylalanine in this position. It is thought that aromatic amino acids in that position block extension of the isoprenyl chain beyond fifteen carbons, and that the restriction can be alleviated by replacing the phenylalanine with a less-bulky amino acid such as serine.

As in the *Bacillus* FPP synthases mentioned above, the FPP synthase from *Saccharomyces cerevisiae* has a tyrosine at the fifth position before the first aspartate rich domain. Site directed mutagenesis was used to alter the sequence of the *ERG20* gene to code for a serine instead of

a tyrosine at that position. The method used to introduce the mutation relied on PCR amplification of the entire pJMB19-31 plasmid using mutagenic oligonucleotides that introduced the desired mutation, and is outlined in the instruction booklet for the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The oligonucleotides contained sequences corresponding to bases #1063 to #1097 and the reverse complement of bases # 1063 to #1097 of Gene Bank Accession #J05091. The sequences of the oligonucleotides are given below, with the changes indicated by small case letters. An alteration of A to T was made at position #1084 to change the encoded amino acid from tyrosine to serine. Also, an alteration of T to C was made at position #1074 to create a new *PstI* site, which allowed for rapid identification of the mutant gene. This latter mutation was silent in that it did not change the encoded amino acid.

SEQ ID NO:50:

Y95S-SN 5'-GCATTGAGTTGcTGCAGGCTTcCTTCTTGGTCGCC-3'

20 SEQ ID NO:51:

Y95S-ASN 5'-GGCGACCAAGAAGgAAGCCTGCAgCAACTCAATGC-3'

The two oligonucleotides were used to amplify pJMB19-31, and the resulting PCR product was ligated to itself to reform the circular plasmid, except that *ERG20* gene now contained the desired mutation. The resulting plasmid is

referred to as pHS31.Y95S, and this plasmid was transformed into the *erg9* mutant strain SWE23-DE91 to form SWE23-DE91/pHS31.Y95S. Shake flask experiments were carried out to compare farnesol and GG production by strains over-expressing the wild-type *ERG20* gene and the mutated *ERG20* gene. Strains were grown overnight in SCE-ura, and this was used to inoculate flasks containing YPDE medium. These cultures were grown at 30°C for 72 hr, then harvested for dry cell weight and isoprenoid analysis. The data from this experiment is presented in Table 27.

TABLE 27

Strain	FPP Synthase	Dry Cell Wt	Farnesol		GG	
			mg/ml	% Dry Wt.	mg/ml	% Dry Wt.
SWE23-DE91/ JMB19-31	Wild type	4.7	0.22	4.76	0.05	1.1
SWE23-DE91/ pHS31.Y95S	Tyr to Ser Mutant	4.9	0.01	0.2	0.13	2.7

20

These data show that the farnesol:GG ratio is dramatically altered by over-expression of the tyr to ser mutant of the *ERG20* gene in an *erg9* mutant strain. The strain over-expressing the mutant *ERG20* gene exhibited proportionally more GG than the strain over-expressing the wild-type *ERG20* gene. In addition, the total amount of GG produced by the strain over-expressing the mutant *ERG20* was higher while the total amount of farnesol was lower as compared to the strain over-expressing the wild-type *ERG20* gene. The decrease in farnesol level was not completely

reflected in the GG pool, suggesting that some of the FPP may be converted to other compounds besides GG. Alternatively, it is possible that feedback inhibition plays a role in regulating the amount of GG accumulated by these strains.

The foregoing description of the invention has been presented for purposes of illustration and description. Furthermore, the description is not intended to limit the invention to the form disclosed herein. Consequently, variations and modifications commensurate with the above teachings, and the skill or knowledge of the relevant art, are within the scope of the present invention. The embodiments described hereinabove are further intended to explain best modes known of practicing the invention and to enable others skilled in the art to utilize the invention in such, or other, embodiments and with the various modifications required by the particular applications or uses of the invention. It is intended that the appended claims be construed to include alternative embodiments to the extent permitted by the prior art.

What is claimed is:

1. A method for producing  $\alpha$ -tocopherol or  $\alpha$ -tocopheryl esters comprising:

(a) biologically producing a compound selected from  
5 the group consisting of farnesol and geranylgeraniol; and

(b) chemically converting said compound into  $\alpha$ -tocopherol or an  $\alpha$ -tocopheryl ester.

2. The method of Claim 1, wherein said compound is geranylgeraniol having a first, second, third and fourth  
10 olefin moieties and wherein said step of chemically converting comprises:

(a) reducing at least one of said second, third and fourth olefin moieties of said geranylgeraniol to form an allylic alcohol; and

15 (b) forming  $\alpha$ -tocopherol or an  $\alpha$ -tocopheryl ester from said allylic alcohol and a hydroquinone.

3. The method of Claim 2, wherein said reducing step (a) comprises:

adding a protecting group to said geranylgeraniol to  
20 protect the first olefin moiety of said geranylgeraniol from reduction; and

reducing at least one of the second, third and fourth olefin moieties of said protected geranylgeraniol; and

removing said protecting group from said reduced protected geranylgeraniol to provide said allylic alcohol.

4. The method of Claim 3, wherein said protecting  
5 group is a hydroxy protecting group.

5. The method of Claim 4, wherein said hydroxy protecting group is an ester.

6. The method of Claim 5, wherein said ester is selected from the group consisting of isobutyrate and  
10 pivaloate.

7. The method of Claim 2, wherein said reducing step comprises hydrogenation.

8. The method of Claim 2, wherein said allylic alcohol comprises phytol.

9. The method of Claim 2, wherein formation of  
15 said  $\alpha$ -tocopherol or an  $\alpha$ -tocopheryl ester comprises contacting said allylic alcohol with an acid in the presence of said hydroquinone.

10. The method of Claim 2, wherein said  
20 hydroquinone is a trimethyl hydroquinone.

11. The method of Claim 10, wherein said trimethyl hydroquinone is 2,3,5-trimethyl hydroquinone.

12. The method of Claim 1, wherein said compound is farnesol and wherein said step of chemically converting  
25 comprises:



(a) converting farnesol to a first intermediate comprising sufficient carbon atoms to form a trimethyltridecyl substituent group of vitamin E when said intermediate is reacted with a hydroquinone to form  
5 vitamin E; and

(b) reacting said intermediate compound with a hydroquinone to form vitamin E.

13. The method of Claim 12, wherein said converting step comprises:

10 oxidizing said farnesol to farnesal; and  
forming a methyl ketone from said farnesal.

14. The method of Claim 13, further comprising:  
reducing olefin moieties in said methyl ketone to  
form an alkyl methyl ketone; and

15 forming an allylic alcohol from said alkyl methyl  
ketone.

15. The method of Claim 12, wherein said intermediate comprises isophytol.

16. The method of Claim 12, wherein said  
20 hydroquinone is a trimethyl hydroquinone.

17. The method of Claim 16, wherein said trimethyl hydroquinone is 2,3,5-trimethyl hydroquinone.

18. The method of Claim 1, wherein said compound is farnesol and wherein said step of chemically converting  
25 comprises:

(a) oxidizing said farnesol to farnesal;

- (b) forming a methyl ketone from said farnesal;
- (c) reducing olefin moieties in said methyl ketone to form an alkyl methyl ketone;
- (d) forming an allylic alcohol from said alkyl methyl ketone, wherein said allylic alcohol comprises a sufficient number of carbon atoms to form at least a trimethyltridecyl substituent group of vitamin E when vitamin E is formed from said allylic alcohol and a corresponding hydroquinone;
- and
- (e) forming vitamin E from said compound and a hydroquinone.

19. The method of Claim 18, wherein said allylic alcohol comprises isophytol.

20. The method of Claim 18, wherein said hydroquinone is a trimethyl hydroquinone.

21. The method of Claim 20, wherein said trimethyl hydroquinone is 2,3,5-trimethyl hydroquinone.

22. The method of Claim 1, wherein said compound is farnesol.

23. The method of Claim 1, wherein said compound is geranylgeraniol.

24. A method for producing  $\alpha$ -tocopherol or  $\alpha$ -tocopheryl esters comprising:

- (a) culturing a microorganism in a fermentation medium to produce a product selected from the group consisting of farnesyl phosphate, farnesol, geranylgeranyl phosphate and geranylgeraniol, wherein the action of squalene synthase of said microorganism is reduced;
- (b) recovering said product; and
- (c) chemically converting said product into  $\alpha$ -tocopherol or an  $\alpha$ -tocopheryl ester.

25. The method of Claim 24, wherein said fermentation medium comprises a squalene synthase inhibitor.

26. The method of Claim 24, wherein said microorganism is genetically modified to decrease the action of squalene synthase.

27. The method of Claim 26, wherein said microorganism is further genetically modified to increase the action of HMG-CoA reductase.

28. The method of Claim 27, wherein the action of HMG-CoA reductase is increased by overexpression of HMG-CoA reductase or the catalytic domain thereof in the microorganism.

29. The method of Claim 28, wherein said microorganism is further genetically modified to increase

the action of a protein selected from the group consisting of acetoacetyl Co-A thiolase, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl  
5 pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

30. The method of Claim 29, wherein the microorganism has been genetically modified to increase  
10 the action of farnesyl pyrophosphate synthase.

31. The method of Claim 30, wherein the microorganism has been genetically modified to overexpress farnesyl pyrophosphate synthase.

32. The method of Claim 24, wherein said  
15 microorganism is an *erg9* mutant.

33. The method of Claim 32, wherein said microorganism comprises a *erg9Δ::HIS3* deletion/insertion allele.

34. The method of Claim 24, wherein said recovering  
20 step comprises recovering said product from said microorganism.

35. The method of Claim 24, wherein said product is secreted into said fermentation medium by said microorganism and wherein said step of recovering  
25 comprises purification of said product from said fermentation medium.

36. The method of Claim 24, wherein said microorganism is a fungi.

37. The method of Claim 36, wherein said fungi has been genetically modified to express at least a portion  
5 of the enzymes in the mevalonate independent pathway.

38. The method of Claim 37, wherein said fungi has been genetically modified to express an enzyme selected from the group consisting of D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate  
10 reductoisomerase.

39. The method of Claim 36, wherein said fungi is a yeast and said yeast is blocked in the ergosterol pathway and is genetically modified to take up exogenous sterols under aerobic conditions.

15 40. The method of Claim 24, wherein said microorganism is a bacteria.

41. The method of Claim 40, wherein said bacteria has been genetically modified to express at least a portion of the enzymes in the mevalonate pathway.

20 42. The method of Claim 41, wherein said bacteria has been genetically modified to express an enzyme selected from the group consisting of acetoacetyl Co-A thiolase, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, and phosphomevalonate  
25 decarboxylase.

43. The method of Claim 24, wherein said microorganism is a microalgae.

44. The method of Claim 43, wherein said microalgae is selected from the group consisting of  
5 *Chlorella* and *Prototheca*.

45. The method of Claim 24, wherein said microorganism has been genetically modified to increase phosphatase action.

46. The method of Claim 29, wherein the  
10 microorganism has been genetically modified to increase the action of geranylgeranyl pyrophosphate synthase.

47. The method of Claim 46, wherein the microorganism has been genetically modified to overexpress geranylgeranyl pyrophosphate synthase.

48. A method for producing  $\alpha$ -tocopherol or  $\alpha$ -tocopheryl esters comprising:

(a) biologically producing a first compound selected from the group consisting of geranylgeraniol and geranylgeranyl pyrophosphate;

(b) contacting said first compound with a geranylgeranyl reductase to form a second compound selected from the group consisting of phytol and phytyl diphosphate; and

(c) chemically converting said second compound into  $\alpha$ -tocopherol or an  $\alpha$ -tocopheryl ester.

49. A method, as claimed in Claim 48, wherein said step of contacting is conducted *in vivo* using a microorganism having geranylgeranyl reductase activity.

50. A method, as claimed in Claim 48, wherein said step of contacting is conducted in a biotransformation process.

51. A method, as claimed in Claim 48, wherein said first compound is geranylgeraniol and said second compound is phytol.

52. A method, as claimed in Claim 48, wherein said first compound is geranylgeranyl pyrophosphate and said second compound is phytyl diphosphate.

53. A method, as claimed in Claim 48, wherein said step of chemically converting comprises reacting said second compound or a derivative thereof with a

hydroquinone to form  $\alpha$ -tocopherol or an  $\alpha$ -tocopheryl ester.

54. A method, as claimed in Claim 48, wherein said step of contacting comprises purifying said first  
5 compound and transforming said first compound with isolated geranylgeranyl reductase or microorganisms having geranylgeranyl reductase activity.

55. The method of Claim 54, wherein said microorganism is further genetically modified to increase  
10 the action of geranylgeranyl reductase.

56. The method of Claim 55, wherein the action of geranylgeranyl reductase is increased by overexpression of geranylgeranyl reductase.



57. A method for producing a compound selected from the group consisting of farnesol and geranylgeraniol comprising:

(a) culturing a microorganism in a fermentation medium comprising a compound selected from the group consisting of isoprenol and prenol to produce a product selected from the group consisting of farnesyl phosphate, farnesol, geranylgeranyl phosphate and geranylgeraniol; and

10 (b) recovering said product.

58. The method of Claim 57, wherein said microorganism is further genetically modified to increase the action of dimethylallyl transferase.

59. The method of Claim 58, wherein the action of dimethylallyl transferase is increased by overexpression of dimethylallyl transferase in the microorganism.

60. The method of Claim 59, wherein the microorganism has been genetically modified to increase the action of farnesyl pyrophosphate synthase.

20 61. The method of Claim 60, wherein the microorganism has been genetically modified to overexpress farnesyl pyrophosphate synthase.

62. The method of Claim 59, wherein the microorganism has been genetically modified to increase the action of geranylgeranyl pyrophosphate synthase.

63. The method of Claim 60, wherein the microorganism has been genetically modified to overexpress geranylgeranyl pyrophosphate synthase.

64. The method of Claim 57, wherein the  
5 microorganism has been genetically modified to increase the action of an enzyme selected from the group consisting of isoprenol kinase and prenol kinase.

65. The method of Claim 57, wherein the  
10 microorganism has been genetically modified to overexpress an enzyme selected from the group consisting of isoprenol kinase and prenol kinase.

66. The method of Claim 57, wherein said microorganism is an *erg9* mutant.

67. A method for producing farnesol comprising:

(a) culturing a microorganism in a fermentation medium to produce a product selected from the group consisting of farnesyl phosphate and farnesol, wherein the action of squalene synthase of said microorganism is reduced; and

(b) recovering said product.

68. The method of Claim 67, wherein said fermentation medium comprises a squalene synthase inhibitor.

69. The method of Claim 67, wherein said microorganism is genetically modified to decrease the action of squalene synthase.

70. The method of Claim 69, wherein said microorganism is further genetically modified to increase the action of HMG-CoA reductase.

71. The method of Claim 70, wherein the action of HMG-CoA reductase is increased by overexpression of HMG-CoA reductase or the catalytic domain thereof in the microorganism.

72. The method of Claim 70, wherein said microorganism is further genetically modified to increase the action of a protein selected from the group consisting of acetoacetyl Co-A thiolase, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl

pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

73. The method of Claim 72, wherein the  
5 microorganism has been genetically modified to increase the action of farnesyl pyrophosphate synthase.

74. The method of Claim 73, wherein the microorganism has been genetically modified to overexpress farnesyl pyrophosphate synthase.

10 75. The method of Claim 67, wherein said microorganism is an *erg9* mutant.

76. The method of Claim 75, wherein said microorganism comprises a *erg9Δ::HIS3* deletion/insertion allele.

15 77. The method of Claim 67, wherein said recovering step comprises recovering said product from said microorganism.

78. The method of Claim 67, wherein said product is secreted into said fermentation medium by said  
20 microorganism and wherein said step of recovering comprises purification of said product from said fermentation medium.

79. The method of Claim 67, wherein said product is intracellular farnesyl phosphate and farnesol and said  
25 step of recovering comprises isolating said farnesyl phosphate and farnesol from said microorganism.

80. The method of Claim 67, wherein said product is intracellular farnesyl phosphate and said step of recovering further comprises dephosphorylating said farnesyl phosphate to produce farnesol.

5 81. The method of Claim 67, wherein said microorganism is a fungi.

82. The method of Claim 81, wherein said fungi has been genetically modified to express at least a portion of the enzymes in the mevalonate independent pathway.

10 83. The method of Claim 82, wherein said fungi has been genetically modified to express an enzyme selected from the group consisting of D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

15 84. The method of Claim 81, wherein said fungi is a yeast and said yeast is blocked in the ergosterol pathway and is genetically modified to take up exogenous sterols under aerobic conditions.

20 85. The method of Claim 67, wherein said microorganism is a bacteria.

86. The method of Claim 85, wherein said bacteria has been genetically modified to express at least a portion of the enzymes in the mevalonate pathway.

25 87. The method of Claim 86, wherein said bacteria has been genetically modified to express an enzyme selected from the group consisting of acetoacetyl Co-A

thiolose, HMG-CoA synthase, HMG CoA reductase, mevalonate kinase, phosphomevalonate kinase, and phosphomevalonate decarboxylase.

88. The method of Claim 67, wherein said  
5 microorganism is a microalgae.

89. The method of Claim 88, wherein said microalgae is selected from the group consisting of *Chlorella* and *Prototheca*.

90. A microorganism for producing farnesol by a biosynthetic process, said microorganism having a genetic modification to reduce the action of squalene synthase in said microorganism and a genetic modification to increase  
5 the action of a protein selected from the group consisting of acetoacetyl Co-A thiolase, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl pyrophosphate isomerase,  
10 farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

91. The microorganism of Claim 90, wherein said genetic modification to increase the action of a protein  
15 comprises integrating multiple copies of genes for said protein into the genome of said microorganism.

92. The microorganism of Claim 91, wherein said genetic modification to increase the action of a protein increases the expression of a gene encoding said protein.

20 93. The microorganism of Claim 92, wherein said genetically modified microorganism is an *erg9* mutant.

94. A method for producing geranylgeraniol comprising:

(a) culturing a microorganism in a fermentation medium to produce a product selected from the group consisting of geranylgeranyl phosphate and geranylgeraniol, wherein the action of squalene synthase of said microorganism is reduced; and

(b) recovering said product.

95. The method of Claim 94, wherein said fermentation medium comprises a squalene synthase inhibitor.

96. The method of Claim 94, wherein said microorganism is genetically modified to decrease the action of squalene synthase.

97. The method of Claim 96, wherein said microorganism is further genetically modified to increase the action of HMG-CoA reductase.

98. The method of Claim 97, wherein the action of HMG-CoA reductase is increased by overexpression of HMG-CoA reductase or the catalytic domain thereof in the microorganism.

99. The method of Claim 97, wherein said microorganism is further genetically modified to increase the action of a protein selected from the group consisting of acetoacetyl Co-A thiolase, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase,



phosphomevalonate decarboxylase, isopentenyl pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

5           100. The method of Claim 99, wherein the microorganism has been genetically modified to increase the action of geranylgeranyl pyrophosphate synthase.

          101. The method of Claim 100, wherein the microorganism has been genetically modified to  
10 overexpress geranylgeranyl pyrophosphate synthase.

          102. The method of Claim 94, wherein said microorganism is an *erg9* mutant.

          103. The method of Claim 102, wherein said microorganism comprises a *erg9Δ::HIS3* deletion/insertion  
15 allele.

          104. The method of Claim 94, wherein said recovering step comprises recovering said product from said microorganism.

          105. The method of Claim 94, wherein said product is  
20 secreted into said fermentation medium by said microorganism and wherein said step of recovering comprises purification of said product from said fermentation medium.

          106. The method of Claim 94, wherein said product is  
25 intracellular geranylgeranyl phosphate and intracellular and extracellular geranylgeraniol and said step of

recovering comprises isolating said geranylgeranyl phosphate and geranylgeraniol from said microorganism and isolating geranylgeraniol from said fermentation medium.

107. The method of Claim 94, wherein said product is intracellular geranylgeranyl phosphate and said step of recovering further comprises dephosphorylating said geranylgeranyl phosphate to produce geranylgeraniol.

108. The method of Claim 94, wherein said microorganism is a fungi.

109. The method of Claim 108, wherein said fungi has been genetically modified to express at least a portion of the enzymes in the mevalonate independent pathway.

110. The method of Claim 109, wherein said fungi has been genetically modified to express an enzyme selected from the group consisting of D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

111. The method of Claim 108, wherein said fungi is a yeast and said yeast is blocked in the ergosterol pathway and is genetically modified to take up exogenous sterols under aerobic conditions.

112. The method of Claim 94, wherein said microorganism is a bacteria.

113. The method of Claim 112, wherein said bacteria has been genetically modified to express at least a portion of the enzymes in the mevalonate pathway.

114. The method of Claim 113, wherein said bacteria has been genetically modified to express an enzyme selected from the group consisting of acetoacetyl Co-A thiolase, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, and phosphomevalonate decarboxylase.

115. The method of Claim 94, wherein said microorganism is a microalgae.

116. The method of Claim 115, wherein said microalgae is selected from the group consisting of *Chlorella* and *Prototheca*.

117. A microorganism for producing geranylgeraniol by a biosynthetic process, said microorganism having a genetic modification to reduce the action of squalene synthase in said microorganism and a genetic modification  
5 to increase the action of a protein selected from the group consisting of acetoacetyl Co-A thiolase, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl pyrophosphate isomerase,  
10 farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

118. The microorganism of Claim 117, wherein said genetic modification to increase the action of a protein  
15 comprises integrating multiple copies of genes for said protein into the genome of said microorganism.

119. The microorganism of Claim 117, wherein said genetic modification to increase the action of a protein increases the expression of a gene encoding said protein.

20 120. The microorganism of Claim 117, wherein said genetically modified microorganism is an *erg9* mutant.

121. A method for producing vitamin A from farnesol comprising:

(a) preparing an  $\alpha,\beta$ -unsaturated polyene carbonyl compound from farnesol; and

5 (b) cyclizing said  $\alpha,\beta$ -unsaturated polyene carbonyl compound to form a cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound; and


(c) converting said cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound to vitamin A.

10 122. The method of Claim 121, wherein said preparing step comprises:

oxidizing said farnesol to farnesal; and

forming said  $\alpha,\beta$ -unsaturated polyene carbonyl compound from said farnesal.

15 123. The method of Claim 121, wherein said  $\alpha,\beta$ -unsaturated polyene carbonyl compound is of the formula:




wherein

20 Z is O or CHCO<sub>2</sub>R, and

R is C<sub>1</sub>-C<sub>10</sub> hydrocarbyl.

124. The method of Claim 121, wherein said cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound is of the formula:

190



wherein

Z is O or  $\text{CHCO}_2\text{R}$ , and

R is  $\text{C}_1\text{-C}_{10}$  hydrocarbyl.

5 125. The method of Claim 124, wherein Z is  $\text{CHCO}_2\text{R}$ .

126. The method of Claim 125, wherein said  
converting step comprises reduction of an ester group to  
an alcohol group.

127. The method of Claim 124, wherein Z is O.

10 128. The method of Claim 127, wherein said  
converting step comprises:

conducting a chemical reaction to transform Z from O  
to  $\text{CHCO}_2\text{R}$  or  $\text{CHCN}$ ; and

reducing Z to form vitamin A.

15 129. The method of Claim 121, wherein said farnesol  
is produced biologically.

130. The method of Claim 129, wherein biological  
production comprises:

(a) culturing a microorganism in a  
20 fermentation medium to produce a product selected from  
the group consisting of farnesyl phosphate and farnesol,  
wherein the action of squalene synthase of said  
microorganism is reduced; and

(b) recovering said product.

131. The method of Claim 130, wherein said microorganism is genetically modified to decrease the action of squalene synthase.

5        132. The method of Claim 131, wherein said microorganism is further genetically modified to increase the action of HMG-CoA reductase.

133. The method of Claim 132, wherein the action of HMG-CoA reductase is increased by overexpression of HMG-  
10    CoA reductase or the catalytic domain thereof in the microorganism.

134. The method of Claim 132, wherein said microorganism is further genetically modified to increase the action of a protein selected from the group  
15    consisting of acetoacetyl Co-A thiolase, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl  
pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-  
20    xylulose 5-phosphate reductoisomerase.

135. The method of Claim 134, wherein the microorganism has been genetically modified to increase the action of farnesyl pyrophosphate synthase.

136. The method of Claim 130, wherein said  
25    microorganism is an *erg9* mutant.

137. The method of Claim 130, wherein said product is secreted into said fermentation medium by said microorganism and wherein said step of recovering comprises purification of said product from said fermentation medium.

138. The method of Claim 130, wherein said product is intracellular farnesyl phosphate and farnesol and said step of recovering comprises isolating said farnesyl phosphate and farnesol from said microorganism.

139. The method of Claim 130, wherein said product is intracellular farnesyl phosphate and said step of recovering further comprises dephosphorylating said farnesyl phosphate to produce farnesol.

140. The method of Claim 121, wherein said microorganism is a fungi.

141. The method of Claim 140, wherein said fungi has been genetically modified to express at least a portion of the enzymes in the mevalonate independent pathway.

142. The method of Claim 141, wherein said fungi has been genetically modified to express an enzyme selected from the group consisting of D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

143. The method of Claim 140, wherein said fungi is a yeast and said yeast is blocked in the ergosterol



pathway and is genetically modified to take up exogenous sterols under aerobic conditions.

144. The method of Claim 130, wherein said microorganism is a bacteria.

5        145. The method of Claim 144, wherein said bacteria has been genetically modified to express at least a portion of the enzymes in the mevalonate pathway.

10       146. The method of Claim 145, wherein said bacteria has been genetically modified to express an enzyme selected from the group consisting of acetyl Co-A thiolase, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, and phosphomevalonate decarboxylase.

15       147. The method of Claim 130, wherein said microorganism is a microalgae.

148. The method of Claim 147, wherein said microalgae is selected from the group consisting of *Chlorella* and *Prototheca*.

149. A method for producing  $\beta$ -carotene comprising:

(a) chemically producing retinal from farnesol; and

(b) subjecting said retinal to a reductive coupling condition to produce said  $\beta$ -carotene.

150. The method of Claim 149, wherein said chemical step comprises:

(a) preparing an  $\alpha,\beta$ -unsaturated polyene carbonyl compound from said farnesol; and

(b) cyclizing said  $\alpha,\beta$ -unsaturated polyene carbonyl compound to form a cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound;

(c) converting said cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound to retinol; and

(d) oxidizing said retinol to said retinal.

151. The method of Claim 149, wherein said farnesol is produced biologically.

152. The method of Claim 151, wherein biological production comprises:

(a) culturing a microorganism in a fermentation medium to produce a product selected from the group consisting of farnesyl phosphate and farnesol, wherein the action of squalene synthase of said microorganism is reduced; and

(b) recovering said product.

153. The method of Claim 152, wherein said microorganism is genetically modified to decrease the action of squalene synthase.

154. The method of Claim 153, wherein said  
5 microorganism is further genetically modified to increase the action of HMG-CoA reductase.

155. The method of Claim 154, wherein the action of HMG-CoA reductase is increased by overexpression of HMG-CoA reductase or the catalytic domain thereof in the  
10 microorganism.

156. The method of Claim 155, wherein said microorganism is further genetically modified to increase the action of a protein selected from the group consisting of acetyl Co-A thiolase, HMG-CoA synthase,  
15 mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

20 157. The method of Claim 156, wherein the microorganism has been genetically modified to increase the action of farnesyl pyrophosphate synthase.

158. The method of Claim 152, wherein said microorganism is an *erg9* mutant.

25 159. The method of Claim 152, wherein said product is secreted into said fermentation medium by said

microorganism and wherein said step of recovering comprises purification of said product from said fermentation medium.

160. The method of Claim 152, wherein said product  
5 is intracellular farnesyl phosphate and farnesol and said step of recovering comprises isolating said farnesyl phosphate and farnesol from said microorganism.

161. The method of Claim 152, wherein said product  
is intracellular farnesyl phosphate and said step of  
10 recovering further comprises dephosphorylating said farnesyl phosphate to produce farnesol.

162. The method of Claim 152, wherein said microorganism is a fungi.

163. The method of Claim 162, wherein said fungi has  
15 been genetically modified to express at least a portion of the enzymes in the mevalonate independent pathway.

164. The method of Claim 162, wherein said fungi has been genetically modified to express an enzyme selected from the group consisting of D-1-deoxyxylulose 5-  
20 phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

165. The method of Claim 162, wherein said fungi is a yeast and said yeast is blocked in the ergosterol pathway and is genetically modified to take up exogenous  
25 sterols under aerobic conditions.

166. The method of Claim 152, wherein said microorganism is a bacteria.

167. The method of Claim 166, wherein said bacteria has been genetically modified to express at least a  
5 portion of the enzymes in the mevalonate pathway.

168. The method of Claim 167, wherein said bacteria has been genetically modified to express an enzyme selected from the group consisting of acetyl Co-A thiolase, HMG-CoA synthase, HMG-CoA reductase, mevalonate  
10 kinase, phosphomevalonate kinase, and phosphomevalonate decarboxylase.

169. The method of Claim 152, wherein said microorganism is a microalgae.

170. The method of Claim 169, wherein said  
15 microalgae is selected from the group consisting of *Chlorella* and *Prototheca*.

171. A method for producing  $\beta$ -carotene comprising:  
producing  $C_{40}$ -sulfone from a retinyl halide and  
retinylphenylsulfone; and

converting said  $C_{40}$ -sulfone to  $\beta$ -carotene.

5        172. The method of Claim 171, wherein said producing  
step comprises contacting said retinylphenylsulfone with  
a base

173. The method of Claim 171, wherein said  
converting step comprises an elimination process.




FIG. 1A-i

2/21




FIG. 1A-ii



3/21




FIG. 1A-iii

4/21




FIG. 1A-iv

5/21











FIG. 1B-i

6/21

**2-C-methyl-D-erythritol 4-P  
(MEP)****Isopentenyl pyrophosphate**

Isomerase

**Dimethylallyl pyrophosphate****Geranyl pyrophosphate****Farnesyl pyrophosphate****FIG. 1B-ii**

7/21




FIG. 1B-iii

8/21




FIG. 1B-iv

9/21




FIG. 2

10/21




FIG. 3



11/21




FIG. 4

12/21




FIG. 5




FIG. 6

14/21




FIG. 7

15/21




FIG. 8

16/21




FIG. 9-i

17/21




FIG. 9-ii

18/21




FIG. 10



19/21




FIG. 11

20/21




FIG. 12

21/21




FIG. 13

## SEQUENCE LISTING

<110> Millis, James R.  
Saucy, Gabriel G  
Maurina-Brunker, Julie  
McMullin, Thomas W.

<120> METHOD OF VITAMIN PRODUCTION

<130> 3161-29

<140> not yet assigned

<141> 1999-07-06

<150> 60/091,983

<151> 1998-07-06

<160> 51

<170> PatentIn Ver. 2.0

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(23)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 1

ctcagtacgc tggtagccgt cac

23

<210> 2

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(27)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 2

gatggatccc aatatgtgta gctcagg

27

<210> 3

<211> 22

<212> DNA

<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(22)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 3  
gcgcattccac gggctatata aa 22

<210> 4  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(26)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 4  
gcggatccta ttatgtaagt acttag 26

<210> 5  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(22)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 5  
gagcatccac gggctatata aa 22

<210> 6  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(26)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 6  
tccccccggg cgcagacttc acgctc 26

<210> 7  
<211> 31  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(31)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 7  
gatccgcggc tcaagctagc ggtattatgc c 31

<210> 8  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(29)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 8  
gactctagag tttagcgagtc tggaaaatc 29

<210> 9  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(28)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 9  
gtaggatcca tggaattgag caatagag 28

<210> 10  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(33)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 10

aattccaagc ttgcggccgc tctagaacgc gtg

33

<210> 11

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(32)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 11

gatccacgcg ttctagagcg gccgcaagct tg

32

<210> 12

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(25)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 12

gaattcgttt ataaggacag cccga

25

<210> 13

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(26)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 13

ctgcagtctt taactgacgg cagcga

26

<210> 14  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(52)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 14  
agctgaattc gagctcggta cccgggctct agagtcgacc tgcaggcatg ca 52

<210> 15  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(52)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 15  
agcttgcatg cctccaggtc gactctagag cccgggtacc gagctcgaat tc 52

<210> 16  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(29)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 16  
gacggatccg tggaatatcc cgatatcc 29

<210> 17  
<211> 34  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(34)



<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 17

ctcggatccg gacggattac aacaggtatt gtcc

34

<210> 18

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(31)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 18

cagaattcac catggccgtg acttcctcct c

31

<210> 19

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(32)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 19

caagatctca tacattcaat cctcatggac ac

32

<210> 20

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(31)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 20

gagaattctt aacacgcatg atccccacgg c

31

<210> 21

<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(32)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 21  
ctggatccgt caaatccgtg aatcgtaacg ag

32

<210> 22  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(33)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 22  
ggccggatcc atattacgta gaaatggctt cag

33

<210> 23  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(27)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 23  
gccgctcgag ggtccttata tagtttg

27

<210> 24  
<211> 38  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(38)  
<223> PRIMER

<220>  
 <223> Description of Artificial Sequence:PRIMER  
  
 <400> 24  
 tctagaggca cctgtcactt tggaaaaaaa atatacgc 38  
  
 <210> 25  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_feature  
 <222> (1)..(26)  
 <223> PRIMER  
  
 <220>  
 <223> Description of Artificial Sequence:PRIMER  
  
 <400> 25  
 ccgcggggccg gaaatgctct ctgttc 26  
  
 <210> 26  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_feature  
 <222> (1)..(26)  
 <223> PRIMER  
  
 <220>  
 <223> Description of Artificial Sequence:PRIMER  
  
 <400> 26  
 cacgtcgacc attcaaactt tactac 26  
  
 <210> 27  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <221> misc\_feature  
 <222> (1)..(19)  
 <223> PRIMER  
  
 <220>  
 <223> Description of Artificial Sequence:PRIMER  
  
 <400> 27  
 gagggcccgg tccagacat 19  
  
 <210> 28  
 <211> 27  
 <212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(27)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 28

cccggtatt gagcacgtga gtatacg

27

<210> 29

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(26)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 29

ggatccggca agtgcacaaa caatac

26

<210> 30

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(21)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 30

ccaaatataa ctcgagcttt g

21

<210> 31

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)..(19)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 31  
gcaaagtcca ccaccgcag 19

<210> 32  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(27)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 32  
gccacgtgcc cccgggtttc tctagcc 27

<210> 33  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(33)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 33  
ggaaaagagc tcgataatta ttgatgatag atc 33

<210> 34  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(21)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 34  
ccgttttgga tcctagatca g 21

<210> 35  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(26)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 35  
gttcccgggt .tattgtcctg catttg

26

<210> 36  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(28)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 36  
aagagctcat ctgataatag atcaagcg

28

<210> 37  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(26)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 37  
aggagctcaa cgacaataaa tggctg

26

<210> 38  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(24)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 38

gtcctctaga tcttgaatga aatc

24

<210> 39  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(23)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 39  
ctttgagctc gtacaagaag cag

23

<210> 40  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(21)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 40  
ctaagctttg cgcccgtgaa g

21

<210> 41  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(24)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 41  
gttctagaag ttttcaaagc agag

24

<210> 42  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature

<222> (1) .. (27)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 42

gggattcgaa ttctgtcgcg ctgtaac

27

<210> 43

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1) .. (28)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 43

tgggatccgt aacggcttta gcgagctg

28

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1) .. (20)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 44

gattccgcgt aaggatccccg

20

<210> 45

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1) .. (19)

<223> PRIMER

<220>

<223> Description of Artificial Sequence:PRIMER

<400> 45

ccagcatcta gaccaccag

19



<210> 46  
<211> 35  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(35)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 46  
gactgcagct ggccgctggg tattctgtcg tagtt

35

<210> 47  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(32)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 47  
gatctagatc acgcgtacgc agaaggtttt gc

32

<210> 48  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(25)  
<223> PRIMER

<220>  
<223> Description of Artificial Sequence:PRIMER

<400> 48  
gaattccaat tcagcgggta acctt

25

<210> 49  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)..(29)  
<223> PRIMER

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:PRIMER

&lt;400&gt; 49

aagctttgct tgaacccaaa agggcggtta

29

&lt;210&gt; 50

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(35)

&lt;223&gt; PRIMER

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:PRIMER

&lt;400&gt; 50

gcattgagtt gctgcaggct tccttcttgg tcgcc

35

&lt;210&gt; 51

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_difference

&lt;222&gt; (1)..(35)

&lt;223&gt; PRIMER

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:PRIMER

&lt;400&gt; 51

ggcgaccaag aaggaagcct gcagcaactc aatgc

35

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/15264

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07C 45/41; C07D 301/03, 303/04, 311/74; C12P 1/02

US CL : 435/171; 549/408, 519; 560/104; 568/315

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/171; 549/408, 519; 560/104; 568/315

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS-ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	RANDALL et al. Protein Isoprenylation in Suspension-Cultured Tobacco Cells, Plant Cell, 1993. Vol. 5. pages 433-442.	1-56, 121-148
A	AVALOS et al. Terpenoid Biosynthesis in Cell Extracts of Wild-type and Mutant Strains of Gibberella Fujikuroi, Biochimica et Biophysica Acta, 1988. Vol. 966, pages 257-265, especially pages 257-264.	57-120, 149-173
A	MOSQUEDA-CANO et al. Environmental and Developmental regulation of Carotenogenesis in the Dimorphic Fungus Mucor Rouxii, Current Microbiology, 1995. Vol. 31, pages 141-145, especially pages 141-143.	149-173

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

08 SEPTEMBER 1999

Date of mailing of the international search report

09 NOV 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

TAOFIQ A. SOLOLA

*[Signature]*

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/15264

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-56, drawn to biological process of making alpha-tocopherol.

Group II, claim(s) 57-89 and 94-116, drawn to biological process of making farnesol and geranylgeraniol.

Group III, claim(s) 90-93, drawn to microorganism for making farnesol.

Group IV, claim(s) 117-120, drawn to microorganism for making geranylgeraniol.

Group V, claim(s) 121-148, drawn to a chemical process of making vitamin A.

Group VI, claim(s) 149-173, drawn to a process of making beta-carotene.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature among groups I-VI is tocopherol which is known in the art.

The special technical feature in group I is that it is a biological process for making alpha-tocopherol. The special technical feature in group II is that it is a biological process for making farnesol and geranylgeraniol. The special technical feature in group III is that it is a microorganism for making farnesol. The special technical feature in group IV is that it is a microorganism for making geranylgeraniol. The special technical feature in group V is that it is a process for making vitamin A. The special technical feature in group VI is that it is a process for making beta-carotene.

**THIS PAGE BLANK (USPTO)**